

NTP RESEARCH REPORT ON BIOLOGICAL ACTIVITY OF BISPHENOL A (BPA) STRUCTURAL ANALOGUES AND FUNCTIONAL ALTERNATIVES

NTP RR 4

OCTOBER 2017

NTP Research Report on Biological Activity of Bisphenol A (BPA) Structural Analogues and Functional Alternatives

Research Report 4

October 2017

National Toxicology Program Public Health Service U.S. Department of Health and Human Services ISSN: 2473-4756

Research Triangle Park, North Carolina, USA

Table of Contents

Tables	iii
Figures	iii
About This Report	iv
Peer Review	vi
Protocol Review	vi
Publication Details	vii
Acknowledgments	vii
Abstract	viii
Introduction Background Objectives	1
Methods Systematic Review Methods	
Formulate the Study Question	
Search For and Select Studies for Inclusion Literature Search Strategy	
Searching Other Resources	
Study Selection Criteria	
Extract Data from Studies	6
Assess Internal Validity ("Risk of Bias") of Individual Human and Animal Studies	6
Structural and Biological Similarity Analysis	
Structural Similarity Analysis	
HTS Data	
Biological Similarity Analysis Based on HTS Data	7
Integrated Chemical and Biological Similarity	8
Results	
Literature Search Results	
Survey of Evidence	
Human Evidence	
Animal Evidence	
In Vitro Evidence	
Health Outcomes and Mechanistic Findings	
Repeated Dose Effects	
Reproductive and Developmental Effects	
Estrogenic and Anti-estrogenic Activity	
Androgenic and Anti-androgenic Activity	
Thyroid and Anti-thyroid Activity	
Other Receptor Activity	
Acute Toxicity and DNA Damage	22

Biological Activity of Bisphenol A (BPA) Structural Analogues and Functional Alternatives

Other Endpoints	23
Structural and Biological Similarity Analysis	
Structural Similarity Analysis	
Biological Similarity Analysis Based on HTS Data	
Integrated Chemical and Biological Similarity	
Discussion	
Data Gaps and Research Needs	
Limitations of the Review	
Summary	32
References	
Appendix A. Supplemental Materials	A-1

Tables

Table 1. BPA Analogues Included in Systematic Review	1
Table 2. PECO (Populations, Exposures, Comparators Outcomes) Statement	
Table 3. Inventory of Published Literature by Chemical and Evidence Stream1	0
Table 4. Summary of Animal Evidence	2
Table 5. Summary of In Vitro Evidence1	4
Table 6. Summary of Most Sensitive Endpoints in Subchronic Studies1	5
Table 7. Summary of In Vitro Estrogen Endpoints	7

Figures

Figure 1. Study Flow Diagram	9
Figure 2. Estrogenic Activity	20
Figure 3. Structural Similarity of BPA Analogues to BPA and E2	24
Figure 4. Biological Similarity Analyses in Tox21	26
Figure 5. Biological Similarity of BPA Analogues to E ₂ and BPA in Context of the Entire	
Tox21 Library	28
Figure 6. Integrated Structural and Biological Similarity of the BPA Analogues to E ₂ and	
BPA	29

This report has been reformatted to meet new NTP publishing requirements; its content has not changed.

About This Report

Authors

Katherine E. Pelch¹, Jessica A. Wignall³, Alexandra E. Goldstone³, Pam K. Ross³, Robyn B. Blain³, Andrew J. Shapiro¹, Stephanie D. Holmgren², Jui-Hua Hsieh¹, Daniel Svoboda⁴, Scott S. Auerbach¹, Frederick M. Parham¹, Scott A. Masten¹, Kristina A. Thayer⁵

¹Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

²Office of the Director, National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

³ICF, Fairfax, Virginia, USA

⁴SciOme LLC, Research Triangle Park, North Carolina, USA

⁵National Center for Environmental Assessment, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA

Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

Katherine E. Pelch, Ph.D., Project Lead Andrew J. Shapiro, M.S. Jui-Hua Hsieh, Ph.D. Scott S. Auerbach, Ph.D. Frederick M. Parham, Ph.D. Scott A. Masten, Ph.D.

Office of the Director, National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA Stephanie D. Holmgren, M.S.L.S., MBA

ICF, Fairfax, Virginia, USA

Jessica A. Wignall, M.S. Alexandra E. Goldstone, M.S. Pam K. Ross, M.S. Robyn B. Blain, Ph.D.

SciOme LLC, Research Triangle Park, North Carolina, USA Daniel Svoboda, Ph.D.

National Center for Environmental Assessment, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA

Kristina A. Thayer, Ph.D. (formerly Division of the National Toxicology Program, National Institute of Environmental Health Sciences)

Contributors

Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

Comments and discussion on study design or conduct, and review of draft versions of the manuscript Michael J. DeVito, Ph.D. Suzanne E. Fenton, Ph.D. Kembra L. Howdeshell, Ph.D. Gloria D. Jahnke, Ph.D. Andrew A. Rooney, Ph.D. Vicki L. Sutherland, Ph.D. Christina Teng, Ph.D. Raymond T. Tice, Ph.D. Vickie R. Walker, B.S.

Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

Comments and discussion on study design or conduct, and review of draft versions of the manuscript Kenneth S. Korach, Ph.D. Yin Li, Ph.D.

U.S. Environmental Protection Agency, Washington, DC, USA

Comments and discussion on study design or conduct Caroline L. Baier-Anderson, Ph.D.

ICF, Durham, North Carolina, USA

ICF staff management and support Cara C. Henning, Ph.D.

Social & Scientific Systems, Inc., Durham, North Carolina, USA

Assistance in the data extraction process Beverly A. Warden, Ph.D.

Peer Review

The draft research report on the study of biological activity of bisphenol A (BPA) structural analogues and functional alternatives was evaluated by the reviewers listed below. These reviewers served as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, reviewers determined if the design and conditions of these NTP studies were appropriate and ensured that this NTP Research Report presented the experimental results and conclusions fully and clearly.

Peer Reviewers

Nicholas J. Cabaton, Ph.D. INRA/Toxalim

René Viñas, Ph.D. Grocery Manufacturers Association

Anne Marie Vinggaard, Ph.D. Technical University of Denmark

Vickie S. Wilson, Ph.D. U.S. Environmental Protection Agency

Protocol Review

The protocol and design were evaluated by the reviewers listed below.

Johanna R. Rochester, Ph.D. The Endocrine Disruption Exchange/ICF

Cheryl S. Watson, Ph.D. The University of Texas Medical Branch at Galveston

Publication Details

Publisher: National Toxicology Program

Publishing Location: Research Triangle Park, NC

ISSN: 2473-4756

DOI: http://dx.doi.org/10.22427/NTP-RR-4

Report Series: NTP Research Report Series

Report Series Number: 4

Official citation: Pelch K, Wignall J, Goldstone A, Ross P, Blain R, Shapiro A, Holmgren S, Hsieh J-H, Svoboda D, Auerbach S et al. 2017. NTP research report on biological activity of bisphenol A (BPA) structural analogues and functional alternatives. Research Triangle Park, NC: National Toxicology Program. Research Report 4.

Acknowledgments

This research was supported by the National Institute of Environmental Health Sciences/Division of the National Toxicology Program.

Abstract

Background: Recent studies report widespread usage or exposure to a variety of chemicals with structural or functional similarity to bisphenol A (BPA), referred to as BPA analogues or derivatives. These have been detected in foodstuffs, house dust, environmental samples, human urine or blood, and thermal paper. Compared to BPA relatively little is known about potential toxicity of these compounds.

Objective: To identify and summarize human, animal, and mechanistic toxicity data for 24 BPA analogues of emerging interest to research and regulatory communities.

Methods: The objective was addressed by two efforts: 1) a systematic review of the available research; and 2) analysis of data available from the high throughput screening programs Tox21/ToxCast. We used systematic review methods to identify relevant studies from the published literature. Over 5,100 literature studies were screened for relevance and 166 were considered relevant. Analyses of the high throughput screening data focused on assessing structural and biological similarity among the BPA analogues and between BPA or estradiol (E_2).

Results: Reports on 16 of the 24 analogues were found in the published literature. There were no studies of human health effects, animal toxicity or mechanistic studies for 8 of the 24 compounds. The only human health effect that was reported was dermal sensitization to 4,4-BPF, 2,2-BPF or BPS. The majority of the available research was conducted in vitro. Analysis of the Tox21/ToxCast data showed that in general, BPA analogues and derivatives are more structurally and biologically similar to BPA, and to each other, than to E₂. Taken together, the published literature and the data available in Tox21/ToxCast demonstrate that many of the BPA analogues that are potential replacements for BPA have biological activity within the range of activity observed for BPA.

Conclusion: The results of these analyses suggest that many of these chemicals may have endocrine activity in vivo. Given that these chemicals have potential widespread use, they should be pursued in further testing and reconsidered as appropriate replacements for BPA in consumer products.

Introduction

Background

Bisphenol A (BPA) is a high production volume chemical used in the manufacture of polycarbonate plastics, epoxy resins, as a dye developer in thermal paper, and as a polymerization inhibitor in the formation of some polyvinyl chloride plastics¹⁻³. Polycarbonates are in consumer products such as plastic dinnerware, microwave ovenware, eyeglass lenses, toys, pacifiers, impact-resistant safety equipment, compact discs and automobile parts. Epoxy resins are used in protective linings of canned food and beverage containers, drinking water storage tanks, wine vat linings, some paints, floorings, and some dental composites¹⁻³. The types of thermal paper products where BPA might be used as a developer include cash register receipts and certain medical technical paper^{1; 4}. Consequently, human exposure is widespread. BPA has been detected in the urine of 92% of participants surveyed in the United States National Health and Nutrition Examination Survey (NHANES) in 2003 to 2004⁵. BPA has been reported to cause a wide range of adverse health outcomes in experimental animal studies; similar findings in humans have also been linked to BPA exposure in observational epidemiology studies^{2; 3; 6; 7}.

Structure	Abbreviation (CASRN)	Detection	Structure	Abbreviation (CASRN)	Detection
но – С – С – С – ОН С – С – С – ОН	BPS (80-09-1)	blood ⁸ , food ⁹ , dust ¹⁰ , sediment ¹¹ , receipts ¹²⁻¹⁵ , urine ^{16; 17}	HO OF	2,4-BPS (5397-34-2)	receipts ¹⁵
HO	4,4-BPF (620-92-8)	food ^{9; 18; 19} , dust ¹⁰ , sediment ¹¹ , <i>receipts</i> ¹⁵ , urine ^{16;} ¹⁷ , PCP ²⁰ , municipal sewage sludge ²¹	HO-C-S-O-O	BPS-MAE (97042-18-7)	receipts ¹⁵
но-Су-Су-Он	BPAP (1571-75-1)	food ⁹ , dust ¹⁰ , sediment ¹¹ , <i>receipts</i> ¹⁵	но	TGSA (41481-66-7)	receipts ¹⁵
но-€	BPAF (1478-61-1)	food ⁹ , dust ¹⁰ , sediment ¹¹ , municipal sewage sludge ²¹	С с с с с с с с с с с с с с с с с с с с	BPS-MPE (63134-33-8)	receipts ¹⁵
но-Су-СН ₃ Су-он	BPB (77-40-7)	food ^{9; 19; 22-25} , dust ¹⁰ , sediment ¹¹ , blood ^{26; 27} , urine ²⁸	ноон	BPC (79-97-0)	receipts ¹⁵
но п,с сн,	BPP (2167-51-3)	food ⁹ , dust ¹⁰	HO H	BPPH (24038-68-4)	receipts ¹⁵
нососон	BPZ (843-55-0)	food ^{9; 18} , sediment ¹¹ , PCP ²⁰	HO SOUTH OF HO	DD-70 (93589-69-6)	receipts ¹⁵

Table 1. BPA Analogues In	cluded in Systematic Review
---------------------------	-----------------------------

Structure	Abbreviation (CASRN)	Detection	Structure	Abbreviation (CASRN)	Detection
	D-8 (95235-30-6)	blood ²⁹ , receipts ²⁹	HO-O-\$-O-Q-\$-O-9-4 HO-O-\$-O-Q-\$-O-9-4 HO-O-\$-O-Q-\$-O-9-4 HO-O-\$-O-Q-\$-O-9-4 HO-O-\$-O-Q-\$-O-9-4 HO-O-\$-O-Q-\$-O-9-4 HO-O-\$-O-Q-\$-O-Q-\$-O-9-4 HO-O-\$-O-\$-O-Q-\$-O-\$-O-\$-O-\$-0-9-4 HO-O-\$-O-\$-O-\$-O-\$-0-\$-0-9-10-0-\$-0-9-10-0-\$-0-9-10-\$-0-9-10-\$-0-9-10-\$-0-9-\$-	D-90 (191680-83-8)	receipts ¹⁵
OH OH	2,2-BPF (2467-02-9)	resins ³⁰	O ^{%1,C°C,1} %O	BTUM (151882-81-4)	receipts ¹⁵
но-С-Ч-С-Н-ОН	BPE (2081-08-5)	municipal sewage sludge ²¹	но от от	MBHA (5129-00-0)	receipts ¹⁵
H ₃ C CH ₃ H ₀ C CH ₃ CH ₃ HO CH ₃ CH ₃	TMBPA (5613-46-7)	polycarbonate resin ³¹	uc−O−J+J+D−o+	Pergafast 201 (232938-43-1)	receipts ¹⁵
	BDP (5945-33-5)	flame retardant	0.10.1070.1010	UU (321860-75-7)	receipts ¹⁵

Italics indicate that this chemical has been suggested for use as described, but its use or detection has not been confirmed. Full chemical names can be found in <u>Supplemental Table 1</u>, posted online. Abbreviations: PCP (personal care products).

Recent studies report widespread exposure to a variety of chemicals with structural or functional similarity to BPA, often referred to as BPA analogues or derivatives (and henceforth referred to as BPA analogues) (Table 1). BPA analogues have been detected in foodstuffs^{9; 18}, house dust¹⁰, river and lake sediment¹¹, personal care products³², and thermal paper^{12; 14}. Importantly, BPA analogues have also been detected in human biological specimens^{8; 16; 17; 26-28}. Several chlorinated and brominated derivatives of BPA are used as flame retardants^{1-3; 33}. Other chemicals (e.g. MBHA) have also been identified as theoretical alternatives to BPA in thermal paper, although the extent to which they are actually being used is not known¹⁵.

In contrast to BPA, most BPA analogues are poorly understood with respect to potential toxicity^{15; 34}. Use of these compounds may increase as companies move towards using alternatives to BPA in consumer products³⁵⁻³⁷. The health effects of two BPA analogues, bisphenol S and bisphenol F (BPS and BPF) have been recently reviewed using systematic review methodology³⁸, and the United States Environmental Protection Agency's (US EPA) Design for the Environment program completed an alternative assessment in January 2014 in which the potential human health and environmental impacts of chemical alternatives to BPA in thermal paper were summarized¹⁵. However, the literature for some analogues is growing rapidly.

Objectives

The objective of this review is to answer the question: "What is the biological activity of BPA analogues of emerging public health concern?" Our specific aims were to

• identify all of the publicly available human, animal, and in vitro literature concerning health outcomes or biological responses of BPA analogues with the highest potential for human exposure (Table 1);

- extract data from the relevant studies;
- assess the risk of bias of individual animal and human studies;
- synthesize and summarize the existing evidence based on associated health outcome or biological response;
- evaluate the structural and biological similarity of the analogues to each other, to BPA, and to the potent estrogen estradiol (E₂) within the National Toxicology Program's (NTP) Tox21 and US EPA's ToxCast high throughput screening (HTS) platforms; and
- identify data gaps and research needs that could aid in assessment or development of BPA alternatives.

Methods

Systematic Review Methods

Methods for the systematic review are briefly summarized below and are available in more detail in the evaluation protocol³⁹. Systematic review processes were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement criteria⁴⁰ and following the OHAT framework for conducting a systematic review⁴¹.

Formulate the Study Question

A literature search strategy was initially developed for 27 BPA structural and/or functional analogues and refined during problem formulation (described in the evaluation protocol) to focus on the 24 BPA analogues listed in Table 1 (with additional details provided in <u>Supplemental Table 1</u>, posted online. In brief, analogues were prioritized for inclusion in the systematic review based on (1) detection in the environment (e.g., dust, water, sewage), foodstuff, or human biological samples; (2) identification by the US EPA Design for the Environment (DfE) program as being a potential alternative to BPA in thermal paper (henceforth referred to as the "US EPA DfE report")¹⁵; (3) use as a halogenated flame retardant; and (4) considered of emerging interest, i.e. relatively data-poor and not the focus of many previous or on-going hazard or risk evaluations.

To address our overall objective we developed a PECO (Populations, Exposures, Comparators, Outcomes) statement (Table 2) to aid in developing an answerable question, the search terms, and the inclusion/exclusion criteria for our systematic review^{42; 43}. The overall objective and PECO statement were based on a series of problem formulation steps that included assembling an NIEHS/NTP evaluation design team with expertise in BPA and BPA alternatives, toxicology, epidemiology, systematic review, information science, and analysis of high throughput screening data; and consultation with scientists at state governments and other Federal agencies. More details about problem formulation activities can be found in the evaluation protocol³⁹.

PECO Element	Evidence
Populations	Human, animal (whole organism), or ex vivo/in vitro models utilizing organs, tissues, cell lines, or cellular components (e.g., cell-free receptor binding assays).
Exposures	Exposure to at least one of the 24 BPA analogues listed in Table 1.
Comparators	Humans, animals, organs, tissues, cell lines, or cellular components exposed to a lower level of a BPA analogue than the more highly exposed subjects or treatment groups, or vehicle-only treatment.
Outcomes	Any health outcome or type of biological response.

Table 2. PECO (Populations, Exposures, Comparators Outcomes) Statement

Search For and Select Studies for Inclusion

Literature Search Strategy

Prior to the literature search, the SciFinder database was searched using each chemical's chemical abstracts service registration number (CASRN) to retrieve synonym names as well as old or additional CASRNs. Six databases were initially searched on March 28, 2014: Embase, PubMed, SciFinder, Scopus, Toxline and Web of Science. The search strategy was customized for each database because of differences in syntax. In addition, a broader search of the literature using the phrase "bisphenol A (analogue or analog)" was done, in order to retrieve studies that had not specified analogues in the title or abstract. The search was not limited by language or publication date. A literature search update was performed on March 23, 2015. The search update did not include searches for PHBB, TBBPA, or TCBPA because these compounds were not prioritized after problem formulation as they have been the focus of prior literature-based evaluations. The specific language used for each database and numbers of studies retrieved are available in the evaluation protocol.

Searching Other Resources

Additional relevant publications were searched for by reviewing studies from the database search that did not contain original data (e.g., reviews), the US EPA DfE report¹⁵, an NTP background document on BPA alternatives³⁴, and the European Chemicals Agency (ECHA) database that contains registration dossiers submitted for REACH chemicals

(https://echa.europa.eu/information-on-chemicals/registered-substances). Though the ECHA database was searched, relevant data could not always be analyzed to the same degree as other included studies because the information is not peer reviewed and the database often only contains summaries of study findings. For example, the study's No Observed Effect Level (NOEL) may be listed, but the study summary does not present underlying data such as mean or standard deviation. When available, relevant findings from studies in ECHA are presented separately from those available in the published literature. Additionally, the numbers of studies available in ECHA for each chemical and study type are listed in the results tables in order to indicate the availability of the data.

Study Selection Criteria

Studies were screened for inclusion using a structured form in DistillerSR (Evidence Partners; <u>http://www.evidencepartners.com</u>). In order to be eligible for inclusion, studies needed to comply with the criteria specified by the PECO statement (Table 2). Studies that did not meet the PECO criteria were excluded. In addition, the following exclusion criteria were applied: studies that did not contain original data, such as reviews, editorials, or commentaries, or that were conference abstracts.

Two members of the evaluation design team (K.E.P. and K.A.T. or P.R.) independently conducted title and abstract screening of the search results to determine whether a reference met the inclusion criteria; studies not excluded based on the title and abstract were screened through a full-text review. Full-text copies of potentially relevant studies were reviewed by one author (K.P.) and exclusions confirmed by a second author (K.A.T. or P.R.). Discrepant screening

results were resolved by discussion. Native-language speakers at NIH facilitated the assessment of eligibility status of non-English studies.

Although beyond the scope of the current review, we also tracked studies reporting information on human exposure (detection in human blood, urine, or tissues) (<u>Supplemental Table 2</u>, posted online); wildlife (<u>Supplemental Table 3</u>, posted online); absorption, distribution, metabolism, and excretion (ADME) (<u>Supplemental Table 4</u>, posted online); and studies assessing the health effects of PHBB, TCBA, and TBBPA, which were not included past problem formulation as they have been the focus of prior literature-based evaluations (<u>Supplemental Table 5</u>, <u>Supplemental Table 6</u>, and <u>Supplemental Table 7</u>, respectively, posted online).

Extract Data from Studies

Data were extracted from studies that met the inclusion criteria using DRAGON software^{44; 45}. For each study, data extraction was done by one of the contract staff and reviewed for completeness and accuracy by a senior contractor (J.W.) and by K.E.P. The following data were collected for each study: authors, journal, reference information, year of publication, chemical, purity, dose or concentration tested, species/strain, cell line/tissue type, assay, endpoint, and AC_{50} (when reported). Dose and concentration level specific effects were summarized based on statistical significance as reported in the research studies. For in vivo studies, measures of effect at each dose or concentration level were extracted (e.g., mean, median, and measures of precision or variance). Findings from in vivo studies for continuous endpoints were converted to percent of control response using numbers presented in tabular form or by use of the WebPlot Digitizer⁴⁶ from graphical depictions of data. For in vitro studies, the effects were summarized as increase, decrease, or no change from a vehicle control at each dose tested. One limitation is that in the in vitro studies authors often express results as a percentage of the positive or negative control response which may miss subtle induction or inhibition effects only apparent when looking at raw data. Disagreement was resolved by discussion between reviewers. Data extraction results are stored and visualized using Health Assessment Workspace Collaborative (HAWC)⁴⁷ and are available for download in Excel format (https://hawcproject.org/assessment/46/).

Assess Internal Validity ("Risk of Bias") of Individual Human and Animal Studies

Internal validity, often referred to as "risk of bias" in systematic review, was assessed for individual human and animal studies using the OHAT risk of bias tool^{41; 48}. In brief, risk of bias questions addressed randomization, allocation concealment, similarity of conditions across groups, blinding during the study, characterization of the treatment, adequacy of the outcome assessment, concerns for missing data, and other potential threats to internal validity such as failure to control for litter effects in developmental studies. Each risk of bias question was answered on a 4-point scale: "definitely low risk of bias," "probably low risk of bias," "probably high risk of bias," and "definitely high risk of bias." Risk of bias was independently assessed by one senior contract staff (R.B.), reviewed by another (P.R), with a final review conducted by K.E.P. Any discrepancies were resolved by consensus, arbitration by an additional member of the review team, or consultation with technical advisors as needed. Risk of bias was not assessed for in vitro studies because a tool analogous to that used for human and animal studies has not yet been finalized for the NTP method.

Structural and Biological Similarity Analysis

Structural Similarity Analysis

Chemical structures (SMILES strings) were retrieved from the US EPA annotation of the Tox21 10K library⁴⁹ (Supplemental Table 1, posted online). Structures were not available for two BPA analogues that are polymers (D90 and UU). For chemicals that were not contained in the Tox21 library a SMILES string was identified in the EPA Chemical Dashboard (https://comptox.epa.gov/dashboard) by searching with CASRN. Smiles strings were loaded into the Leadscope Model Applier software (Version 3.1; Columbus, OH) and the presence or absence of a total of 8,026 structural features representing medicinal chemistry building blocks were annotated to the chemicals. Tanimoto coefficients (chemical structure similarity metric) for the structural features were then calculated for all pairs of chemicals. Pairs of chemicals with Tanimoto coefficients close to 1 are quite similar and those close to 0 have limited similarity.

HTS Data

Analyses of HTS data from Tox21⁵⁰ and ToxCast⁵¹ focused on evaluating structural and biological similarity among the BPA analogues and relative to BPA or E₂. Fifteen BPA analogues (TGSA, BPC, 4,4-BPF, TBBPA, PHBB, BPS, TCBPA, 2,2-BPF, BPE, TMBPA, BPAF, BPZ, BPB, BPPH, BPS-MPE) were included in the Tox21 library, 4 (TGSA, TBBPA, BPAF, BPB) were included in the ToxCast Phase I/II libraries, and 6 were included in the ToxCast E1K library (PHBB, BPS, TCBPA, 2,2-BPF, BPB, BPAF) (<u>Supplemental Table 1</u>, posted online), which is an additional set of 800 compounds that are part of the Endocrine Disruption Screening Program (EDSP21) and that have only been tested in the endocrine-related subset of ToxCast assays⁵². Although not included in the HTS similarity profiling.

Biological Similarity Analysis Based on HTS Data

The biological similarity was assessed either in the scope of BPA analogues themselves (analysis #1), in the scope of pharmaceutical estrogens (analysis #2) or in the scope of the whole Tox21 library (analysis #3). In the first analysis, the activity values (AC_{50} ; concentration eliciting a half-maximal response) of chemicals in Tox21 assays were retrieved from https://ntp.niehs.nih.gov/sandbox/tox21-activity-browser/⁵³. Activities that were potentially confounded by interferences such as compound auto-fluorescence and compound cytotoxicity were flagged as inconclusive⁵³. The similarity of chemicals was viewed as a dendrogram based on the results of hierarchical clustering with average linkage using AC_{50} values (-log10(M), 1M is set for inactives or inconclusives). At the time of analysis, 24 assays targeting nuclear receptor signaling pathways and stress response pathways were used (Supplemental Table 8, posted online). Most Tox21 assays detect the target of transcriptional factor activity using reporter gene transcription technology (https://ncats.nih.gov/tox21/projects/nrassays). BPA and E₂ were included for comparison. The ToxPI tool⁵⁴ was used to compare the potency (AC_{50}) between BPA analogues, BPA, and E₂, relative to the most potent chemicals in the library (Supplemental Table 8, posted online).

In the second analysis, the activity values (wAUC, weighted area under the curve)⁵³ from 55 assays (cell viability assays included) including 441 outputs were used. The activity of the BPA

analogues was first compared to that of a set of Tox21 chemicals similar to E_2 , then more broadly to the entire Tox21 chemical library. The E_2 set was defined as all of the Tox21 chemicals with Tanimoto similarity to beta-estradiol of greater than 0.5 (see Appendix A. Supplemental Materials).

In a third analysis, similarity to BPA or E₂ was determined for the BPA analogues in Tox21 in addition to all other chemicals run as part of Tox21. Log transformed +1 wAUC values from a total of 441 assay metrics across 55 assays were used to determine the Pearson correlation coefficient between E₂ or BPA and chemicals in the Tox21 library. Assays for which there were no data for one or both of the chemicals were omitted from the calculation. A bootstrap resampling method was used to calculate the 95% confidence intervals. For each pair of chemicals, a bootstrap sample was generated by resampling with replacement from the pairs of wAUC values for those chemicals, and the correlation coefficient for these resampled values was generated. This procedure was performed 1,000 times. If the resampled data could not be used to compute a correlation coefficient (e.g., if all data points had wAUC values of 0 (i.e., inactive) for both assays), the value of the correlation coefficient was treated as 0. The 95% confidence limit was calculated as the range from the 2.5th to 97.5th percentiles of the bootstrapped values. P values for the correlation coefficients were also calculated. The p value of the observed correlation was calculated as the fraction of the bootstrapped correlation with absolute values greater than the observed correlation value, under the null hypothesis of no correlation. Chemicals with less than high quality ("A" rating for purity, defined as >90% and molecular weight identity confirmed) were removed from the analysis to avoid spurious results. For visualization purposes correlation values represent an average by CASRN when the chemical was present more than once in the library (i.e., the chemical had multiple Tox21 IDs).

Integrated Chemical and Biological Similarity

Chemical structural similarity data from above was merged with biological similarity data from the biological similarity analysis #3 to yield a plot illustrating a trend of increasing biological similarity with chemical similarity for the BPA analogues in the context of the entire Tox21 library.

Results

Literature Search Results

The literature searches yielded 5,124 unique studies and an additional 8 studies were identified while reviewing included studies. Of these, 4,783 were excluded during title and abstract screening. Three hundred forty nine studies were reviewed at the full text level, and 166 were identified as relevant to the PECO statement (Figure 1). Nine of the 166 studies (5%) were non-English⁵⁵⁻⁶³.



Figure 1. Study Flow Diagram

Study flow diagram. Describes the number of studies processed at each step of the evaluation. ^aRecords were broadly characterized by evidence stream (human, animal, in vitro), type of health outcome, and chemical. No results are extracted or summarized.

There was very little to no toxicity data available for many of the BPA analogues. Sixteen of the 24 BPA analogues had been reported on in at least 1 publication, but only ten had been evaluated in more than three studies. Most studies reported on in vitro data (n = 130), whereas fewer (n = 40) reported on in vivo data and only 4 studies reported on human epidemiological data (Figure 1, Table 3). There were no studies recovered from the literature search for eight of the 24 BPA analogues (BPS-MAE, BPS-MPE, BTUM, D-90, DD-70, MBHA, TGSA, UU). These eight BPA analogues were listed in the 2014 US EPA DfE Report where their potential hazards were summarized based largely on values from estimation software, professional judgment, analogy to experimental data for a structurally similar compound, or, where available, submitted

confidential studies¹⁵ (<u>Supplemental Table 11</u>, posted online). One of these chemicals (BPS-MAE) and BDP, BPS, and Pergafast 201 were included in the ECHA database (See Appendix A. Supplemental Materials).

Chemical	Human	Animal	In Vitro
4,4-BPF	3	15	61
BPS	1	9	52
BPAF	0	10	41
BPB	0	9	35
BPC	0	5	22
BPE	0	3	23
BPZ	0	3	15
TMBPA	0	1	14
BPAP	0	2	9
BPP	0	0	6
2,2-BPF	0	2	1
BDP	0	1	2
2,4-BPS	0	1	1
ВРРН	0	0	2
D-8	0	0	2
Pergafast 201	0	0	1

Table 3. Inventory of Published Literature by Chemical and Evidence Stream

Survey of Evidence

Human Evidence

Four human studies reported information on exposure to BPA analogues and contact dermatitis⁶⁴⁻⁶⁷. No other health outcomes were assessed in the human studies. In the four human studies patients or workers with suspected allergic contact dermatitis were patch tested with one or more of the BPA analogues or additional chemicals that they may have come in contact with including plastics, epoxy resins, glues, and hardeners. Dermal patch testing with BPF (both the 2,2- and 4,4-isomers) caused some reactions in patients or workers^{64; 65; 67}. In contrast, dermal patch testing with BPS did not elicit an effect⁶⁶.

Animal Evidence

Forty experimental animal studies reporting on 13 BPA analogues were identified from the published literature and are summarized in Table 4 following the definitions provided in¹⁵. The most commonly studied BPA analogues were 4,4-BPF (n = 15 studies), BPAF (n = 10 studies), BPB (n = 9 studies) and BPS (n = 9 studies). Eleven studies assessed uterotrophic responses (4,4-BPF, BPS, BPZ, BPB, 2,2-BPF, BPAF, BPC, BPAP), five studies assessed subchronic exposure (BPAF, 4,4-BPF, BPZ, BPS), eleven studies assessed sensitization), and none assessed

chronic toxicity. Doses in rodent studies ranged from 2 to 32,000 mg/kg-day. Only one rodent developmental study, for BPAF, was identified from the published literature⁶⁸. Otherwise all developmental or reproductive studies from the published literature were in fish models testing concentrations of 0.1 to 1,500 μ g/L. Additional animal studies including developmental, reproductive and aquatic toxicology endpoints were identified in the ECHA database for BPS, BDP, BPS-MAE, and Pergafast 201 (Table 4).

	4,4- BPF	BPS	BPAF	BPB	BPC	BPE	BPZ	TMBPA	BPAP	2,2-BPF	BDP	2,4-BPS	BPS- MAE	Pergafast
Number of Studies	15	9 [31]	10	9	5	3	3	1	2	2	1 [126]	1	[21]	[14]
Endpoint Classifica	ation (Nu	mber of Studi	ies by End	dpoint)										
Acute Toxicity	1 ^R ,1 ^{Rb}	$1^{R}, 1^{Rb}, 1^{GP}$ [$5^{R}, 2^{M}, 2^{GP}$]	1 ^R	_	1 ^R	_	_	_	_	_	[21 ^R , 2 ^M]	1 ^R , 1 ^{Rb}	[4 ^R]	[3 ^R]
Carcinogenicity	-	_	_	_	_	_	_	_	_	_	_	_	_	_
Reproductive	_	$2^{ZF} [1^R]$	2^{ZF}	_	_	_	_	_	_	_	[2 ^R]	_	[1 ^R]	[1 ^R]
Developmental	$1^{\rm ZF}$	$2^{ZF} [1^R]$	1 ^R , 3 ^{ZF}	1^{ZF}	_	1^{ZF}	_	_	1^{ZF}	_	[9 ^R]	_	[2 ^R]	_
Neurological	_	1^{ZF}	_	_	_	_	_	-	_	_		_	_	_
Repeated Dose	1^{R}	1 ^R [3 ^R]	$2^{R}, 1^{ZF}$	_	_	_	1^{R}	-	_	_	[16 ^R]	_	[1 ^R]	[3 ^R]
Skin Sensitization	1^{GP}	1 ^{GP} [1 ^M , 2 ^{GP}]	-	_	_	-	_	_	_	1^{GP}	[14 ^{GP}]	-	[2 ^{GP}]	[1 ^{GP}]
Eye Irritation	1^{Rb}	$1^{Rb} [4^{Rb}]$	_	_	1^{Rb}	_	_	_	_	_	[13 ^{Rb} , 1 ^P]	_	[2 ^{Rb}]	[1 ^{Rb}]
Dermal Irritation	$1^{\text{GP}}, 1^{\text{Rb}}$	1 ^{GP} [3 ^{Rb} , 1 ^{GP}]	-	_	1^{Rb}	-	_	-	-	1^{GP}	[13 ^{Rb}]	-	[2 ^{Rb}]	-
Endocrine Activity	8 ^R	$1^{R}, 1^{ZF}$	3 ^R	7 ^R	1 ^R	_	2 ^R	1^{Fr}	1 ^R	1^{R}	_	_	_	_
Aquatic Toxicity (Acute)	1 ^D	$2^{D} [2^{F}, 2^{D}]$	-	1 ^D	1 ^D	1 ^F , 1 ^D	-	-	_	_	1 ^D [12 ^F , 14 ^D]	_	[2 ^F , 2 ^D]	[1 ^{ZF} , 1 ^D]
Aquatic Toxicity (Chronic)	_	[1 ^D]	-	_	_	-	_	_	_	_	[1 ^{ZF} , 1 ^F , 8 ^D]	-	[1 ^F , 1 ^D]	[1 ^F , 1 ^D]
Other Studies	$1^{M}, 1^{GP}$	1^{F}	_	_	2^{P}	_	_	-	_	_	_	_	_	_
Doses Tested														
Range (mg/kg) in Mammalian Studies	2– 1,000	10-32,000	4– 11,000	2–600	25–63	_	6–300	_	not listed	2–200	15–5,000	1,400– 10,000	100– 2,000	12.5– 2,000
Range (µg/L) in Aquatic Studies	200– 14,016	0.1–500,000	5– 23,536	242– 16,692	-	214– 14,998	-	2.84–284	290– 20,325	_	21– 100,000	_	66– 14,000	890– 86,000

Table 4. Summary of Animal Evidence

Superscript indicates species: ^RRat, ^MMouse, ^{GP}Guinea Pig, ^{Rb}Rabbit, ^PPoultry, ^{Fr}Frog, ^{ZF}Zebra Fish, ^FOther Fish, ^DDaphnia. Numbers in [] are from ECHA database and are not included in any of the summary or overall counts. – indicates no studies were found.

In Vitro Evidence

One hundred thirty in vitro studies reporting on 16 BPA analogues were identified in the published literature. These studies are summarized in Table 5. Although many of the studies evaluated multiple BPA analogues or other chemicals, approximately half (70/130) reported on the effects of only a single BPA analogue, thus limiting ability to make direct comparisons across studies on the BPA analogues. Eighty-six of the 130 studies evaluated the ability of the BPA analogues to interact with nuclear receptors; for example, interaction with the estrogen receptor was reported in 68 studies and interaction with the androgen receptor was reported in 18 studies). In vitro studies of genetic toxicity were also summarized in the ECHA database for BPS, BDP, BPS-MAE, and Pergafast 201 (Table 5).

Health Outcomes and Mechanistic Findings

Repeated Dose Effects

Subchronic effects of repeated exposure (13–28 days) to BPAF, 4,4-BPF, BPZ or BPS were evaluated in five rodent studies in the published literature⁶⁹⁻⁷³ (Figure A-1, Figure A-2) and 23 additional studies in the ECHA database. These studies evaluated changes in body and organ weight as well as other signs of toxicity, such as clinical chemistry. Overall, the most sensitive endpoints include body, kidney, brain, and liver weight (Table 6). In addition to the publicly available literature, there were 28- and 90-day repeated dose studies available in the ECHA database for BPS, BPS-MAE, BDP and Pergafast 201 (Table 6). BDP did not appear to cause any treatment related effects, including on body weight^{74; 75}, and there were no study details available for the one study reporting subchronic exposure of rats to BPS-MAE⁷⁶.

Reproductive and Developmental Effects

Only one rodent developmental study was identified from the published literature. In this study, rats were dosed with BPAF via gavage at 200 to 500 mg/kg-day from gestation day 14 to 18 and testosterone production was evaluated in the male offspring at gestation day 18⁶⁸. Developmental exposure to BPAF did not alter fetal testosterone production in this assay. In addition, there were reproductive and developmental rodent studies identified in the ECHA database for BPS, Pergafast 201, BDP, and BPS-MAE, which are summarized in <u>Supplemental Table 1</u>, posted online.

Pergafast 201 decreased F1 body weight at the same dose that caused maternal kidney and liver toxicity (200 mg/kg-day). BPS reduced the number of F1 offspring at the same dose that disrupted maternal estrus cyclicity and implantation (300 mg/kg-day). There were no effects reported for BDP and no information available for BPS-MAE.

Reproductive and developmental effects of exposure to six BPA analogues (4,4-BPF, BPS, BPAF, BPB, BPE, BPAP) were tested in zebrafish models (Table 4)⁷⁷⁻⁸². Developmental exposure to all of these BPA analogues except 4,4-BPF (which was only tested in a single study) caused some degree of morphological malformation ranging from pericardial edema to otic vesicle deformities, for example. Steroidogeneisis and hatching endpoints were disrupted in adult zebrafish exposed to BPS or BPAF^{79; 81}.

	4,4- BPF	BPS	BPAF	BPB	BPC	BPE	BPZ	TMBPA	BPAP	BPP	2,4- BPS	2,2- BPF	BDP	BPPH	D-8	Perga fast 201	BPS- MAE
Number of Studies in Published Literature	61	52	41	35	22	23	15	14	8	6	1	1	2	2	2	1	0
Endpoint Classification (Total Number for	Each E	ndpoin	nt)														
Estrogen Receptor (68)	32	26	29	25	13	13	11	8	5	3	-	1	-	1	2	[1]	_
Androgen Receptor (18)	13	11	5	6	3	4	2	1	_	_	_	_	_	_	1	1	_
Thyroid Receptor (6)	1	1	3	1	3	1	-	4	_	_	_	_	_	_	_	_	_
Cytotoxicity (11)	2	7	1	1	1	1	_	_	-	-	_	_	1	-	1	1	_
Miscellaneous/Not Otherwise Classified (25)	13	11 [1]	1	3	1	3	-	3	1	-	_	_	1	-	1	1	_
Adipocytes (3)	2	2	_	2	-	2	-	_	-	-	-	-	-	-	_	-	_
Pregnane X Receptor (3)	3	3	2	1	_	1	1	1	_	-	_	-	-	_	_	_	_
Constitutive Androstane Receptor (2)	2	2	1	_	_	_	1	1	_	-	_	-	-	_	_	_	_
Estrogen Related Receptor γ (3)	2	1	3	2	_	2	-	-	1	_	_	_	_	_	_	_	_
Retinoic Acid Receptor y (2)	2	2	-	2	_	2	1	-	_	_	_	_	_	_	_	_	_
Retinoid-related Orphan Receptor $\gamma(1)$	1	1	-	-	1	1	1	-	1	1	_	_	_	1	_	_	_
Glucocorticoid Receptor (3)	2	2	1	-	1	_	1	_	-	1	_	_	_	-	_	_	_
Aryl Hydrocarbon Receptor (1)	1	1	_	1	_	1	_	_	_	_	_	_	_	_	_	_	_
Albumin or SHBG Binding (5)	1	2	2	1	_	_	_	_	_	_	_	_	_	_	_	_	_
Genotoxicity (14)	8	6 [10]	5	-	6	1	1	1	1	1	1	_	[36]	-	-	[3]	[4]

Numbers in [] are from ECHA database and are not included in any of the summary or overall counts. – indicates no studies were found.

Study	Animal Group	Endpoint Doses Tested (mg/kg/-day)		NOEL (mg/kg-day)	LOEL (mg/kg-day)	Direction of Change (% Change Relative to Control at LOEL)	
Published Literature							
4,4-BPF							
Higashihara et al. ⁶⁹	Female Crj:CD (Sprague-Dawley) rat	kidney weight	20, 100, 500	20	100	↑ (8.1%)	
Higashihara et al. ⁶⁹	Female Crj:CD (Sprague-Dawley) rat	body weight	20, 100, 500	_	20	↓ (11.6%)	
Higashihara et al. ⁶⁹	Female Crj:CD (Sprague-Dawley) rat	brain weight	20, 100, 500	-	20	↑ (14.1%)	
BPAF							
Feng et al. ⁷¹	Male Sprague-Dawley rat	body weight	2, 10, 50, 200	10	50	↓ (12.3%)	
Umano et al. ⁷⁰	Female Sprague-Dawley rat	body weight	10, 30, 100	10	30	↓ (7.3%)	
BPZ							
Yamasaki and Okuda ⁷²	Male CRL:CD (Sprague-Dawley) rat	heart weight	30, 100, 300	30	100	↓ (10.9%)	
Yamasaki and Okuda ⁷²	Male CRL:CD (Sprague-Dawley) rat	serum T4	30, 100, 300	_	30	↑ (14.7%)	
ECHA Database							
BPS	Male Wistar rat	kidney weight	100, 300, 1000	_	100	↑ (10%)	
BPS-MAE	Female Crj:CD (Sprague Dawley) IGS rat	clinical signs	40, 200, 1000	200	_	Details not provided.	
BPS-MAE	Male Crj:CD (Sprague Dawley) IGS rat	kidney weight	40, 200, 1000	40	200	↑ (Details not provided.)	
BDP	Male and female Sprague-Dawley rat	_	_	1000	_	Details not provided.	
Pergafast 201	Female Wistar rat	liver weight	12.5, 25, 50, 150	_	12.5	↑ (14.7%)	

Table 6. Summary of Most Sensitive Endpoints in Subchronic Studies	

- indicates no studies were found.

Estrogenic and Anti-estrogenic Activity

Seven studies evaluated the effects of BPAF, BPB, 2,2-BPF, 4,4-BPF, BPS, and BPZ on the uterotrophic response and 68 studies assessed estrogenic effects in vitro, mostly for 4,4-BPF (32), BPS (26), BPAF (29), BPB (25), BPC (13), BPE (13), TMBPA (8), and BPAP (6) (Table 5). Like BPA, the BPA analogues were shown to have varying levels of estrogenic activity in the test systems evaluated, but the majority had activity within the same order of magnitude as BPA. However, all chemicals tested were less potent than positive control reference agonists such as E₂.

In vivo estrogenic endpoints evaluated included (a) the uterotrophic response (Figure 2, Figure A-3, Figure A-4)⁸³⁻⁸⁹, (b) the uterine glycogen deposition response⁹⁰, (c) assessment of vaginal smears for cornified cells^{87; 91-93}, and (d) measurement of vitellogenin^{78; 80-82} or other E₂-responsive genes in fish⁷⁹. The uterotrophic assay is a standard assay in which juvenile or ovariectomized rodents are administered test substance for three to five days after which time the effects on uterine growth are observed. The BPA analogues tested in this assay (BPAF, BPB, 2,2-BPF, 4,4-BPF, BPS, BPZ) were all uterotrophic (Figure 2, Figure A-3, Figure A-4). Because the chemicals were not tested over the same dose range it is difficult to assess which chemical is the most potent in this assay. In general, however, 2,2-BPF and BPS appeared to be weaker than the other tested analogues. Another well-characterized assay for determining estrogenicity is the induction of vitellogenin (VTG) gene or protein expression in juvenile or male fish. BPS⁸⁰ and BPAF^{78; 81; 82} both induced plasma or liver VTG expression (Figure A-5). In the one study that evaluated both BPA and BPAF, BPAF was more potent (more estrogenic) than BPA at inducing VTG⁸².

In vitro estrogenic endpoints were evaluated for fourteen BPA analogues in 68 studies (Table 5). In vitro estrogenic endpoints evaluated included (a) receptor binding, (b) modulation of cellular proliferation, (c) modulation of reporter genes transfected into immortalized cell lines, (d) modulation of endogenous estrogen-responsive genes and proteins (e.g. progesterone receptor) or steroidogenesis, (e) the ability to recruit co-regulatory elements, (f) induction of non-genomic signaling pathways, and (g) interaction of ER with ERE. Because of the wealth of in vitro estrogenic endpoints, the results of each of these types of assays is discussed in detail in Appendix A. Supplemental Materials.

The largest number of chemicals were tested in the MCF7 cell proliferation and the reporter gene assays (Table 7). Ten of the BPA analogues demonstrated estrogen receptor agonism in one or more of the assays at concentrations $\leq 1 \mu M$ (BPE, BPP, BPAF, BPS, 4,4-BPF, BPC, BPB, BPZ, BPAP, TMBPA). BPAF was consistently one of the most potent BPA analogues in the estrogen agonist and antagonist assays (Figure 2C). Conversely BPS and TMBPA, tended to be some of the least potent BPA analogues in stimulating MCF7 cell proliferation⁵⁶ but one of the weakest at binding ER⁹⁴. D8 was not active in any of the estrogen activity assays it was tested in (ER binding, reporter gene, and steroidogenesis assays)⁹⁵⁻⁹⁷ but did antagonize E₂ activity at 50 μ M⁹⁵. In Tox21 BPAF was the most potent ER agonist of the BPA analogues, and was more potent than BPA. BPZ, BPC, TMBPA, 4,4-BPF, BPB, BPE, BPS displayed ER agonism similar to BPA (AC₅₀ between 0.2 and 2 μ M). PHBB was weaker (AC₅₀ ~20 μ M). 2,2-BPF, TCBPA, TBBPA only stimulated the partial receptor at ~50 μ M. ER antagonism at ~50 μ M was observed for TGSA, TCBPA, BPZ, BPC, TMBPA, BPAF, BPE, BPE, and BPB.

Lowest Effect Level Reported (µM)							
	ER Binding	MCF7 Cell Proliferation	Reporter Gene Assay	Tox21 ER Reporter Assay	Endogenous Gene and Protein Expression ^a	Steroidogenesis	ER Binding to ERE
BPE	100	0.00001	0.01	_	10	3.14	_
BPP	_	0.00001	2.51	_	_	_	_
BPAF	0.0003	0.001	0.001	_	0.01	_	0.01
BPS	1	0.01	0.0001	_	10	ND	1
4,4-BPF	0.01	0.01	0.01	_	1	3.14	0.01
BPC	0.01	0.01	0.04	_	0.1	_	1
BPB	0.023	0.01	0.1	_	0.1	6.25	0.01
BPZ	_	10	0.0043	_	10	_	0.01
BPAP	_	10	5	_	10	-	0.01
BPPH	_	10	_	_	_	-	_
TMBPA	_	_	0.73	_	1	_	0.01
D-8	ND	_	ND	_	_	ND	_
Pergafast 201	_	_	_	_	_	ND	_

^aMost of these tested at only a single dose. ND, not detected.



Uterine Weight After 3 Day Exposure in Weanling Rats



В

2,2'-Bisphenol F	Rat, Crj:CD(SD) (♀, N=6)	0	H H
	(¥, ₩-5)	2 20 200	
4,4'-Bisphenol F	Rat, Crj:CD(SD) (♀, N=6)	0 100 300 1,000	
Bisphenol AF	Rat, Crj:CD(SD) (♀, N=6)	0 8 40 100	
Bisphenol B	Rat, Crj:CD(SD) (♀, N=6)	0 2 20 200	
Bisphenol S	Rat, Crj:CD(SD) (♀, N=6)	0 20 100 500	
Bisphenol Z	Rat, Crj:CD(SD) (♀, N=6)	0 6 30 150	
	Bisphenol AF Bisphenol B Bisphenol S	(♀, N=6) Bisphenol AF Rat, CrjCD(SD) Bisphenol B Rat, CrjCD(SD) Bisphenol B Rat, CrjCD(SD) Bisphenol S Rat, CrjCD(SD) Bisphenol S Rat, CrjCD(SD) Bisphenol Z Rat, CrjCD(SD)	100 300 300 1,000 Bisphenol AF Rat, CrjCD(SD) 0 (Q, N=6) 8 40 100 Bisphenol B Rat, CrjCD(SD) 0 (Q, N=6) 0 2 200 200 200 Bisphenol S Rat, CrjCD(SD) 0 (Q, N=6) 0 20 Bisphenol S Rat, CrjCD(SD) 0 100 500 100 Bisphenol Z Rat, CrjCD(SD) 0 (Q, N=6) 0 20 30 100 500



Figure 2. Estrogenic Activity

(A) Summary of uterotrophic responses (dry, absolute uterine weight) following three days of exposure in weanling rats. Live link with all available uterotrophic data available in Figure A-3; (B) Summary of uterotrophic responses (dry, absolute uterine weight) by dose and % change from control for studies with subcutaneous exposure. Live link available for all routes of exposure and data reporting subtypes (dry or wet weight, relative or absolute) available in Figure A-4; (C) Scatterplot showing the relationship between reported AC₅₀ values (μ M) for BPA and BPAF, 4,4-BPF or BPS. Agonist assays are shown with closed diamonds and antagonist assays are shown with open circles. The color of the symbol indicates the type of assay (androgen-blue; estrogen-red; cell toxicity-black, estrogen related receptor (ERR)-purple, glucocorticoid receptor-green; steroidogeneisis of other hormones-orange). When the BPA analogue has an AC₅₀ more potent than BPA the points fall above the black line and when the BPA analogue has an AC₅₀ less potent than BPA the points fall below the black line.

Androgenic and Anti-androgenic Activity

In vivo endpoints to assess androgen-regulated outcomes included (a) the Hershberger assay⁸⁵, (b) disruption of testis function in rats exposed as adults⁷¹ or developmentally⁶⁸, and (c) male reproductive organ weights after subchronic exposure^{69-71; 98-100}. The lack of effects following developmental and subchronic exposures to BPAF, 4,4-BPF, BPZ, BPS, BPS-MAE, BDP, or Pergafast 201 have already been discussed above^{68-72; 74; 75; 98-101}. In the Hershberger assay adult male Brl Han:WIST Jcl rats were exposed for 10 days to 50, 200 or 600 mg/kg-day BPAF, BPB or 4,4-BPF via oral gavage⁸⁵. There were few effects reported from the Hershberger assay except that exposure to BPB (200 and 600 mg/kg-day) and BPAF (200 mg/kg-day) decreased the relative bulbo cavernous/levator 2ani muscle weight and BPAF (600 mg/kg-day) increased relative glans penis weight (Figure A-13).

Both androgen agonism (Figure A-14) and antagonism (Figure A-15) were assessed in vitro. Androgen endpoints in vitro included (a) receptor binding, (b) reporter gene activity, (c) cellular proliferation, and (d) steroidogenic production of testosterone, androstenedione, or dehydroepiandrosterone. Androgen receptor (AR) binding was only explored for two analogues, BPB and BPS; BPB was found to bind AR with similar potency to BPA^{102; 103} whereas BPS only bound AR weakly¹⁰². Eight analogues (BPAF, BPB, BPC, BPE, 4,4-BPF, BPS, BPZ, TMBPA) were tested for AR agonist activity (Figure A-14). There was very limited evidence of weak agonism for two analogues (4,4-BPF, and BPS), but this was not replicated in other studies of the same chemicals. All eight analogues were, however, anti-androgenic in the range of 0.01 to 100 µM (Figure A-15). TMBPA and BPAF were the most potent anti-androgens, with TMBPA ten times more potent that the positive control anti-androgen flutamide¹⁰⁴. Of the anti-androgenic analogues, BPS appeared to be the weakest, acting as an anti-androgen in some assays but not others. Two additional BPA analogues, D-8 and Pergafast 201, were also tested for AR activity in a single study in which neither analogue altered androgen steroidogenesis⁹⁷ (Figure A-11). In Tox21, none of the analogues were AR agonists. Like BPA, TBBPA, BPAF, BPB, BPZ, BPE, 4,4-BPF, 2,2-BPF, BPC, TGSA, TMBPA were AR antagonists in the Tox21 assays between 3 and 100 µM. BPS, TCBPA, PHBB, were inactive in Tox21 AR antagonist assays.

Thyroid and Anti-thyroid Activity

In vivo studies of thyroid disruption were identified for 4,4-BPF, BPAF, BPS, TMBPA, and BPZ and included evaluation of thyroid hormone levels in rats^{69; 70; 72} or fish^{80; 81}, and disruption of frog metamorphosis¹⁰⁵ (Figure A-16). Subchronic (28 day) studies were performed in young adult rats in which increased plasma T4 was observed in males exposed to 4,4-BPF (500 mg/kg-day)⁶⁹, BPAF (100 mg/kg-day)⁷⁰, or BPZ (30 mg/kg-day)⁷² and in females exposed to 4,4-BPF (20 mg/kg-day) and BPAF (100 mg/kg-day). In male rats treated with 500 mg/kg-day 4,4-BPF the T4 increase was accompanied by a decrease in plasma T3 and an increase in relative thyroid weight⁶⁹. In adult zebrafish treatment for 75 days with BPS or 28 days with BPAF had seemingly opposite effects: exposure to BPS reduced plasma T3 and T4 in males (10 and 100 μ g/L) and females (100 μ g/L), whereas exposure to BPAF increased whole body homogenate levels of free T3 in females at 1000 μ g/L but had no effect in males^{80; 81}. In developing frogs TMBPA treatment (28.4 and 284 μ g/L) for 9 days suppressed tail regression and spontaneous metamorphosis¹⁰⁶.

In vitro studies of thyroid hormone receptor activity were identified for 4,4-BPF, BPS, BPAF, BPB, BPC, BPE, and TMBPA^{104; 107-111}. Endpoints used to assess thyroid hormone activity in vitro included (a) TR binding, (b) TR reporter gene activity in yeast, (c) growth hormone (GH) production in GH3 pituitary cells, (d) cellular proliferation of GH3 cells, and (e) inhibition of deiodinase or sulfotransferase activity in liver microsomes as a measure of receptor antagonism (Figure A-17, Figure A-18). Receptor binding was only assessed for TMBPA and BPC, both of which bound TR within the range of 1-100 μ M¹⁰⁷. TMBPA induced TRa and β mediated reporter gene activity between the doses of 1 and 10 µM¹¹⁰ and GH production in GH3 cells¹⁰⁴, but did not induce GH3 cell proliferation¹¹¹. The opposite effects were noted for BPC, which stimulated GH3 cell proliferation¹¹¹, but did not induce GH production¹⁰⁴. There was no evidence that BPAF, BPB, BPE, 4,4-BPF, or BPS were thyroid hormone agonists as none of these chemicals stimulated GH production in GH3 cells¹⁰⁴. BPAF, however, disrupted thyroid hormone homeostasis by inhibiting deiodinase and sulfotransferase activity in liver microsomes^{108; 109}. In the Tox21 assays there is no evidence that the BPA analogues were TR agonists or antagonists with the exception of TCBPA, which appeared to be a TR antagonist but this was confounded by concurrent cytotoxicity.

Other Receptor Activity

The ability of BPA analogues to interact with additional nuclear receptors (PXR, CAR, ERRy, RARy, RORy, GR, and AhR) was also explored in the in vitro studies we identified (Figure A-19). There were three or fewer in vitro studies identified for each of these nuclear receptors. Of these, only ERRy was also evaluated in vivo, where three of five tested BPA analogues disrupted otolith development in zebrafish⁷⁷. In vitro 4,4-BPF, BPAF, BPB, and BPE bound ERRy, induced the expression of a reporter gene, and antagonized the activity of the ERR γ inverse-agonist 4-hydroxytamoxifen^{112; 113}. Several of the analogues were found to be agonists for PXR and one or more CAR isoform (4,4-BPF, BPAF, BPB, BPE, BPZ, TMBPA)^{114;} ¹¹⁵, which was consistent with the results from Tox21 that indicated these and BPC to be agonists and BPZ and BPAF to be CAR antagonists. However, some of these findings were not repeated with endogenously expressed receptors^{116; 117}. TMBPA, BPAF, BPC BPB, were found to be GR antagonists in Tox21. Though there was relatively little information on GR activity in the published literature it appeared that 4,4-BPF competitively bound GR but BPP and BPS did not^{118; 119}. 4,4-BPF, BPB, BPE, and BPZ did not bind RARy, nor did they or BPAF, BPAP, BPC, and BPS bind ROR $\gamma^{120; 121}$. In contrast, in the Tox21 analysis, BPAF, BPC, BPB, TGSA were identified as RORy antagonists.

Acute Toxicity and DNA Damage

Acute oral and dermal toxicity studies reported the lethality in 50% of the exposed animals (LD_{50}) following a single exposure. The studies identified from the database search all appeared to be company documents submitted to US EPA and contained very few study details^{73; 122-124}. Of these studies, BPC had the lowest LD₅₀ of 25 mg/kg in orally exposed mice. The oral LD₅₀ for BPAF, 2,4-BPS, and BPS ranged from 3,600 to >7,000 mg/kg. Several studies of acute oral and dermal toxicity for BPS, Pergafast 201, BDP and BPS-MAE were also identified in the ECHA database where the LD₅₀ was in the rage of 1,600 to >5,000 mg/kg.

In vitro analyses of DNA damage and toxicity were identified in the published literature as well as in the ECHA database and included (a) Ames test, (b) CHO/HGPRT mutation assay,

(c) chromosomal aberration assays, (d) Comet assay, (e) micronucleus assay, (f) cellular proliferation, (g) cell transformation assay, and (h) expression of p53 or yH2AX (Figure A-20). The tests use different cell types, different methods with or without metabolic activation, and not all reported if concurrent cytotoxicity was an issue. As noted in the figure, a large number of the studies found some increase in genotoxicity compared to vehicle treatment conditions. There were also some decreases in measures of genotoxicity that could not always be explained by increases in cytotoxicity. 4.4-BPF was the most studied (Table 5) with increases in genotoxicity noted in the Ames assay with and without metabolic activation and in cell transformation studies. Similar results were also observed with BPAF, but more consistent results were observed for increased chromosomal aberration. Genotoxicity was consistently increased by BPC as observed in the cell transformation, chromosomal aberration, micronuclei assays, or the Ames assay with or without metabolic activation. The other analogues tested for genotoxicity (BPAP, BPB, BPE, BPP, BPS, BPZ, and TMBPA) either had conflicting results or there were not enough of the same tests to form conclusions (Figure A-20), but there was a suggestion of increased genotoxicity for each of these. In Tox21, BPAF and BPB induced p53 between 50 and 60 µM. In most cases the mitochondrial toxicity assay was the most sensitive assay for cell stress in Tox21. For the most part the AC₅₀ for mitochondrial toxicity was $\geq 10 \,\mu$ M, except for TCBPA and BPAF, in which the AC₅₀ was $<5 \mu$ M. There were no indications of DNA damage or cell stress after BPS exposure in the Tox21 assays.

Other Endpoints

A handful of additional endpoints have been explored for the BPA analogues. Binding to alpha fetoprotein or sex hormone binding globulin has been evaluated for BPB, 4,4-PBF, and BPAF^{103;}^{125; 126}. In vitro neurotoxicity was assessed for BDP and BPAF^{127; 128}. A few studies evaluated the lipid metabolism and adipogenic activity of BPS, BPB, 4,4-BPF, and BPE^{117; 129; 130}. Along with various other phenolic compounds, 4,4-BPF has been extracted from the Chinese medical herb *Gastrodia elata* Blume and has been evaluated as a smooth muscle relaxant^{63; 131} an anti-inflammatory¹³², and a platelet anti-aggregating agent¹³³. Other miscellaneous effects explored include the effects of BPS on rat hearts and isolated myocytes¹³⁴, inhibition of the hypoxic response of human hepatoma cells¹³⁵, and stimulation of cells to release alkali metal cations¹³⁶.

Structural and Biological Similarity Analysis

The analyses of BPA analogues in chemical structure and HTS space is unique because not only do they allow for more analogues to be directly compared to one another than in any of the published reports, but they can also provide a broader perspective of how similar the chemicals are when considered in the context of a larger chemical set such as the entire Tox21 library (>8,000 chemicals).

Structural Similarity Analysis

The structural similarity to BPA or E_2 was assessed for the 25 BPA analogues that were tested in Tox21 (Figure 3). Two BPA analogues, D-90 and UU, were not considered in this analysis because they are polymers. Using chemical structural features to evaluate the relationship between E_2 and the BPA analogues shows a clear separation between E_2 and the BPA analogues with BPZ being the most structurally similar to E_2 (i.e., had the highest Tanimoto Coefficient). The BPA analogues are more structurally similar to BPA, with BPB, 4,4-BPF and BPE being

very similar to BPA and TGSA and PHBB being most dissimilar. A complete list of Tanimoto similarity metrics between BPA and Tox21 library can be found in <u>Supplemental Table 13</u> and <u>Supplemental Table 14</u> (column E), posted online.



Figure 3. Structural Similarity of BPA Analogues to BPA and E2

Structural similarity of BPA analogues to (A) BPA or (B) E₂. The horizontal axis is the Tanimoto coefficient (reverse scale; decreasing similarity left to right), a measure of similarity based on the presence or absence of structure features (Leadscope Enterprise v3.4) relative to the reference chemical. A larger coefficient indicates greater structural similarity. Dark circles indicate BPA analogues present in the Tox21 collection (note: BPPH, BPAP and BPS-MPE were only run in a limited number of Tox21 assays), triangles are BPA analogues absent from the collection (2,4-BPS, BPS-MAE, BPP, BPPH, DD-70, D-8, BTUM, MBHA, Pergafast 201, BDP), squares are BPA analogues present in the Tox21 collection, but not considered in elsewhere in this review (TBBPA, TCBPA, PHBB), and small circles are 8,278 non-BPA analogue chemicals from the Tox21 collection. Points are jittered in the vertical direction for clarity.

Biological Similarity Analysis Based on HTS Data

Ten BPA analogues were tested either in ToxCast Phase II or the E1K library. These chemicals were tested in a range of 316 to 882 different medium or high throughput assays. Analysis of these chemicals in ToxCast, which covers a wider biological space than Tox21, included assays on cell cycle disruption, DNA binding, growth factors, cell adhesion molecules, cytokines, and proteases that were not assessed in Tox21. The BPA analogues were listed as active in anywhere from 4% to 30% of tested ToxCast assays, most typically in assays for nuclear receptors, DNA binding, GPCR, cell cycle, and cytokines (Figure A-21). Subsequent assessments of biological

similarity consider only the Tox21 data because more chemicals were tested in this platform. Figure 4 shows the half-maximal concentration (AC₅₀) for each BPA analogue in the Tox21 assays. The ER agonism assay was the most sensitive assay for 8 of the 13 BPA analogues tested in Tox21. The BPA analogues were similar to BPA in that they tended to be 100 to 10,000 fold weaker than E_2 in stimulating ER activity. Based on evaluation of the dendogram in Figure 4, BPB had the most similar activity to BPA across the Tox21 assays, followed by BPC and BPAF. TGSA,which was not an ER agonist, had the most dissimilar activity compared to BPA, and was the only BPA analogue to activate the aryl hydrocarbon receptor (AhR). These findings are highlighted by the similarity of the ToxPI profiles for compounds within groups and the difference in ToxPI profiles between the groups (Figure 4).

The biological activity of the 13 BPA analogues was compared to that of 14 pharmacological E_2 analogues. In thirteen assays, including two AR antagonist assays, at least half of both the BPA analogue and E_2 analogue sets had decreasing activity (indicating antagonism or cytotoxicity). In three assays, including two ER agonist assays, at least half of both analogue sets had increasing (agonist) activity. For 10 of the Tox21 assay channels, including PPAR antagonist and aromatase inhibition assays, the BPA analogues set tended to have decreasing activity, while the E_2 analogue set was not consistently active. BPA analogues activated Nrf2 signaling whereas the pharmacological E_2 analogues did not. A complete listing of results of the analysis can be found in Appendix A. Supplemental Materials, and Supplemental Table 10, posted online.

Another biological similarity analysis determined the relative similarity of 13 Tox21 BPA analogues (including TCBPA, TBBPA, and PHBB) in Tox21 to BPA and E₂ in the context of the entire Tox21 library (Figure 5). This was done by determining the Pearson correlation coefficient between E₂ or BPA and the entire Tox21 library. E₂ appeared to be most similar to BPB and TMBPA. The least similar analogues to E₂ were BPPH and BPAP, neither of which were significantly associated with E₂. Overall, the BPA analogues exhibit much greater biological similarity to BPA than the average chemical in the Tox21 library. Like the above analysis, BPA appeared to be most similar to BPB, BPC, and BPE. The least similar analogues to BPA were BPS, BPAP and BPPH. All analogues, even those least similar to BPA, exhibited highly significant association with BPA in this analysis. <u>Supplemental Table 13</u> and <u>Supplemental Table 14</u>, posted online, provide a complete listing of BPA and E₂ correlation values, respectively, for the entire Tox21 library along with confidence intervals and an association statistic. Note: the values in the supplementary table are listed by substance (i.e., not averaged by CASRN) hence the same CASRN may have multiple correlation values.

Biological similarity of BPA analogues to BPA and E₂ in context of the entire Tox21 Library. The horizontal axis is the Pearson Correlation Coefficient (reverse scale; decreasing similarity left to right), computed from Tox21 HTS Assay profiles for BPA analogues each compared to BPA or E₂. A larger coefficient (i.e., close to 1) indicates greater biological similarity to BPA. Dark circles are BPA analogues, squares are BPA analogues in the Tox21 library that are not considered elsewhere in this review (TBBPA, TCBPA PHBB), triangles are reference chemicals, and small circles are 6,053 non-BPA analogues from the Tox21 collection. Points are jittered in the vertical direction for clarity. Some chemicals are present in the chemical library more than once. For these chemicals, the Pearson Correlation Coefficients were averaged to acquire a single correlation value per CASRN identifier pair. No BPA analogues were negatively correlated. BPPH, BPAP and BPS-MPE were included in the Tox21 library, however they were only screened in a limited number of assays and are therefore not included in the analysis.

Biological Activity of Bisphenol A (BPA) Structural Analogues and Functional Alternatives



Figure 4. Biological Similarity Analyses in Tox21

Biological similarity of BPA analogues evaluated in Tox21 HTS library. Plot and ToxPI depiction of selected assays based on half maximal concentrations (AC₅₀). The 24 assays in which one or more BPA analogue was active are each represented by a different symbol in the plot. Chemicals are sorted on the x-axis based on their activity similarity. The

Biological Activity of Bisphenol A (BPA) Structural Analogues and Functional Alternatives

dendogram beneath the scatterplot displays the Euclidean distance based on respective activities and a hierarchical clustering with average linkage. Raw data are available in <u>Supplemental Table 8</u>, posted online. In the ToxPI depiction of biological similarity the height of the pie slice for each assay category indicates how active that chemical is for that type of assay (i.e., $-\log(AC_{50})$) relative to the most potent chemical-assay pair within the library (i.e., dioxin and AhR agonism). The dendogram was generated based on biological similarity across the assays shown. Abbreviations are as follows: Nuclear factor erythroid 2-related factor 2 (Nrf2), estrogen receptor (ER), androgen receptor (AR), farnesoid X receptor (Fxr), Aryl hydrocarbon receptor (AhR), peroxisome proliferator-activated receptor (PPAR), thyroid receptor (TR), glucocorticoid receptor (GR), constitutive androstane receptor (CAR), retinoid-related orphan receptor (ROR), retinol signaling pathway (RSP).


Figure 5. Biological Similarity of BPA Analogues to E₂ and BPA in Context of the Entire Tox21 Library

Integrated Chemical and Biological Similarity

In vitro assay results such as those from Tox21 and chemical structure can provide complementary information on the biological effects of chemicals. We present in Figure 6 a plot that integrates the biological (from Figure 5) and chemical structure similarity (from Figure 3) of the BPA analogues relative to E₂ and BPA. This was done in the context of the chemicals from the Tox21 library, hence several of the analogues were not included, due to lack of or limited HTS data (2,4-BPS, BPPH, BPS-MAE, BPP, DD-70, BPS-MPE, D8, BPAP, BTUM, MBHA, Pergafast 201, and BDP) or lack of both HTS and structure information (D-90, UU). Chemicals shown at the upper right of the graph have the highest degree of combined similarity to BPA or E_2 (Figure 6). In the case of E_2 , the BPA analogues tend to cluster in the middle to lower left of the graph, albeit still showing some distinction from the overall set of Tox21 compounds. BPAP is not shown on the E_2 plots because its biological correlation with E_2 was less than 0.25. With BPA, the chemicals in the upper right of the graph include BPB, BPE, BPF, BPAF, and BPC. An overall assessment of the analysis suggests most of the BPA analogues exhibit a relatively high degree of combined similarity to BPA as they are all shifted to the upper right relative compared to the average chemical in the Tox21 library, suggesting that most of the BPA analogues are likely to share biological effects with BPA. This finding is less robust with E₂, although the association with E_2 is still significant (Supplemental Table 14, posted online), therefore suggesting a marginal degree of similarity may exist between E_2 and the BPA analogues.





Integrated structural and biological similarity of the BPA analogues to BPA or E_2 . Pearson correlation coefficients to BPA or E_2 of chemicals represented by multiple samples in the chemical library were averaged to acquire a single correlation value per CASRN identifier pair. BPA analogues that were not included in the Tox21 library could not be included in the graph because biological similarity could not be determined. Dark circles are BPA analogues, squares are BPA analogues in the Tox21 library that are not considered elsewhere in this review (TBBPA, TCBPA PHBB), triangles are reference chemicals, and small circles are 6,053 non-BPA analogues from the Tox21 collection. BPPH, BPAP and BPS-MPE were included in the Tox21 library, however they were only screened in a limited number of assays and are therefore not included in the analysis.

Discussion

In this review we sought to identify, synthesize and summarize the existing evidence based on associated health outcome or biological response for 24 BPA structural or functional analogues. The systematic literature search identified 166 relevant studies as well as data from the publicly available databases for the high throughput screening platforms Tox21 and ToxCast and the ECHA database. From the published literature and database searches we identified one or more studies for 17 of the BPA analogues and no studies for seven of the chemicals. The majority of the available data were in vitro (n = 130 studies), but there were also a significant amount of animal (n = 39 studies) and a few human studies (n = 4). The in vitro work focused largely on the ability of the BPA analogues to act as endocrine disrupting chemicals by binding to, activating or antagonizing various steroid receptors. Of the BPA analogues with one or more study available, there is growing evidence suggesting that most are of high concern. Eight of the 16 chemicals reviewed here and in the DfE received either a high or very high hazard ID in one or more category of human health effect or ecotoxicity (4,4-BPF, BPC, BPS, BPS-MAE, BPS-MPE, D8, Pergafast 201, and TGSA), indicating that these chemicals are of high concern¹⁵. However, these conclusions were not always based on empirical, publicly available data. The current review adds additional information and makes greater use of available in vitro data by presenting the biological and chemical similarities of the BPA analogues. When considered together, these data highlight that BPAF, BPAP, BPB, BPE, BPP, BPZ, and TMBPA are also of concern given their ability to affect endocrine related endpoints at concentrations below 1 µM. For the remaining BPA analogues, there is an overall lack of empirical evidence from which to draw conclusions. In some cases, the hazard classifications seem to range from low to moderate (UU, D-90) based on confidential studies submitted to US EPA¹⁵. For others (BPPH, 2,4-BPS, DD-70, MBHA, BTUM) there are estimates of high ecotoxicity hazard but empirical evidence is lacking¹⁵. Importantly, a lack of evidence does not indicate a lack of effect, rather it indicates that more research is needed to fully characterize the biological activity of the data poor BPA analogues.

Data Gaps and Research Needs

For some BPA analogues (4,4-BPF, BPAF, BPAP, BPB, BPC, BPE, BPP, BPPH, BPS, BPZ, Pergafast 201, TMBPA) there is sufficient evidence to suggest the potential for endocrine disruption. Despite this, we noted several limitations to the evidence base:

- Some chemicals are very data poor. For seven chemicals (BPS-MPE, BTUM, D-90, DD-70, MBHA, TGSA, UU) there were no studies either in the published literature or publicly available databases. Only 10 of the 24 chemicals were investigated in three or more studies.
- While not the focus of this review, it is apparent that there is a need for more exposure assessment. This information would help prioritize which data poor chemicals should be assessed in additional toxicological testing. As it is, the lack of exposure information makes it difficult to prioritize the data poor chemicals for subsequent testing, even when there is concern for potential hazard.
- For three chemicals (BPS-MAE, BDP, and Pergafast 201), the majority of available data was found in the ECHA database. While most of the studies included in the ECHA database are conducted according to guideline study procedures, the reports in

the ECHA database are generally lacking in presentation of study details, including methods and effect sizes.

- Risk of bias was assessed for the animal studies identified from the published literature (Figure A-22) and from the ECHA database (Figure A-23). Overall there was a general lack of reporting of key study features including randomization to study groups, allocation concealment, and blinding research personnel throughout the study and at outcome assessment. Future studies should include appropriate considerations in study design, conduct, and reporting in order to minimize bias for the exposure and outcomes considered. At a minimum, studies should include randomization of treatment and blinding of outcome assessors.
- It is important to fully characterize the nature of the dose response of each chemical on the various biological endpoints. The majority of in vitro and in vivo studies utilized more than one dose of the chemicals. The exception, however, was the assessment of gene expression which was most often performed with only a single treatment level. For a few chemicals, the only evidence for a given effect is based on a test of a single dose (e.g., MCF7 cell proliferation after treatment with BPP or BPZ). We strongly encourage researchers to perform a full dose response for all main effects tested in research studies. In this regard, since many of the endpoints examined pertain to disruption of the endocrine system, it is important that researchers be aware of the possibility for non-monotonic response curves and include low, environmentally relevant doses.
- Along similar lines, it was not always clear from some of the in vitro studies exactly what doses were tested. In some instances, only an AC₅₀ was presented with no indication of the range of doses tested [e.g., Zhang et al.¹³⁷] In other instances, results were presented qualitatively (+ or activity) [e.g., Kolle et al.¹³⁸] or relative to a positive control [e.g., Coleman et al.¹³⁹], which makes comparison of results across studies difficult. Characterization with and without metabolic activation was primarily only evident in studies of genotoxicity. While some in vitro studies utilized cell lines that display limited metabolic competency, others did not. Given how metabolism can dramatically alter the activity of these and similar chemicals, future research would benefit from further exploring this question.

Limitations of the Review

This review used a systematic review methodology to search for and extract the available data for 24 BPA analogues as of March 2015. As stated in the objectives, the aim of this review was to extract and compile all of the available evidence for this set of chemicals. Given the number of chemicals investigated, the diversity of the various biological effects that were reported, and the lack of an available tool for assessing risk of bias of in vitro studies, providing evidence synthesis conclusions was not an aim of this review. Rather, this review has highlighted the extent and nature or dearth of information available for these 24 BPA analogues. While this review was being conducted, BPA structural and functional analogues have continued to receive much needed research attention. Therefore, a further limitation of this review is the difficulty in incorporating the rapidly growing literature in this field. As such, we are aware of several more recent studies that have not been included in this data synthesis [for example Kataria et al.¹⁴⁰; Catanese and Vandenberg¹⁴¹; Wang et al.¹⁴²; Chen et al.¹⁴³].

Summary

Our results add to a growing literature indicating that risk characterizations of BPA need to expand and should begin to consider BPA structural and functional analogues¹⁴⁴. This is especially important given that the evidence presented in the current review highlights that many of the BPA analogues are active at concentrations similar to or lower than BPA. Given that many of the BPA analogues are already known to be in use (because they are found in consumer products, house dust, or in biomonitoring specimens), it is important that we increase our knowledge about their potential biological activities. We hope that this systematic review of the literature can serve as a starting point for considering the class of BPA analogues more broadly. It is our hope that future analyses can integrate information from data-rich chemicals such as BPA, BPAF, and BPS to inform scientists about the predicted biological activity of the data poor analogues and thereby avoid situations of regrettable substitution.

References

1. European Food Safety Authority (EFSA). Public consultation on the draft opinion on bisphenol A (BPA) – exposure assessment. Parma, Italy: European Food Safety Authority; 2013. https://www.efsa.europa.eu/en/consultations/call/130724 [Accessed: 8/23/13]

2. Food and Agriculture Organization and World Health Organization (FAO/WHO). 2011. Joint Food and Agriculture Organization of the United Nations and World Health Organization (FAO/WHO) expert meeting to review toxicological and health aspects of bisphenol A: Final report, including report of stakeholder meeting on bisphenol A, 1-5 November 2010. Ottawa, Canada: Food and Agriculture Organization of the United Nations and World Health Organization. http://apps.who.int/iris/bitstream/10665/44624/1/97892141564274_eng.pdf.

3. National Toxicology Program (NTP). 2008. NTP-CERHR monograph on the potential human reproductive and developmental effects of bisphenol A. RTP, NC: National Toxicology Program/CERHR. <u>https://ntp.niehs.nih.gov/ntp/ohat/bisphenol/bisphenol.pdf</u>.

4. Östberg T, Noaksson E. Bisfenol A in svenska kvitton: analysresultat. Ösavagen, Sweden: Institutet för Tillämoa Grön Kemi; 2010.

5. Ye X, Bishop AM, Reidy JA, Needham LL, Calafat AM. Parabens as urinary biomarkers of exposure in humans. Environ Health Perspect. 2006; 114(12). <u>http://dx.doi.org/10.1289/ehp.9413</u>

6. Rochester JR. Bisphenol A and human health: a review of the literature. Reprod Toxicol. 2013; 42:132-155. <u>http://dx.doi.org/10.1016/j.reprotox.2013.08.008</u>

7. vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, Farabollini F, Guillette LJ, Jr., Hauser R, Heindel JJ et al. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod Toxicol. 2007; 24(2):131-138. http://dx.doi.org/10.1016/j.reprotox.2007.07.005

8. Liao C, Liu F, Alomirah H, Loi VD, Mohd MA, Moon HB, Nakata H, Kannan K. Bisphenol S in urine from the United States and seven Asian countries: occurrence and human exposures. Environ Sci Technol. 2012; 46(12):6860-6866. <u>http://dx.doi.org/10.1021/es301334j</u>

9. Liao C, Kannan K. Concentrations and profiles of bisphenol A and other bisphenol analogues in foodstuffs from the United States and their implications for human exposure. J Agr Food Chem. 2013; 61(19):4655-4662. <u>http://dx.doi.org/10.1021/jf400445n</u>

10. Liao C, Liu F, Guo Y, Moon HB, Nakata H, Wu Q, Kannan K. Occurrence of eight bisphenol analogues in indoor dust from the United States and several Asian countries: implications for human exposure. Environ Sci Technol. 2012; 46(16):9138-9145. http://dx.doi.org/10.1021/es302004w

11. Liao C, Liu F, Moon HB, Yamashita N, Yun S, Kannan K. Bisphenol analogues in sediments from industrialized areas in the United States, Japan, and Korea: spatial and temporal distributions. Environ Sci Technol. 2012; 46(21):11558-11565. http://dx.doi.org/10.1021/es303191g 12. Liao C, Liu F, Kannan K. Bisphenol S, a new bisphenol analogue, in paper products and currency bills and its association with bisphenol A residues. Environ Sci Technol. 2012; 46(12):6515-6522. <u>http://dx.doi.org/10.1021/es300876n</u>

13. Becerra V, Odermatt J. Detection and quantification of traces of bisphenol A and bisphenol S in paper samples using analytical pyrolysis-GC/MS. The Analyst. 2012; 137(9):2250-2259. http://dx.doi.org/10.1039/c2an15961a

14. Becerra V, Odermatt J. Interferences in the direct quantification of bisphenol S in paper by means of thermochemolysis. J Chromatogr A. 2013; 1275:70-77. http://dx.doi.org/10.1016/j.chroma.2012.12.034

15. United States Environmental Protection Agency (US EPA). Bisphenol A alternatives in thermal paper (Final Report January 2014). U.S. Environmental Protection Agency; 2014. <u>https://www.epa.gov/sites/production/files/2014-05/documents/bpa_final.pdf</u> [Accessed: 3/31/14]

16. Zhou F, Zhang L, Liu A, Shen Y, Yuan J, Yu X, Feng X, Xu Q, Cheng C. Measurement of phenolic environmental estrogens in human urine samples by HPLC-MS/MS and primary discussion the possible linkage with uterine leiomyoma. J Chromatogr B. 2013; 938:80-85. http://dx.doi.org/10.1016/j.jchromb.2013.08.032

17. Zhou X, Kramer JP, Calafat AM, Ye X. Automated on-line column-switching high performance liquid chromatography isotope dilution tandem mass spectrometry method for the quantification of bisphenol A, bisphenol F, bisphenol S, and 11 other phenols in urine. J Chromatogr B. 2014; 944:152-156. <u>http://dx.doi.org/10.1016/j.jchromb.2013.11.009</u>

18. Cacho JI, Campillo N, Vinas P, Hernandez-Cordoba M. Stir bar sorptive extraction coupled to gas chromatography-mass spectrometry for the determination of bisphenols in canned beverages and filling liquids of canned vegetables. J Chromatogr A. 2012; 1247:146-153. http://dx.doi.org/10.1016/j.chroma.2012.05.064

19. Grumetto L, Gennari O, Montesano D, Ferracane R, Ritieni A, Albrizio S, Barbato F. Determination five bisphenols in commercial milk samples by liquid chromatography couple to fluorescence detection. J Food Prot. 2013; 76(9):1590-1596. <u>http://dx.doi.org/10.4315/0362-028X.JFP-13-054</u>

20. Cacho JI, Campillo N, Vinas P, Hernandez-Cordoba M. Stir bar sorptive extraction with EG-Silicone coating for bisphenols determination in personal care products by GC-MS. J Pharm Biomed Anal. 2013; 78-79:255-260. <u>http://dx.doi.org/10.1016/j.jpba.2013.02.023</u>

21. Song S, Song M, Zeng L, Wang T, Liu R, Ruan T, Jiang G. Occurrence and profiles of bisphenol analogues in municipal sewage sludge in China. Environ Pollut. 2014; 186:14-19. http://dx.doi.org/10.1016/j.envpol.2013.11.023

22. Cunha SC, Almeida C, Mendes E, Fernandes JO. Simultaneous determination of bisphenol A and bisphenol B in beverages and powdered infant formula by dispersive liquid-liquid micro-extraction and heart-cutting multidimensional gas chromatography-mass spectrometry. Food Addit Contam A. 2011; 28(4):513-526. <u>http://dx.doi.org/10.1080/19440049.2010.542551</u>

23. Cunha SC, Cunha C, Ferreira AR, Fernandes JO. Determination of bisphenol A and bisphenol B in canned seafood combining QuEChERS extraction with dispersive liquid-liquid microextraction followed by gas chromatography-mass spectrometry. Anal Bioanal Chem. 2012; 404(8):2453-2463. <u>http://dx.doi.org/10.1007/s00216-012-6389-5</u>

24. Cunha SC, Fernandes JO. Assessment of bisphenol A and bisphenol B in canned vegetables and fruits by gas chromatography–mass spectrometry after QuEChERS and dispersive liquid–liquid microextraction. Food Control. 2013; 33(2):549-555. http://dx.doi.org/10.1016/j.foodcont.2013.03.028

25. Grumetto L, Montesano D, Seccia S, Albrizio S, Barbato F. Determination of bisphenol a and bisphenol B residues in canned peeled tomatoes by reversed-phase liquid chromatography. J Agric Food Chem. 2008; 56(22):10633-10637. <u>http://dx.doi.org/10.1021/jf802297z</u>

26. Cobellis L, Colacurci N, Trabucco E, Carpentiero C, Grumetto L. Measurement of bisphenol A and bisphenol B levels in human blood sera from healthy and endometriotic women. Biomed Chromatogr. 2009; 23(11):1186-1190. <u>http://dx.doi.org/10.1002/bmc.1241</u>

27. Cobellis L, Panariello A, Campitiello MR, Nocerino A, Pacilio C, Salzillo ME, Castaldi MA, Boccia O, Borrelli A. [Relationship between endometriosis and exposure to BPA and BPB]. Giorn It Ost Gin. 2010; 32(1):44-48.

28. Cunha SC, Fernandes JO. Quantification of free and total bisphenol A and bisphenol B in human urine by dispersive liquid-liquid microextraction (DLLME) and heart-cutting multidimensional gas chromatography-mass spectrometry (MD-GC/MS). Talanta. 2010; 83(1):117-125. <u>http://dx.doi.org/10.1016/j.talanta.2010.08.048</u>

29. Thayer KA, Taylor KW, Garantziotis S, Schurman S, Kissling GE, Hunt D, Herbert B, Church R, Jankowich R, Churchwell MI et al. Bisphenol A, Bisphenol S, and 4-Hydroxyphenyl 4-Isoprooxyphenylsulfone (BPSIP) in Urine and Blood of Cashiers. Environ Health Persp. 2015. http://dx.doi.org/10.1289/ehp.1409427

30. Bruze M, Persson L, Trulsson L, Zimerson E. Demonstration of contact sensitizers in resins and products based on phenol-formaldehyde. Contact Dermatitis. 1986; 14(3):146-154. http://dx.doi.org/10.1111/j.1600-0536.1986.tb01194.x

31. Kruse J, Dolgner K, Greve H, Zaporojtchenko V, Faupel F. Dispersion of gold nanoclusters in TMBPA-polycarbonate by a combination of thermal embedding and vapour-induced crystallization. J Phys D Appl Phys. 2006; 39(23):5086. <u>http://dx.doi.org/10.1088/0022-3727/39/23/028</u>

32. Liao C, Kannan K. A survey of bisphenol A and other bisphenol analogues in foodstuffs from nine cities in China. Food Addit Contam A. 2014; 31(2):319-329. http://dx.doi.org/10.1080/19440049.2013.868611

33. Voordeckers JW, Fennell DE, Jones K, Haggblom MM. Anaerobic biotransformation of tetrabromobisphenol A, tetrachlorobisphenol A, and bisphenol A in estuarine sediments. Environ Sci Technol. 2002; 36(4):696-701. <u>http://dx.doi.org/10.1021/es011081h</u>

34. National Toxicology Program (NTP). 2013. Draft summary of endocrine disruption literature for bisphenol A analogs and derivatives supporting nomination for toxicological evaluation by the National Toxicology Program. RTP, NC: National Toxicology Program.

35. Finnish Institute of Occupational Health (FIOH). 2014. Bisphenol A exposure in Finnish workplaces. Finish Institute of Occupational Health. <u>http://www.ttl.fi/fi/verkkokirjat/Sivut/Bisfenoli.aspx</u>

36. Food and Drug Administration (FDA). Indirect Food Additives: Polymers. Final Rule. 2012. 77 FR 41899. <u>https://www.govinfo.gov/content/pkg/fr-2012-07-17/html/2012-17366.Htm</u> [Accessed: 25 July 2013]

37. Food and Drug Administration (FDA). Indirect Food Additives: Adhesives and Components of Coatings. Final Rule. 2013. 78 FR 41840 https://www.federalregister.gov/documents/2013/07/12/2013-16684/indirect-food-additives-adhesives-and-components-of-coatings [Accessed: 25 July 2013]

38. Rochester JR, Bolden AL. Bisphenol S and F: a systematic review and comparison of the hormonal activity of bisphenol A substitutes. Environ Health Persp. 2015; 123(7):643-650. http://dx.doi.org/10.1289/ehp.1408989

39. National Toxicology Program (NTP). 2014. Literature Review of Bisphenol A (BPA) Analogues. RTP, NC: National Toxicology Program. <u>https://doi.org/10.22427/NTP-DATA-RR-4</u>

40. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-1012. http://dx.doi.org/10.1016/j.jclinepi.2009.06.005

41. Rooney AA, Boyles AL, Wolfe MS, Bucher JR, Thayer KA. Systematic review and evidence integration for literature-based environmental health science assessments. Environ Health Persp. 2014; 122(7):711-718. <u>http://dx.doi/10.1289/ehp.1307972</u>

42. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. West Sussex, England: John Wiley & Sons; 2011.

43. AHRQ training modules for the systematic reviews methods guide. U.S. Department of Health and Human Services; 2014. [Accessed: 10/11/13] http://www.effectivehealthcare.ahrq.gov/index.cfm/tools-and-resources/slide-library/.

44. ICF. From systematic review to sssessment development: managing big (and small) datasets with DRAGON. ICF International; 2013. <u>https://www.icf.com/solutions-and-apps/dragon-dose-response</u>

45. ICF. DRAGON: An online tool for systematic review. ICF International; 2016. https://www.icf.com/technology/dragon [Accessed: 12/1/2016]

46. Rohatgi A. WebPlotDigitizer. 2015. http://arohatgi.info/webplotdigitizer [Accessed: 3/30/16]

47. Shapiro AJ. Health Assessment Workplace Collaborative. 2014. <u>https://hawcproject.org</u> [Accessed: 1/6/16] 48. National Toxicology Program (NTP). 2015. OHAT risk of bias tool. RTP, NC: Office of Health Assessment and Translation (OHAT), National Toxicology Program. http://ntp.niehs.nih.gov/go/38673.

49. United States Environmental Protection Agency (US EPA). Distributed structure-searchable toxicity (DSSTox) database. United States Environmental Protection Agency; 2015. <u>https://www.epa.gov/chemical-research/distributed-structure-searchable-toxicity-dsstox-database</u> [Accessed: 11/1/15]

50. Tice RR, Austin CP, R.J. K, Bucher JR. Improving the human hazard characterization of chemicals: A Tox21 update. Environ Health Persp. 2013; 121:756-765 http://dx.doi.org/10.1289/ehp.1205784

51. Kavlock R, Chandler K, Houck K, Hunter S, Judson R, Kleinstreuer N, Knudsen T, Martin M, Padilla S, Reif D et al. Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem Res Toxicol. 2012; 25(7):1287-1302. http://dx.doi.org/10.1021/tx3000939

52. United States Environmental Protection Agency (US EPA). Endocrine disruptor screening program for the 21st century: (EDSP21 work plan). Washington, DC: United States Environmental Protection Agency; 2011. <u>https://www.epa.gov/sites/production/files/2015-07/documents/edsp21_work_plan_summary_overview_final.pdf</u>

53. Hsieh JH, Sedykh A, Huang R, Xia M, Tice RR. A data analysis pipeline accounting for artifacts in Tox21 quantitative high-throughput screening assays. J Biomol Screen. 2015; 20(7):887-897. <u>http://dx.doi.org/10.1177/1087057115581317</u>

54. Reif DM, Sypa M, Lock EF, Wright FA, Wilson A, Cathey T, Judson RR, Rusyn I. ToxPi GUI: an interactive visualization tool for transparent integration of data from diverse sources of evidence. Bioinformatics. 2013; 29(3):402-403. <u>http://dx.doi.org/10.1093/bioinformatics/bts686</u>

55. Zhang SS, Liu Y, Liu SS, Zhu XW. [Detecting the cytotoxicities of five bisphenol A analogues to the MCF-7 human breast carcinoma cell line through different endpoints]. Huan Jing Ke Xue. 2012; 33(11):3935-3940.

56. Muroi T, Matsuzawa M, Kurata S. Relationship between the molecular structures and estrogenic activity of bisphenol A and its chemical analogs. Kanagawa Shigaku. 2003; 38(2-3):77-91.

57. Zhang HC, Chen LY, Liu SS, Yin DQ. [Jointed estrogenic activities of bisphenol A and three of its analogs]. Huan Jing Ke Xue. 2009; 30(1):260-265.

58. Wang L, Yi Z-S, Li L-C, Liu H-Y, Mo L-Y, Zhang A-Q. [CoMSIA study of estrogen compounds binding to estrogen receptor beta based on docking]. Guilin Li Gong Da Xue Xue Bao. 2010; 30(4):625-631.

59. Xiao Q, Wang X, Wang L. Studies on quantitative structure--Genotoxicity of substituted benzenes on the human lymphocyte. Zhongguo Huanjing Kexue. 2004; 25(1):18-22.

60. Yoo I-K, Choe W-S. Screening of peptide sequences with affinity to bisphenol A by biopanning. Korean J Microbiol. 2013; 49(2):211-214. <u>http://dx.doi.org/10.7845/kjm.2013.3039</u>

61. Li Y, Hu S-Q, Yin D-Q. Primary screening and evaluation of endocrine disrupting activities of eleven substituted phenols. Environ Chem-Beijing. 2003; 22(4):385-389.

62. Asano K, Ono A, Hashimoto S, Inoue T, Kanno J. Screening method of endocrine disrupting chemicals using a surface plasmon resonance sensor. Bunseki Kagaku. 2002; 51(6):389-396. http://dx.doi.org/10.2116/bunsekikagaku.51.389

63. Zhang W-M, Yang L, Li X-F, Lin Q, Li G-H, Wei W-B. Screening of active compounds from Gastrodia elata Blume for vascular smooth muscle relaxation. Chin J Exp Tradit Med Formul. 2011; 17:157-160.

64. Hayakawa R, Matsunaga K, Takeuchi Y, Tatsumi H, Masamoto Y. Occupational contact dermatitis from bisphenol F. Skin Res. 1985; 27(3):494-500. https://doi.org/10.11340/skinresearch1959.27.494

65. Bruze M, Zimerson E. Contact allergy to dihydroxydiphenyl methanes (bisphenol F). Derm Beruf Umwelt. 1985; 33(6):216-220.

66. Jelen G, Cavelier C, Protois JP, Foussereau J. A new allergen responsible for shoe allergy chloroacetamide. Contact Dermatitis. 1989; 21(2):110-111. <u>http://dx.doi.org/10.1111/j.1600-0536.1989.tb04709.x</u>

67. Shmidt E, Farmer SA, Davis MD. Patch-testing with plastics and glues series allergens. Dermatitis. 2010; 21(5):269-274.

68. Furr JR, Lambright CS, Wilson VS, Foster PM, Gray LE, Jr. A short-term in vivo screen using fetal testosterone production, a key event in the phthalate adverse outcome pathway, to predict disruption of sexual differentiation. Toxicol Sci. 2014; 140(2):403-424. http://dx.doi.org/10.1093/toxsci/kfu081

69. Higashihara N, Shiraishi K, Miyata K, Oshima Y, Minobe Y, Yamasaki K. Subacute oral toxicity study of bisphenol F based on the draft protocol for the "Enhanced OECD Test Guideline no. 407". Arch Toxicol. 2007; 81(12):825-832. <u>http://dx.doi.org/10.1007/s00204-007-0223-4</u>

70. Umano T, Tanaka R, Yamasaki K. Endocrine-mediated effects of 4,4'-(hexafluoroisopropylidene)diphenol in SD rats, based on a subacute oral toxicity study. Arch Toxicol. 2012; 86(1):151-157. <u>http://dx.doi.org/10.1007/s00204-011-0731-0</u>

71. Feng Y, Yin J, Jiao Z, Shi J, Li M, Shao B. Bisphenol AF may cause testosterone reduction by directly affecting testis function in adult male rats. Toxicol Lett. 2012; 211(2):201-209. http://dx.doi.org/10.1016/j.toxlet.2012.03.802

72. Yamasaki K, Okuda H. Comparison of endocrine-mediated effects of two bisphenol A related compounds, 2,2-bis(4-cyanatophyenyl)propane and 4,4'-cyclohexylidenebisphenol, based on subacute oral toxicity studies using rats. Toxicol Lett. 2012; 208(2):162-167. http://dx.doi.org/10.1016/j.toxlet.2011.11.001

73. Eastman Kodak. Letter concerning enclosed information on bisphenol S with attachments. Rochester, NY: Eastman Kodak Company. 1991.

74. European Chemicals Agency (ECHA). Exp Key Repeated dose toxicity: oral.002. European Chemicals Agency; 2010. <u>http://echa.europa.eu/registration-dossier/-/registered-dossier/5460/7/6/2/?documentUUID=c0770bc7-80bf-4c24-b95d-5e31c8e4458814228</u> [Accessed: 3/29/16]

75. European Chemicals Agency (ECHA). Exp Key Repeated dose toxicity: oral.003. European Chemicals Agency; 1997. <u>http://echa.europa.eu/registration-dossier/-/registered-dossier/5460/7/6/2/?documentUUID=a8856985-28ab-4914-bb7e-0faf31efad6e</u> [Accessed: 3/29/16]

76. European Chemicals Agency (ECHA). Exp Key Repeated dose toxicity: oral.001. European Chemicals Agency; 2003. <u>http://echa.europa.eu/registration-dossier/-/registered-dossier/13018/7/6/2/?documentUUID=cb7e9a3f-f61c-4195-8769-23a42c22313f</u> [Accessed: 3/31/16]

77. Tohme M, Prud'homme SM, Boulahtouf A, Samarut E, Brunet F, Bernard L, Bourguet W, Gibert Y, Balaguer P, Laudet V. Estrogen-related receptor gamma is an in vivo receptor of bisphenol A. Faseb J. 2014; 28(7):3124-3133. <u>http://dx.doi.org/10.1096/fj.13-240465</u>

78. Shi J, Jiao Z, Zheng S, Li M, Zhang J, Feng Y, Yin J, Shao B. Long-term effects of Bisphenol AF (BPAF) on hormonal balance and genes of hypothalamus-pituitary-gonad axis and liver of zebrafish (Danio rerio), and the impact on offspring. Chemosphere. 2015; 128c:252-257. http://dx.doi.org/10.1016/j.chemosphere.2015.01.060

79. Ji K, Hong S, Kho Y, Choi K. Effects of bisphenol s exposure on endocrine functions and reproduction of zebrafish. Environ Sci Technol. 2013; 47(15):8793-8800. http://dx.doi.org/10.1021/es400329t

80. Naderi M, Wong MY, Gholami F. Developmental exposure of zebrafish (Danio rerio) to bisphenol-S impairs subsequent reproduction potential and hormonal balance in adults. Aquat Toxicol. 2014; 148:195-203. <u>http://dx.doi.org/10.1016/j.aquatox.2014.01.009</u>

81. Yang X, Liu Y, Li J, Chen M, Peng D, Liang Y, Song M, Zhang J, Jiang G. Exposure to Bisphenol AF disrupts sex hormone levels and vitellogenin expression in zebrafish. Environ Toxicol. 2014. <u>http://dx.doi.org/10.1002/tox.22043</u>

82. Song MY, Liang D, Liang Y, Chen MJ, Wang FB, Wang HL, Jiang GB. Assessing developmental toxicity and estrogenic activity of halogenated bisphenol A on zebrafish (Danio rerio). Chemosphere. 2014; 112:275-281. <u>http://dx.doi.org/10.1016/j.chemosphere.2014.04.084</u>

83. Yamasaki K, Noda S, Imatanaka N, Yakabe Y. Comparative study of the uterotrophic potency of 14 chemicals in a uterotrophic assay and their receptor-binding affinity. Toxicol Lett. 2004; 146(2):111-120. <u>http://dx.doi.org/10.1016/j.toxlet.2003.07.003</u>

84. Yamasaki K, Takeyoshi M, Yakabe Y, Sawaki M, Imatanaka N, Takatsuki M. Comparison of reporter gene assay and immature rat uterotrophic assay of twenty-three chemicals. Toxicology. 2002; 170(1-2):21-30. <u>http://dx.doi.org/10.1016/S0300-483X(01)00505-4</u>

85. Yamasaki K, Takeyoshi M, Sawaki M, Imatanaka N, Shinoda K, Takatsuki M. Immature rat uterotrophic assay of 18 chemicals and Hershberger assay of 30 chemicals. Toxicology. 2003; 183(1-3):93-115. <u>http://dx.doi.org/10.1016/S0300-483X(02)00445-6</u>

86. Akahori Y, Nakai M, Yamasaki K, Takatsuki M, Shimohigashi Y, Ohtaki M. Relationship between the results of in vitro receptor binding assay to human estrogen receptor α and in vivo uterotrophic assay: Comparative study with 65 selected chemicals. Toxicol in Vitro. 2008; 22(1):225-231. <u>http://dx.doi.org/10.1016/j.tiv.2007.08.004</u>

87. Stroheker T, Chagnon MC, Pinnert MF, Berges R, Canivenc-Lavier MC. Estrogenic effects of food wrap packaging xenoestrogens and flavonoids in female Wistar rats: a comparative study. Reprod Toxicol. 2003; 17(4):421-432. <u>http://dx.doi.org/10.1016/S0890-6238(03)00044-3</u>

88. Greco AM, Marino G, Scapagnini U, Scardi V. Estrogenic activity of some simple compounds related to diethylstilbestrol. Arch Int Pharmacodyn Ther. 1967; 168(1):149-158.

89. Wang S, Rijk JC, Besselink HT, Houtman R, Peijnenburg AA, Brouwer A, Rietjens IM, Bovee TF. Extending an in vitro panel for estrogenicity testing: the added value of bioassays for measuring antiandrogenic activities and effects on steroidogenesis. Toxicol Sci. 2014; 141(1):78-89. <u>http://dx.doi.org/10.1093/toxsci/kfu103</u>

90. Bitman J, Cecil HC. Estrogenic activity of DDT analogs and polychlorinated biphenyls. J Agr Food Chem. 1970; 18(6):1108-1112. <u>http://dx.doi.org/10.1021/jf60172a019</u>

91. Campbell NR. Molecular structure in relation to oestrogenic activity: derivatives of 4:4'dihydroxydiphenylmethane. Proc R Soc Lond. 1941; 672:528-538.

92. Dodds EC, Lawson W. Molecular structure in relation to oestrogenic activity. Compounds without a phenanthrene nucleus. Proc R Soc Lond B Biol Sci. 1938; 125(839):222-232. http://dx.doi.org/10.1098/rspb.1938.0023

93. Dodds E, Lawson W. Synthetic estrogenic agents without the phenanthrene nucleus. Nature. 1936; 137(3476):996. <u>http://dx.doi.org/10.1038/137996a0</u>

94. Hashimoto Y, Moriguchi Y, Oshima H, Kawaguchi M, Miyazaki K, Nakamura M. Measurement of estrogenic activity of chemicals for the development of new dental polymers. Toxicol In Vitro. 2001; 15(4-5):421-425. <u>http://dx.doi.org/10.1016/S0887-2333(01)00046-7</u>

95. Kuruto-Niwa R, Nozawa R, Miyakoshi T, Shiozawa T, Terao Y. Estrogenic activity of alkylphenols, bisphenol S, and their chlorinated derivatives using a GFP expression system. Environ Toxicol Pharmacol. 2005; 19(1):121-130. <u>http://dx.doi.org/10.1016/j.etap.2004.05.009</u>

96. Terasaki M, Shiraishi F, Fukazawa H, Makino M. Occurrence and estrogenicity of phenolics in paper-recycling process water: pollutants originating from thermal paper in waste paper. Environ Toxicol Chem. 2007; 26(11):2356-2366. <u>http://dx.doi.org/10.1897/06-642R.1</u>

97. Goldinger DM, Demierre AL, Zoller O, Rupp H, Reinhard H, Magnin R, Becker TW, Bourqui-Pittet M. Endocrine activity of alternatives to BPA found in thermal paper in Switzerland. Regul Toxicol Pharmacol. 2015; 71(3):453-462. http://dx.doi.org/10.1016/j.yrtph.2015.01.002 98. European Chemicals Agency (ECHA). Exp Key Repeated dose toxicity: oral.003. European Chemicals Agency; 2014. <u>http://echa.europa.eu/registration-dossier/-/registered-dossier/14986/7/6/2/?documentUUID=627d81e2-b6e0-4a92-8089-5e78906a6c59</u> [Accessed: 3/28/16]

99. European Chemicals Agency (ECHA). Exp supporting repeated dose toxicity: oral. 001. European Chemicals Agency; 1999. <u>https://echa.europa.eu/it/registration-dossier/-/registered-dossier/14986/7/6/2#sApplicantSummaryAndConclusion</u>

100. European Chemicals Agency (ECHA). Exp Key Repeated dose toxicity: oral.002. European Chemicals Agency; 2002. <u>http://echa.europa.eu/registration-dossier/-/registered-dossier/12390/7/6/2/?documentUUID=34800bf1-4b5a-4cf5-9efa-dc08a1cfb31b</u> [Accessed: 3/28/16]

101. European Chemicals Agency (ECHA). Exp Key Repeated dose toxicity: oral.003. European Chemicals Agency; 2000. <u>http://echa.europa.eu/registration-dossier/-/registered-dossier/12390/7/6/2/?documentUUID=a6f44f03-4202-425b-80da-57af98c5607e</u> [Accessed: 3/28/16]

102. Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, Xie Q, Perkins R, Owens W, Sheehan DM. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol. 2003; 16(10):1338-1358. http://dx.doi.org/10.1021/tx030011g

103. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W. Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α -fetoprotein. Toxicol Sci. 2015; 143(2):333-348. <u>http://dx.doi.org/10.1093/toxsci/kfu231</u>

104. Kitamura S, Suzuki T, Sanoh S, Kohta R, Jinno N, Sugihara K, Yoshihara S, Fujimoto N, Watanabe H, Ohta S. Comparative study of the endocrine-disrupting activity of bisphenol A and 19 related compounds. Toxicol Sci. 2005; 84(2):249-259. <u>http://dx.doi.org/10.1093/toxsci/kfi074</u>

105. Goto Y, Kitamura S, Kashiwagi K, Oofusa K, Tooi O, Yoshizato K, Sato J, Ohta S, Kashiwagi A. Suppression of amphibian metamorphosis by bisphenol a and related chemical substances. J Health Sci. 2006; 52(2):160-168. <u>http://dx.doi.org/10.1248/jhs.52.160</u>

106. Goto K, Akiike T, Konno K, Shiba T, Patz M, Takahashi M, Inoue Y, Matsubara M. Thermally stable polyarylenes with low dielectric constant: direction towards the lowest limit of dielectrics. J Photopolym Sci Tec. 2002; 15(2):223-229. http://dx.doi.org/10.2494/photopolymer.15.223

107. Kitamura S, Kato T, Iida M, Jinno N, Suzuki T, Ohta S, Fujimoto N, Hanada H, Kashiwagi K, Kashiwagi A. Anti-thyroid hormonal activity of tetrabromobisphenol A, a flame retardant, and related compounds: Affinity to the mammalian thyroid hormone receptor, and effect on tadpole metamorphosis. Life Sci. 2005; 76(14):1589-1601. http://dx.doi.org/10.1016/j.lfs.2004.08.030 108. Butt CM, Stapleton HM. Inhibition of thyroid hormone sulfotransferase activity by brominated flame retardants and halogenated phenolics. Chem Res Toxicol. 2013; 26(11):1692-1702. http://dx.doi.org/10.1021/tx400342k

109. Butt CM, Wang D, Stapleton HM. Halogenated phenolic contaminants inhibit the in vitro activity of the thyroid-regulating deiodinases in human liver. Toxicol Sci. 2011; 124(2):339-347. http://dx.doi.org/10.1093/toxsci/kfr117

110. Shiizaki K, Asai S, Ebata S, Kawanishi M, Yagi T. Establishment of yeast reporter assay systems to detect ligands of thyroid hormone receptors α and β . Toxicol in Vitro. 2010; 24(2):638-644. <u>http://dx.doi.org/10.1016/j.tiv.2009.10.001</u>

111. Kim H-J, Park H-Y, Kim J-A, Kang I-H, Kim T-S, Han S-Y, Kang T-S, Park K-L, Kim H-S. Assessment of in vitro assay system for thyroid hormone disruptors using rat pituitary GH 3 cells. Toxicol Res. 2006; 22(4):307-313.

112. Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A, Shimohigashi Y. Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Environ Health Persp. 2007; 116(1):32-38. 10.1289/ehp.10587

113. Delfosse V, Grimaldi M, Pons JL, Boulahtouf A, le Maire A, Cavailles V, Labesse G, Bourguet W, Balaguer P. Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes. Proc Natl Acad Sci U S A. 2012; 109(37):14930-14935. <u>http://dx.doi.org/10.1073/pnas.1203574109</u>

114. Dring AM, Anderson LE, Qamar S, Stoner MA. Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem-Biol Interact. 2010; 188(3):512-525. <u>http://dx.doi.org/10.1016/j.cbi.2010.09.018</u>

115. Sui Y, Ai N, Park SH, Rios-Pilier J, Perkins JT, Welsh WJ, Zhou C. Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Persp. 2012; 120(3):399-405. http://dx.doi.org/10.1289/ehp.1104426

116. Imai J, Yamazoe Y, Yoshinari K. Novel cell-based reporter assay system using epitopetagged protein for the identification of agonistic ligands of constitutive androstane receptor (CAR). Drug Metab Pharmacokinet. 2013; 28(4):290-298. http://dx.doi.org/10.2133/dmpk.DMPK-12-RG-112

117. Peyre L, Rouimi P, de Sousa G, Helies-Toussaint C, Carre B, Barcellini S, Chagnon MC, Rahmani R. Comparative study of bisphenol A and its analogue bisphenol S on human hepatic cells: A focus on their potential involvement in nonalcoholic fatty liver disease. Food Chem Toxicol. 2014; 70:9-18. <u>http://dx.doi.org/10.1016/j.fct.2014.04.011</u>

118. Roelofs MJ, Berg M, Bovee TF, Piersma AH, Duursen MB. Structural bisphenol analogues differentially target steroidogenesis in murine MA-10 Leydig cells as well as the glucocorticoid receptor. Toxicology. 2015; 329:10-20. <u>http://dx.doi.org/10.1016/j.tox.2015.01.003</u>

119. Kolsek K, Gobec M, Mlinaric Rascan I, Sollner Dolenc M. Molecular docking revealed potential disruptors of glucocorticoid receptor-dependent reporter gene expression. Toxicol Lett. 2014; 226(2):132-139. <u>http://dx.doi.org/10.1016/j.toxlet.2014.01.047</u>

120. Kamata R, Shiraishi F, Nishikawa J-i, Yonemoto J, Shiraishi H. Screening and detection of the in vitro agonistic activity of xenobiotics on the retinoic acid receptor. Toxicol in Vitro. 2008; 22(4):1050-1061. <u>http://dx.doi.org/10.1016/j.tiv.2008.01.002</u>

121. Nishigori M, Nose T, Shimohigashi Y. Highly potent binding and inverse agonist activity of bisphenol A derivatives for retinoid-related orphan nuclear receptor RORgamma. Toxicol Lett. 2012; 212(2):205-211. <u>http://dx.doi.org/10.1016/j.toxlet.2012.05.020</u>

122. Monsanto Co. Initial submission: Acute oral toxicity of several diphenyl sulfones in rats and rabbits with cover letter dated 08/05/92. St. Louis, MS: Monsanto Company; 1992. OTS0555048. internal-pdf://4186365337/OTS0555048.pdf

123. Dupont. Initial submission: acute oral toxicity of 4,4'-(hexafluoroisopropylidene)diphenol in male rats with cover letter dated 10/15/92. EPA/OTS. 1992; 920010335:#88-920010335.

124. Army Chemical Center. Table V Toxicity Tests. Chemical Biological Coordination Center, Summary Biological Tests, National Research Council. 1954; p. 138-149.

125. Pan F, Xu T, Yang L, Jiang X, Zhang L. Probing the binding of an endocrine disrupting compound-Bisphenol F to human serum albumin: insights into the interactions of harmful chemicals with functional biomacromolecules. Spectroc Acta Pt A-Molec Biomolec Spectr. 2014; 132:795-802. <u>http://dx.doi.org/10.1016/j.saa.2014.05.093</u>

126. Wang X, Yang JC, Wang YJ, Li YH, Wang F, Zhang L. Studies on electrochemical oxidation of estrogenic disrupting compound bisphenol AF and its interaction with human serum albumin. J Hazard Mater. 2014; 276:105-111. <u>http://dx.doi.org/10.1016/j.jhazmat.2014.05.028</u>

127. Hendriks HS, Meijer M, Muilwijk M, van den Berg M, Westerink RH. A comparison of the in vitro cyto- and neurotoxicity of brominated and halogen-free flame retardants: prioritization in search for safe(r) alternatives. Arch Toxicol. 2014; 88(4):857-869. http://dx.doi.org/10.1007/s00204-013-1187-1

128. Lee S, Kim YK, Shin TY, Kim SH. Neurotoxic effects of bisphenol AF on calcium-induced ROS and MAPKs. Neurotox Res. 2013; 23(3):249-259. <u>http://dx.doi.org/10.1007/s12640-012-9353-4</u>

129. Helies-Toussaint C, Peyre L, Costanzo C, Chagnon MC, Rahmani R. Is bisphenol S a safe substitute for bisphenol A in terms of metabolic function? An in vitro study. Toxicol Appl Pharmacol. 2014; 280(2):224-235. <u>http://dx.doi.org/10.1016/j.taap.2014.07.025</u>

130. Masuno H, Iwanami J, Kidani T, Sakayama K, Honda K. Bisphenol a accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci. 2005; 84(2):319-327. <u>http://dx.doi.org/10.1093/toxsci/kfi088</u>

131. Hayashi J, Sekine T, Deguchi S, Lin Q, Horie S, Tsuchiya S, Yano S, Watanabe K, Ikegami F. Phenolic compounds from Gastrodia rhizome and relaxant effects of related compounds on

isolated smooth muscle preparation. Phytochemistry. 2002; 59(5):513-519. http://dx.doi.org/10.1016/S0031-9422(02)00008-0

132. Lee JY, Jang YW, Kang HS, Moon H, Sim SS, Kim CJ. Anti-inflammatory action of phenolic compounds from Gastrodia elata root. Arch Pharm Res. 2006; 29(10):849-858. http://dx.doi.org/10.1007/BF02973905

133. Pyo MK, Jin JL, Koo YK, Yun-Choi HS. Phenolic and furan type compounds isolated from Gastrodia elata and their anti-platelet effects. Arch Pharmacal Res. 2004; 27(4):381-385. http://dx.doi.org/10.1007/BF02980077

134. Gao X, Ma J, Chen Y, Wang HS. Rapid responses and mechanism of action for low-dose bisphenol S on ex vivo rat hearts and isolated myocytes: evidence of female-specific proarrhythmic effects. Environ Health Persp. 2015; 123(6):571-578. http://dx.doi.org/10.1289/ehp.1408679

135. Kubo T, Maezawa N, Osada M, Katsumura S, Funae Y, Imaoka S. Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1α (HIF- 1α): structural requirement of bisphenol A for degradation of HIF- 1α . Biochem Biophys Res Commun. 2004; 318(4):1006-1011. http://dx.doi.org/10.1016/j.bbrc.2004.04.125

136. Hopp L, Megee SO, Lloyd JB. Bisphenols that stimulate cells to release alkali metal cations: a structure-activity study. J Med Chem. 1998; 41(22):4421-4423. http://dx.doi.org/10.1021/jm980315d

137. Zhang H-C, Hu X-L, Yin D-Q, Lin Z-F. Development of molecular docking-based binding energy to predict the joint effect of BPA and its analogs. Hum Exp Toxicol. 2011; 30(4):318-327. <u>http://dx.doi.org/10.1177/0960327110372400</u>

138. Kolle SN, Kamp HG, Huener HA, Knickel J, Verlohner A, Woitkowiak C, Landsiedel R, van Ravenzwaay B. In house validation of recombinant yeast estrogen and androgen receptor agonist and antagonist screening assays. Toxicol In Vitro. 2010; 24(7):2030-2040. http://dx.doi.org/10.1016/j.tiv.2010.08.008

139. Coleman KP, Toscano WA, Wiese TE. QSAR models of the in vitro estrogen activity of bisphenol A analogs. QSAR Comb Sci. 2003; 22(1):78-88. http://dx.doi.org/10.1002/qsar.200390008

140. Kataria A, Levine D, Wertenteil S, Vento S, Xue J, Rajendiran K, Kannan K, Thurman JM, Morrison D, Brody R et al. Exposure to bisphenols and phthalates and association with oxidant stress, insulin resistance, and endothelial dysfunction in children. Pediatr Res. 2017; 81(6):857-864. <u>http://dx.doi.org/10.1038/pr.2017.16</u>

141. Catanese MC, Vandenberg LN. Bisphenol S (BPS) alters maternal behavior and brain in mice exposed during pregnancy/lactation and their daughters. Endocrinology. 2017; 158(3):516-530. <u>http://dx.doi.org/10.1210/en.2016-1723</u>

142. Wang RY, Abbott RD, Zieba A, Borowsky FE, Kaplan DL. Development of a threedimensional adipose tissue model for studying embryonic exposures to obesogenic chemicals. Ann Biomed Eng. 2016; 45(7):1807. <u>http://dx.doi.org/10.1007/s10439-016-1752-x</u>

143. Chen Y, Shu L, Qiu Z, Lee DY, Settle SJ, Que Hee S, Telesca D, Yang X, Allard P. Exposure to the BPA-substitute bisphenol S causes unique alterations of germline function. PLoS Genet. 2016; 12(7). <u>http://dx.doi.org/10.1371/journal.pgen.1006223</u>

144. Thayer KA, Pelch KE, Birnbaum LS, Bucher JR. Bisphenols: More unnecessary surprises. Endocr Disruptors. 2016; 4(1):e1131032. <u>http://dx.doi.org/10.1080/23273747.2015.1131032</u>

145. Hashimoto Y, Nakamura M. Estrogenic activity of dental materials and bisphenol-A related chemicals in vitro. Dent Mater J. 2000; 19(3):245-262.

146. Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins R, Sheehan DM. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci. 2000; 54(1):138-153. http://dx.doi.org/10.1093/toxsci/54.1.138

147. Kitamura S, Sanoh S, Kohta R, Suzuki T, Sugihara K, Fujimoto N, Ohta S. Metabolic activation of proestrogenic diphenyl and related compounds by rat liver microsomes. J Health Sci. 2003; 49(4):298-310. <u>http://dx.doi.org/10.1248/jhs.49.298</u>

148. Perez P, Pulgar R, Olea-Serrano F, Villalobos M, Rivas A, Metzler M, Pedraza V, Olea N. The estrogenicity of bisphenol A-related diphenylalkanes with various substituents at the central carbon and the hydroxy groups. Environ Health Persp. 1998; 106(3):167-174.

149. Stroheker T, Picard K, Lhuguenot JC, Canivenc-Lavier MC, Chagnon MC. Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines. Food Chem Toxicol. 2004; 42(6):887-897. <u>http://dx.doi.org/10.1016/j.fct.2004.01.012</u>

150. Molina-Molina JM, Amaya E, Grimaldi M, Saenz JM, Real M, Fernandez MF, Balaguer P, Olea N. In vitro study on the agonistic and antagonistic activities of bisphenol-S and other bisphenol-A congeners and derivatives via nuclear receptors. Toxicol Appl Pharmacol. 2013; 272(1):127-136. <u>http://dx.doi.org/10.1016/j.taap.2013.05.015</u>

151. Matsushima A, Liu X, Okada H, Shimohigashi M, Shimohigashi Y. Bisphenol AF is a full agonist for the estrogen receptor ERalpha but a highly specific antagonist for ERbeta. Environ Health Persp. 2010; 118(9):1267-1272. <u>http://dx.doi.org/10.1289/ehp.0901819</u>

152. Yamasaki K, Takeyoshi M, Yakabe Y, Sawaki M, Takatsuki M. Comparison of the reporter gene assay for ER-alpha antagonists with the immature rat uterotrophic assay of 10 chemicals. Toxicol Lett. 2003; 142(1-2):119-131. <u>http://dx.doi.org/10.1016/S0378-4274(03)00019-5</u>

153. Rotroff DM, Dix DJ, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, Reif DM, Richard AM, Sipes NS, Abassi YA et al. Real-time growth kinetics measuring hormone mimicry for ToxCast chemicals in T-47D human ductal carcinoma cells. Chem Res Toxicol. 2013; 26(7):1097-1107. <u>http://dx.doi.org/10.1021/tx400117y</u>

154. Vinas R, Watson CS. Mixtures of xenoestrogens disrupt estradiol-induced non-genomic signaling and downstream functions in pituitary cells. Environ Health. 2013; 12(1):26. http://dx.doi.org/10.1186/1476-069x-12-26

155. Li Y, Burns KA, Arao Y, Luh CJ, Korach KS. Differential estrogenic actions of endocrinedisrupting chemicals bisphenol A, bisphenol AF, and zearalenone through estrogen receptor alpha and beta in vitro. Environ Health Persp. 2012; 120(7):1029-1035. http://dx.doi.org/10.1289/ehp.1104689

156. Teng C, Goodwin B, Shockley K, Xia M, Huang R, Norris J, Merrick BA, Jetten AM, Austin CP, Tice RR. Bisphenol A affects androgen receptor function via multiple mechanisms. Chem-Biol Interact. 2013; 203(3):556-564. <u>http://dx.doi.org/10.1016/j.cbi.2013.03.013</u>

157. Ma M, Crump D, Farmahin R, Kennedy SW. Comparing the effects of tetrabromobisphenol-A, bisphenol A, and their potential replacement alternatives, TBBPA-bis(2,3-dibromopropyl ether) and bisphenol s, on cell viability and messenger ribonucleic acid expression in chicken embryonic hepatocytes. Environ Toxicol Chem. 2015; 34(2):391-401. http://dx.doi.org/10.1002/etc.2814

158. Stossi F, Bolt MJ, Ashcroft FJ, Lamerdin JE, Melnick JS, Powell RT, Dandekar RD, Mancini MG, Walker CL, Westwick JK et al. Defining estrogenic mechanisms of bisphenol A analogs through high throughput microscopy-based contextual assays. Chem Biol. 2014; 21(6):743-753. <u>http://dx.doi.org/10.1016/j.chembiol.2014.03.013</u>

159. Li M, Guo J, Gao W, Yu J, Han X, Zhang J, Shao B. Bisphenol AF-induced endogenous transcription is mediated by ERalpha and ERK1/2 activation in human breast cancer cells. PLoS One. 2014; 9(4):e94725. http://dx.doi.org/10.1371/journal.pone.0094725

160. Rivas A, Lacroix M, Olea-Serrano F, Laios I, Leclercq G, Olea N. Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2002; 82(1):45-53. http://dx.doi.org/10.1016/S0960-0760(02)00146-2

161. Letcher RJ, Sanderson JT, Bokkers A, Giesy JP, van den Berg M. Effects of bisphenol Arelated diphenylalkanes on vitellogenin production in male carp (Cyprinus carpio) hepatocytes and aromatase (CYP19) activity in human H295R adrenocortical carcinoma cells. Toxicol Appl Pharmacol. 2005; 209(2):95-104. <u>http://dx.doi.org/10.1016/j.taap.2005.03.013</u>

162. Rosenmai AK, Dybdahl M, Pedersen M, Alice van Vugt-Lussenburg BM, Wedebye EB, Taxvig C, Vinggaard AM. Are structural analogues to bisphenol a safe alternative? Toxicol Sci. 2014; 139(1):35-47. <u>http://dx.doi.org/10.1093/toxsci/kfu030</u>

163. Ashcroft FJ, Newberg JY, Jones ED, Mikic I, Mancini MA. High content imaging-based assay to classify estrogen receptor- α ligands based on defined mechanistic outcomes. Gene. 2011; 477(1-2):42-52. <u>http://dx.doi.org/10.1016/j.gene.2011.01.009</u>

Appendix A. Supplemental Materials

Table of Contents

A.1. Comparison of Pharmaceutical Estrogen Profiles and BPA Analogues	. A-3
A.2. Hazard Summaries Based on Analogy and Estimation from the US EPA DfE Report	. A-3
A.3. Estrogenic and Anti-estrogenic Endpoints	. A-3

Tables

All supplemental tables listed below are available at <u>https://doi.org/10.22427/NTP-DATA-4</u>.

Supplemental Table 1. Inclusion of 27 BPA Analogues in Various Databases
Supplemental Table 2. Biomonitoring Studies
Supplemental Table 3. Wildlife Observational Studies
Supplemental Table 4. ADME Type Studies
Supplemental Table 5. PHBB Inventory
Supplemental Table 6. TCBPA Inventory
Supplemental Table 7. TBBPA Inventory
Supplemental Table 8. Tox21 Activity Data
Supplemental Table 9. Pharmacological Estradiol Analogues
Supplemental Table 10. Comparison of HTS Assays Between BPA Analogues and E ₂ Analogues
Supplemental Table 11. Hazard Summary Profile from the US EPA DfE Report
Supplemental Table 12. Summary of Reproductive and Developmental Toxicity Studies in
ECHA
Supplemental Table 13. Integrated Biological and Structural Similarity to BPA
Supplemental Table 14. Integrated Biological and Structural Similarity to E ₂
Supplemental Table 15. References

Figures

Figure A-1. Crossview of Subchronic Studies	A-6
Figure A-2. Body Weight in Subchronic Studies	A-7
Figure A-3. Crossview of Uterotrophic Response	A-8
Figure A-4. Data Pivot of Uterotrophic Response	A-9
Figure A-5. Vitellogenin Response.	A-10
Figure A-6. Estrogen Receptor Binding Assays	
Figure A-7. Estrogen Receptor Cell Proliferation Assays	A-12
Figure A-8. Estrogen Receptor Reporter Gene Assays	A-13
Figure A-9. Estrogen Receptor Modulation of Endogenous Gene Expression	
Figure A-10. Estrogen Receptor Modulation of Protein Expression	A-15
Figure A-11. Steroidogenesis Assays	A-16
Figure A-12. Estrogen Receptor Other Endpoints	
Figure A-13. Data Pivot of Hershberger Assay	A-18
Figure A-14. Androgen Receptor Agonism Assays	A-19
Figure A-15. Androgen Receptor Antagonism Assays	
Figure A-16. Thyroid Hormone Disruption	A-21

Figure A-17. Thyroid Receptor Agonism Assays	A-22
Figure A-18. Thyroid Receptor Antagonism Assays	A-22
Figure A-19. Other Nuclear Receptor Activities	A-23
Figure A-20. In vitro Genotoxicity Assays	A-24
Figure A-21. Assessment of Active and Inactive Assay of BPA Analogues in ToxCast	A-25
Figure A-22. Risk of Bias of Animal Evidence from Published Literature	A-26
Figure A-23. Risk of Bias of Animal Evidence from ECHA Data	A-26

A.1. Comparison of Pharmaceutical Estrogen Profiles and BPA Analogues

The activity of the BPA analogues was compared to that of a set of Tox21 chemicals similar to E_2 . The E_2 set was defined as all of the Tox21 chemicals with Tanimoto similarity to betaestradiol of greater than 0.5. The chemicals in this set are given in <u>Supplemental Table 9</u>, posted online. The two chemical sets were compared using the direction adjusted, weighted area under curve (wAUC) values for the Tox21 assays. Assay values used were all triplicated assay endpoints, except for the two channels of data used for deriving the ratio in assays where the ratio of two channels was reported.

For each chemical and assay, the median of all replicate wAUC values for that chemical in that assay was obtained. Some chemicals were tested more than once (i.e., have more than one set of triplicate wAUCS), and those values were pooled before calculating the median. For each chemical set and each assay, the assay was assigned an activity sign of 1, indicating consistent increasing wAUC, if more than half of the chemicals (not counting chemicals not tested in that assay) had median wAUC greater than 0 for that assay, a sign of 1 if more than half had median wAUC less than 0, and a sign of 0 otherwise.

Results are shown in <u>Supplemental Table 10</u>, posted online . For sixteen of the assays, both the BPA analogues and the E_2 analogues had the same non-zero sign (sign 1 for three assays, sign -1 for 13 assays), designated Group 1 Assays. (This discussion omits assays with sign 0 for both chemical sets). For 10 of the assays designated Group 2 Assays, the BPA analogues set had a sign of -1 while the E_2 analogue set had a sign of 0. Five other assays designated Group 3 Assays had different signs for the two chemical sets.

A.2. Hazard Summaries Based on Analogy and Estimation from the US EPA DfE Report

For eight analogues (BPS-MAE, BPS-MPE, BTUM, D-90, DD-70, MBHA, TGSA, UU), no published studies were identified by the literature search or in the US EPA DfE report¹⁵. In the US EPA DfE report, hazard summaries of these chemicals were subsequently derived based on analogy, estimation, or evaluation of data in the ECHA database or submitted confidential studies (Supplemental Table 11, posted online). All of these analogues were found or estimated to have a low hazard for acute toxicity, and were estimated as a moderate hazard for carcinogenicity. MBHA achieved a high hazard label for developmental effects based on analogy to BPA and DD-70 achieved a high hazard label for eye irritation based on analogy to a confidential chemical. In contrast to the generally low hazard for human health effects of these analogues, most of them were found or estimated to be moderate, high, or very high hazards for acute or chronic exposure to aquatic organisms. The exceptions were UU and D-90, which were both estimated to be low aquatic toxicity hazards.

A.3. Estrogenic and Anti-estrogenic Endpoints

Binding to the estrogen receptor was assessed for ten BPA analogues (4,4-BPF, BPAF, BPB, BPC, BPE, BPS, BPZ, BPAP, TMBPA, D-8) using a number of different assays (Figure A-6). In some assays, binding to the ER was performed in a cell-free context^{94; 96; 139; 145-148}. In others,

intact cell systems were utilized to evaluate binding to endogenous ER¹⁴⁹ or exogenously expressed ER in mammalian cells^{113; 150} or bacterial cells^{83; 86; 151; 152}. Among the strongest binders to ER were BPAF, BPB, BPZ, and BPAP, binding between 0.01 and 1 μ M, which was four to ten-fold more potent than that reported for BPA. Binding of BPC, 4,4-BPF, BPE, and TMBPA to ER was similar to that of BPA (ranged from >0.01 to <100 μ M), and BPS was the weakest with binding six to 10-fold less potent than BPA (>3 μ M). D-8 did not bind to ER in the presence or absence of the metabolic activator S9 fraction⁹⁶. Several BPA analogues bound ER β more potently than ER α , including BPAF and BPS^{150; 151}.

Induction of cellular proliferation of human breast cancer cell lines (e.g., MCF7 and T47D) is a well-known characteristic of estrogenic chemicals, and was assessed for 11 BPA analogues (4,4-BPF, BPAF, BPAP, BPB, BPC, BPE, BPP, BPPH, BPS, BPZ, TMBPA). In MCF7 cells, the BPA analogues tested were similar to or slightly weaker than BPA in their ability to induce cellular proliferation (Figure A-7), with the exception of BPAF, which was generally reported as equal to or more potent than BPA^{94; 113; 139; 148; 153}. BPS was also interesting in that it was reported as weaker than BPA in inducing MCF7 cell proliferation^{94; 145; 150}, but was much more potent than BPA in inducing mCF7 cell proliferation^{94; 145; 150}, but was much more potent than BPA in inducing for ER binding and cellular proliferation for the chemicals that were tested in both assays with the exception of BPE, which was one of the most potent at inducing cellular proliferation⁵⁶ but one of the weakest at binding ER⁹⁴.

Modulation of reporter genes was assessed in eukaryotic cells transfected with various reporter constructs and with either ER α or ER β in cells that do not endogenously express the receptor (Figure A-8). The yeast estrogen screen (YES), in which both the ER and reporter are transformed into yeast cells, was also used. With the exception of D8, all of the BPA analogues tested in these assays were partial to full agonists capable of eliciting induction of the reporter gene similarly to E₂. The majority of the reported EC₅₀ values were in the order of 0.1-10 μ M for 4,4-BPF, BPB, BPC, BPE, BPP, and TMBPA. BPAF and BPZ were more potent, with EC₅₀ values near 0.01-1 μ M and BPAP and BPS were less potent with EC₅₀ values in the order of 1-10 μ M. The potency of the effect was dependent on cell type and receptor (ER α or ER β). Antagonism was evaluated for 4,4-BPF, BPB, BPC, BPE, BPB, BPC, BPE, BPB, BPC, BPE, BPAF, and TMBPA. Only BPAF and TMBPA were found to antagonize the activity of E₂, but the reports of BPAF antagonism were conflicting and suggest cell type specific effects¹⁰⁴. For example, potent antagonism of BPAF on ER β and weak antagonism on ER α was observed in HeLa cells, but not in HepG2, Ishikawa, or MCF-7 cells^{104; 113; 155; 156}.

In Tox21, BPAF was the most potent ER agonist of the BPA analogues, and was more potent than BPA. BPZ, BPC, TMBPA, 4,4-BPF, BPB, BPE, BPS displayed ER agonism similar to BPA (AC₅₀ between 0.2 and 2 μ M). PHBB was weaker (AC₅₀ ~20 μ M). 2,2-BPF, TCBPA, TBBPA only stimulated the partial receptor at ~50 μ M. ER antagonism at ~50 μ M was observed for TGSA, TCBPA, BPZ, BPC, TMBPA, BPAF, BPE, and BPB.

Modulation of endogenous gene (Figure A-9) and protein (Figure A-10) expression was assessed in eukaryotic cells transfected with ER α or ER β or in cells that endogenously express ER. For the most part, only single doses were evaluated in the gene expression studies. All of the tested BPA analogues (4,4-BPAF, BPAF, BPAF, BPAP, BPB, BPC, BPE, BPS, BPZ, and TMBPA) induced the expression of endogenous estrogen-responsive genes (e.g., prolactin (PRL), growth regulation by estrogen in breast cancer 1 (GREB1), and progesterone receptor (PR)). Though difficult to discern due to the lack of dose response data, BPS appeared the least potent, only inducing gene expression at 300 μ M¹⁵⁷ whereas the other analogues induced expression at 1 or 10 μ M (Figure A-9). In general, when ER β was present there was no induction of endogenous estrogen-responsive genes¹⁵⁸. In the case of BPAF, however, gene expression was decreased relative to control when cells were transfected with ER β and increased with ER α ¹⁵⁹. In addition, 4,4-BPAF, BPAF, BPAP, BPB, BPC, BPS, BPZ, and TMBPA were able to antagonize E₂ induced expression of PRL in HeLA cells transfected with ER α or ER β and GREB1 in MCF7 cells¹⁵⁸.

The same chemicals were evaluated for modulation of ER α , PR, PRL, trefoil factor 1(pS2), or VTG protein expression (Figure A-10). All of the chemicals tested (4,4-BPF, BPAF, BPB, BPC, BPE) increased expression of PR and pS2 in the dose range of 1-10 μ M^{148; 160}. Whereas BPAF, BPP, BPC, and TMBPA antagonized E₂ induced expression of VTG, only BPAF and BPC acted as agonists to induce VTG expression in the absence of E₂¹⁶¹. Stossi et al.¹⁵⁸ reported that 4,4-BPF, BPAF, BPAF, BPB, BPC, BPS, and TMBPA could down regulate ER α levels in MCF7 cells¹⁵⁸.

The production of endogenous estrogens (17β -E₂ and estrone) was assessed for 4,4-BPF, BPB, BPE, BPS, D8 and Pergafast 201 in the human adrenocortical carcinoma cell line, H295R^{97; 162} (Figure A-11). 4,4-BPF, BPB and BPE induced the production of 17β -E₂ and estrone with potencies similar to BPA, whereas BPS was not active in the H295R steroidogenesis assay^{97; 162}. For D8 and Pergafast 201, only the production of 17β -E₂ was evaluated⁹⁷ and both chemicals were inactive.

There were additional estrogen receptor related endpoints that were assessed (Figure A-12). Ashcroft et al.¹⁶³ and Stossi et al.¹⁵⁸ evaluated whether or not the BPA analogues could induce ER binding to the estrogen response element (ERE) of DNA using high content imaging. All of the BPA analogues tested (4,4-BPF, BPAF, BPAP, BPB, BPC, BPS, BPZ, TMBPA) demonstrated clear selectivity for ER β compared to ER α ¹⁵⁸ with BPS and 4,4-BPF not able to induce ER α /ERE binding between 0.001 and 10 μ M. In the same study, BPAP and BPAF were able to induce ER α or ER β homodimerization but BPS showed only weak activity¹⁵⁸. In similar studies Ashcroft et al.¹⁶³ demonstrated that BPB could induce ER α nuclear localization and polymerase II recruitment. Non-genomic effects were only explored for BPS, which was able to activate the extracellular signal-regulated kinase ERK and caspase 8 but not JNK or caspase 9¹⁵⁴.



Figure A-1. Crossview of Subchronic Studies



Figure A-2. Body Weight in Subchronic Studies



Figure A-3. Crossview of Uterotrophic Response

Citation	Chemical	Strain (Sex, N)		Exposure Duration	Route		Dose mg/kg-day)	Control NS Diff Sig Diff H 95% CI
Yamasaki et al. 2002	2,2'-Bisphenol F	Rat, Crj:CD(SD) (♀, N=6)	weanling	3 days	subcutaneous injection	uterine dry weight (absolute)	0 2	+ ⊖ + + ● +
							20 200	
Stroheker et al. 2003	4,4'-Bisphenol F	Rat, Wistar (♀, N=8)	weanling	4 days	oral gavage	uterine dry weight (relative)	0	H o ri
		(4-0)			gavage	weight (relative)	25 50	
							100 200	
Stroheker et al. 2003	4,4'-Bisphenol F	Rat, Wistar (♀, N=8)	weanling	4 days	oral	uterine wet weight (relative)	0	Here and the second sec
		N=0)			gavage	weigrit (relative)	25 50	
							100	H O H
Yamasaki et al. 2004	4,4'-Bisphenol F	Rat, Crj:CD(SD) (♀,	weanling	3 days	subcutaneous	uterine dry weight	200 0	
		N=6)			injection	(absolute)	100 300	H ⊖ H H ⊖ H
							1,000	⊢
Yamasaki et al. 2004	4,4'-Bisphenol F	Rat, Crj:CD(SD) (♀, N=6)	weanling	3 days	subcutaneous injection	uterine dry weight (relative)	0 100	
							300 1,000	
Yamasaki et al. 2004	4,4'-Bisphenol F	Rat, Crj:CD(SD) (♀,	weanling	3 days	subcutaneous injection	weight	0	юн
		N=6)				(absolute)	100 300	Here in the second seco
Yamasaki et al. 2004	4,4'-Bisphenol F	Rat.	weanling	3 days	subcutaneous	uterine wet	1,000 0	⊢
	., r unoproriol P	Crj:CD(SD) (Q, N=6)		0 0090	injection	weight (relative)	100	HeH
							300 1,000	
Greco et al. 1967	4,4'-Bisphenol F	Rat, Wistar (♀, N=5-10)	young adult	4 days	subcutaneous injection	uterine dry weight (relative)	0	
Greco et al. 1967	4,4'-Bisphenol F	Rat, Wistar (♀,	young	5 days	subcutaneous	uterine dry	0.1 0	
		N=5)	adult	,-	injection	weight (relative)	0.5	
Greco et al. 1967	4,4*-Bisphenol F	Rat, Wistar (Ç)	young adult	5 days	subcutaneous injection	uterine dry weight (relative)	0	•
							5	•
Yamasaki et al. 2003b	Bisphenol AF	Rat, Crj:CD(SD) (♀, N=6)	weanling	3 days	subcutaneous injection	uterine dry weight (absolute)	0 8	
		N=0)				(absolute)	40	
Yamasaki et al. 2003b	Bisphenol AF	Rat,	weanling	3 days	subcutaneous	uterine dry	100 0	► ●
		Crj:CD(SD) (♀, N=6)			injection	weight (relative)	8 40	
							100	
Yamasaki et al. 2002	Bisphenol B	Rat, Crj:CD(SD) (♀,	weanling	3 days	subcutaneous injection	weight	0 2	l⊗l ⊦●⊣
		N=6)				(absolute)	20	Het .
Verseeld et el 0004	Planta and O	8-4		0.1			200	
Yamasaki et al. 2004	Bisphenol S	Rat, Crj:CD(SD) (♀, N=6)	weanling	3 days	subcutaneous injection	uterine dry weight (absolute)	20	
							100 500	
Yamasaki et al. 2004	Bisphenol S	Rat, Crj:CD(SD) (♀,	weanling	3 days	subcutaneous injection	uterine dry weight (relative)	0	H O H
		N=6)					20 100	⊢ <mark>⊖⊣</mark> ⊦●⊣
Yamasaki et al. 2004	Bisphenol S	Rat,	weanling	3 days		uterine wet	500 0	
		Crj:CD(SD) (♀, N=6)	-	-	injection	weight (absolute)	20	
							100 500	
Yamasaki et al. 2004	Bisphenol S	Rat, Crj:CD(SD) (♀, N=6)	weanling	3 days	subcutaneous injection	uterine wet weight (relative)	0 20	H ⊖ H H ⊖ H
		.,					100	+ ● +
Yamasaki et al. 2004	Bisphenol Z	Rat,	weanling	3 days	subcutaneous	uterine dry	500 0	
and the set of a set of the set		Crj:CD(SD) (♀, N=6)			injection	weight (absolute)	6	⊢●→
							30 150	
	Bisphenol Z	Rat, Crj:CD(SD) (♀,	weanling	3 days	subcutaneous injection	uterine dry weight (relative)	0	
Yamasaki et al. 2004		CIJ.CD(3D) (¥,					30	
Yamasaki et al. 2004		N=6)						
Yamasaki et al. 2004 Yamasaki et al. 2004	Bisphenol Z	N=6) Rat,	weanling	3 days	subcutaneous	uterine wet	150 0	
		N=6)	weanling	3 days	subcutaneous injection	uterine wet weight (absolute)	0 6	⊢●→
Yamasaki et al. 2004	Bisphenol Z	N=6) Rat, Crj:CD(SD) (♀,			injection	weight (absolute)	0 6 30 150	
		N=6) Rat, Cr;⊂CD(SD) (⊋, N=6) Rat, Cr;⊂CD(SD) (⊋,	weanling	3 days 3 days	subcutaneous injection subcutaneous injection	weight (absolute)	0 6 30	⊢●→
Yamasaki et al. 2004	Bisphenol Z	N=6) Rat, Crj:CD(SD) (♀, N=6) Rat,			injection	weight (absolute) uterine wet	0 6 30 150 0	

Figure A-4. Data Pivot of Uterotrophic Response



Figure A-5. Vitellogenin Response

Citation	Chemical	Cell Type	Observation Time (H)	Receptor Type	🛏 Doses Tested 🛕 Increase 💿 No Change 💎 Decrease IC50 🖶 Ki 🕂 Kd
ashimoto and Nakamura 2000	4,4-Bisphenol F	ER-ES1 complex	1	Alpha	•—•• <u> </u>
Hashimoto et al. 2001	4,4-Bisphenol F	ER-ES1 complex	1	Alpha	•—•• <u> •</u>
Molina-Molina et al. 2013	4,4-Bisphenol F	HeLa	16	Alpha	●-●-●-▼◇▼-▼
Molina-Molina et al. 2013	4,4-Bisphenol F	HeLa	16	Beta	● - ●- ● - ▼
Blair et al. 2000	4,4-Bisphenol F	rat uterine cytosol	20	Endogenous	♦
Kitamura et al. 2003	4,4-Bisphenol F	rat uterine cytosol	40	Endogenous	
Perez et al. 1998	4,4-Bisphenol F	rat uterine cytosol	16	Endogenous	
Stroheker et al. 2004	4,4-Bisphenol F	MCF-7	0.5	Endogenous	
Hashimoto et al. 2001	Bisphenol AF	ER-ES1 complex	1	Alpha	
Delfosse et al. 2012	Bisphenol AF	HeLa		Alpha	
Matsushima et al. 2010	Bisphenol AF	bacteria	12	Alpha	
Delfosse et al. 2012	Bisphenol AF	HeLa		Beta	
Matsushima et al. 2010	Bisphenol AF	bacteria	12	Beta	$\bullet \bullet \bullet \nabla \nabla$
Laws et al. 2006	Bisphenol AF	rat uterine cytosol	18	Endogenous	F−−− ∮ −−−−−1
Laws et al. 2006	Bisphenol AF	rat uterine cytosol	18	Endogenous	∲ (
Perez et al. 1998	Bisphenol AF	rat uterine cytosol	16	Endogenous	• • • • • • • • • •
Hashimoto et al. 2001	Bisphenol B	ER-ES1 complex	1	Alpha	
Sipes et al. 2013	Bisphenol B	not reported		Alpha human	♦
Sipes et al. 2013	Bisphenol B	not reported		Alpha mouse	♦
Sipes et al. 2013	Bisphenol B	not reported		Alpha bovine	♦
Blair et al. 2000	Bisphenol B	rat uterine cytosol	20	Endogenous	♦
Perez et al. 1998	Bisphenol B	rat uterine cytosol	16	Endogenous	• • • • • • •
Perez et al. 1998	Bisphenol C	rat uterine cytosol	16	Endogenous	•—•- • - • - • - • - •
Hashimoto et al. 2001	Bisphenol E	ER-ES1 complex	1	Alpha	•—•• <u> •</u>
Hashimoto and Nakamura 2000	Bisphenol S	ER-ES1 complex	1	Alpha	• • • <u>•</u> <u>•</u>
Hashimoto et al. 2001	Bisphenol S	ER-ES1 complex	1	Alpha	• • • • •
Molina-Molina et al. 2013	Bisphenol S	HeLa	16	Alpha	● - ● - ● - ● - ▼ (▼
Molina-Molina et al. 2013	Bisphenol S	HeLa	16	Beta	● - ●-●- ▼ ▼ ▼
Blair et al. 2000	Bisphenol S	rat uterine cytosol	20	Endogenous	♦
_aws et al. 2006	Bisphenol S	rat uterine cytosol	18	Endogenous	I∳I
Laws et al. 2006	Bisphenol S	rat uterine cytosol	18	Endogenous	
Terasaki 2007	D-8	N/A - ELISA	1	- S9 Alpha +S9	H
Terasaki 2007	D-8	N/A - ELISA	1	Alpha	i

Figure A-6. Estrogen Receptor Binding Assays

Citation	Chemical	Cell Type	Observation Time (H)	Receptor Type	Endpoint Description	Dose Specific Effects Relative to Control
bert et al. 1994	4,4-Bisphenol F	MCF-7	192	Endogenous	cellular DNA	\bullet
shimoto and Nakamura 2000	4,4-Bisphenol F	MCF-7	144	Endogenous	neutral red absorbance	
ashimoto et al. 2001	4,4-Bisphenol F	MCF-7	144	Endogenous	SRB absorbance	
Canai et al. 2001	4,4-Bisphenol F	MCF-7	144	Endogenous	SRB absorbance +ICI	
Kanai et al. 2001	4,4-Bisphenol F	MCF-7	144	Endogenous	SRB absorbance	•
Molina-Molina et al. 2013	4,4-Bisphenol F	MCF-7	144	Endogenous	SRB absorbance	••••
Muroi 2003	4,4-Bisphenol F	MCF-7	144	Endogenous	cellular DNA	• • • • • • •
Perez et al. 1998	4,4-Bisphenol F	MCF-7	144	Endogenous	SRB absorbance	
Pisapia et al. 2012	4,4-Bisphenol F	MCF-7	96	Endogenous	cell number	
Stroheker et al. 2004	4,4-Bisphenol F	MCF-7		Endogenous	DABA fluorimetric assay	۵
Stroheker et al. 2004	4,4-Bisphenol F	MCF-7		Endogenous	DABA fluorimetric assay +E2	· · · ·
Stroheker et al. 2004	4,4-Bisphenol F				DABA fluorimetric assay +TAM	
Delfosse et al. 2012	Bisphenol AF	HeLa	240	Alpha WT	MTT Assay	$\bullet \bullet \overline{\nabla \nabla \nabla \nabla \nabla \nabla \nabla}$
Delfosse et al. 2012	Bisphenol AF	HeLa	240	Alpha 🖉	MTT Assay	• • • • • • • •
Delfosse et al. 2012	Bisphenol AF	HeLa	240	Beta WT	MTT Assay	
Delfosse et al. 2012	Bisphenol AF	HeLa	240	AAR	MTT Assay	• • • • • • • •
Delfosse et al. 2012	Bisphenol AF	MCF-7		Alpha	MTT Assay	• • • • • • • • • • • • • • • • • • •
Li et al. 2013a	Bisphenol AF	MCF-7	168		WST-1 dye	
Hashimoto et al. 2001	Bisphenol AF	MCF-7	144		SRB absorbance	
Kanai et al. 2001	Bisphenol AF	MCF-7	144		SRB absorbance +ICI	
Kanai et al. 2001	Bisphenol AF	MCF-7	144		SRB absorbance	
Muroi 2003	Bisphenol AF	MCF-7	144		cellular DNA	
Perez et al. 1998	Bisphenol AF	MCF-7	144		SRB absorbance	
Li et al. 2013a	Bisphenol AF	T47D	168		WST-1 dye	
Rotroff et al. 2013	Bisphenol AF	T47D	80		cell growth kinetics	
					-	· · ·
Kobayashi et al. 2006	Bisphenol AP	MCF-7	552	Endogenous	cell number	▲
Hashimoto et al. 2001	Bisphenol B	MCF-7	144	-	SRB absorbance	
Muroi 2003	Bisphenol B	MCF-7	144		cellular DNA	
Perez et al. 1998	Bisphenol B	MCF-7	144	-	SRB absorbance	
Pisapia et al. 2012	Bisphenol B	MCF-7	96		cell number	▲
Yang et al. 2014a	Bisphenol B	MCF-7:WS8		•	DPA Assay	
Rotroff et al. 2013	Bisphenol B	T47D	80	Endogenous	cell growth kinetics	↓ ─── ↓
Kanai et al. 2001	Bisphenol C	MCF-7	144		SRB absorbance +ICI	• • <u> </u>
Kanai et al. 2001	Bisphenol C	MCF-7	144		SRB absorbance	•
Muroi 2003	Bisphenol C	MCF-7	144	Endogenous	cellular DNA	
Perez et al. 1998	Bisphenol C	MCF-7	144	Endogenous	SRB absorbance	
Hashimoto et al. 2001	Bisphenol E	MCF-7	144	Endogenous	SRB absorbance	
Muroi 2003	Bisphenol E	MCF-7	144	Endogenous	cellular DNA	
Muroi 2003	Bisphenol P	MCF-7	144	Endogenous	cellular DNA	
Kobayashi et al. 2006	Bisphenol PH	MCF-7	0	Endogenous	cell number	•
Kobayashi et al. 2006	Bisphenol PH	MCF-7	168		cell number	<u> </u>
Kobayashi et al. 2006	Bisphenol PH	MCF-7	264		cell number	Ā
Kobayashi et al. 2006	Bisphenol PH	MCF-7	432		cell number	Ā
Kobayashi et al. 2006	Bisphenol PH	MCF-7	552	-	cell number	Ā
/inas et al. 2013	Bisphenol S	GH3/B6/F10	72	Endogenous	cell number	
Hashimoto and Nakamura 2000		MCF-7	144		neutral red absorbance	
Hashimoto et al. 2001	Bisphenol S	MCF-7	144		SRB absorbance	
Aolina-Molina et al. 2013	Bisphenol S	MCF-7 MCF-7	144	-	SRB absorbance	
Muroi 2003	Bisphenol S	MCF-7 MCF-7	144		cellular DNA +E2	
viuroi 2003				*		
	Bisphenol S	GH3/B6/F10		-	cell number	
Kobayashi et al. 2006	Bisphenol Z	MCF-7	0	•	cell number	•
Kobayashi et al. 2006	Bisphenol Z	MCF-7	168	0	cell number	▲
Kobayashi et al. 2006	Bisphenol Z	MCF-7	264	-	cell number	▲
Kobayashi et al. 2006	Bisphenol Z	MCF-7	432		cell number	▲
Kobayashi et al. 2006	Bisphenol Z	MCF-7	552	Endogenous	cell number	1e-8 1e-7000000000000000000000000000000000000

Figure A-7. Estrogen Receptor Cell Proliferation Assays

Ellation Yamasaki et al. 202								State Results Made Relation to Control
	Districted 22-Disphered F	Cell Type	Tria (4) 24	WT or Mutant Receptor WT wontry	Resploy 1504 Altra	Response Element	Endpoint Beacription (Hospitar (Hopotari)) (Di-styte (EDE-1920-Luci+)	Inna Specific Blacks Existino in Control - Cham Inited & roomer & Init Charge Channel
Defense at al. 2012	4.4-Disphend F	Phile .		WT works	Agen		(DE-SD-GA+) (DE-SD-GA+) (DE-GD-GA+)	
Malma Molecularia 2010 Delbase et al. 2010	4.4 Disphered F 4.4 Disphered F	PREA PREA	4	WT woploy Heard	Alfre Alfre	10%	(DE-schedury) NDI-dotre date F& ET-dotre (DE-schedury)	*******
Caludor et al 2028	4,4 Binghand P	Hepl3		Materi receptor Mill margine	Apta	Oher requires simul	Diabha (Diabha)	
Carte et al. 2000 Mangana et al. 2013 Diuda et al. 2011	4.4 Displand P 4.4 Displand P 4.4 Displand P	Page 22 and reported	24	WT washin	Alpha Ngha	Other response alamant Other response alamant	(DE-NGC) (Frains (schese) MPrains (Sah) (Frains (ner places)	••••
Diata et al. 2011	4.4 Dighend F	ret		wit waytor	Apro	Other suppressionent	(D-401s (Intergetectorites)	
Deals at A. 2011 Deals at A. 2009 Deals at A. 2010 Board at A. 2010 Run at A. 2010 Read at 2014	4.4 Displand F 4.4 Displand F 4.4 Displand F 4.4 Displand F 4.4 Displand F			UT scalar UT scalar UT scalar UT scalar		Other temporate element	(nete-palastacidaes) 601-aptino (nec 2) 671-aptino (nec 2) 671-aptino (nec 2) 671-palastacidaes) 6825-aptino (nete-palastacidaes)	
Ruse at al. 2015 Reset at 2014	4.4-Disphered F	rest .	4	WT wophy WT wophy	Alpha Alpha	Other supported alamand	CP: Excluminescence) http://www.	
Reporting of al. 2016 Reporting of al. 2016	4.4.Disphered P 4.4.Disphered P	pant	3	WT wasping	Apre	Ohe suppressioned Ohe suppressioned	(bela-galachoidan) h(Fl-dylra-Juchenau) BPA-R (scilla saa)	• • • • • • • • • • • • • • • • • • • •
Reporting at al. 2010	4,0 Blutend P	pent Nia		WT waster Materi receptor	Aptes Aptes	Other response attended		
Milma Malma et al. 2010 Definite et al. 2010	A.A.Disphered P	Phia		W7 maple	Bela Bela	3-8W	EFC-techerose) (EFC-techerose) METcheros (secherosei)	• • • • • • • • • • • • • • • • • • •
Define of a 200	4.4 Bighand F 4.4 Bighand F 4.4 Disphand F 4.4 Disphand F 4.4 Disphand F 4.4 Disphand F 4.4 Disphand F 4.4 Disphand F	Here's		Mard receptor	Belo Belo	Of a suppresented	NET temp (sechemes) Cells 48 ER Cells (2010: Antherase) ER Cells (2010: Th' Cell) ER Cells (2010: Th' Cell) ER Cells (2010: Sechemes) SER Suchemes (Seld) ER Suchemes (Seld)	•••••
Calador et A. 2009 Gallo et A. 2000 Margama et al. 2010 Rigarma et al. 2010 Rigarma et al. 2010 Millionae et al. 2010	4.4-Disphered F	Papid mirrorated	24	Mil woglar Mil woglar Mil woglar Mil woglar Mil woglar	Beta	Other temporate-alement Other temporate-alement	(Friend Suchman) Milliona (Sald) EP Suchman John)	
Rosenna et al 2016 Riserves et al 2016	4.4-bighend F 4.4-bighend F	801.4453 MCF.7	22 24	tri waytor Will wagtor	Entroperant Entroperant	5-546 Other temporate alement	ER Juctional activity) ER altification activity)	•••••
Manufa et al 2000 Material Manufacture 2010	4.4 Bighend F	140M	3	WT mapler WT waspin	Entoperant		EPE (surfaceare) EPE (surfaceare) (surfaceare)	
Seeks of A. 2000 Filler at 2014	4.4-Displayed F	reption .	5	WT support	-	Other supported element	(Prayra (uchrani)	••••
Colta d d. 2000 Miserura el d. 2008	4.4 Distand F	Physics .		wit washing	Ben .	Other response-alement	(Intergetechnisten) (Distant (uchersec)	· · · · · ·
Terget A 2212	Extracted P	Cen .	2	wit wasper	Ages	the second dead	pASTI-GR-spha (20.898152234a)	A & A A A A A A A A A A A A A A A A A A
Defines at al. 2010	Barwold	PEGA		WT support	Ages	Other supprise aisment	Diana-M1	A
Local 2018	Balant.M	HEA		WT washing	-	AP-1	EProgram (1002 AP-1 Unit) EProgram (140781 Sec)	:
Linital 2018) Defense at al. 2012	Esteni4	HIGH FIGH		Vit wophy Vit wophy	1010			• • • • • • • • • • • • • • • • • • • •
Metadona et al 2018	Batwool M	PAGE	24	wit wante	Apra	HER	(PE-schease) (PE-schease) (PE-schease) (PE-schease)	• • • • • • • •
Terresold of A. 2003a Liveral, 2013b Defense at al. 2013	Baherolikf	HAGA PAGA	4	WT wontor WT wontor	Ages Ages	1993-094	55-40% (252 DRC	
Defesse at al. 2010 Liveral. 2010	Baheol M	PAGE PAGE		will wonton	Ages	49-1 1	(hates (stitutes) Ehemistan (http://www.	
51414 (H12	Baltwork	195.4	*	wit waytor	Ages	195	WT EIh-stoffe	
Defines et al. 2012	Babest/F	HEA		Nari respire	Apta	Other supporter-aisment	ER-apto-15273	•
Definite at al. 2012 Definite at al. 2012	Balance P	PREA		Muteri receptor	707.0	1048	Criteria (Pr. dura) (PR. landarase) Criteria (Pr. dura)	• • • • • • • • • • • • • • • • • • • •
Local 2018	Report of	Heyld		Nuteri receptor Nuteri receptor UT scaptor UT scaptor	Apra Apra	1.01	(All All All All All All All All All All	
Lineat 20100	Bigherol.4	HUG2		ett soupor	April .	1099 pi0-695 49-1	enigne plå DRI Liej ER-stratue	Å .
Local 2010	Bahera.W	Hapla	*	WT works	April 1	1995	ER-aphanana (Nelh-Isua) WT Elhapha (IRE-an)	• • • •
Lineal 2013 Lineal 2012	Balant P	anaun anaun	1	WT washin WT washin	Apra Apra		EP-styles (EPE-lac) WT EI-styles (EPE-lac)	A
Liveral 2010	Barrest W	ankawa		will wanted	Apra	Other responses element	WTER-sphe (INDian)	<u> </u>
Loca NU	Balant.W	BTRIMS	*	WT mustor	Apra	24246	WT BR-apha (RRE-lac) + BYC2+	*
Line at 2012	Balant.P	and and		Malerd .	April 1	349%	WT Ethiopha (DTC-loc) robility ANJER apple (DTC-loc)	* •
Stratut 2010	Replaced N	and over		Nuteri receptor Inceptor Balant receptor Inceptor	Apta	2494	AP 2 Bit sight (DR-tec) E1 Bit sight (DR) tec)	A
Lineal 2012 Lineal 2012	Report of	hitees .	•	Baland receptor	Nyte Alte	1476	ETERalpha (EPErine) HT Division (EPErine)	<u>+</u>
Dang at al. 2000	Baharol M	pent		receptor WT wanging	Apre			* ••••
During of al. 2005 During of al. 2015 Ruan of al. 2015 Provided, 2014	Balanci M Balanci M Balanci M	past	1	VT waster VT waster VT waster	Apre Apre Apre	One suppresented	Eff-alpho (an-Z) BP-alpho (an-Z) BP (D-Aurhinessanse)	** ** ** *
Pearla 2014 Listat 2013b	Report of	Page 1		WT washes	Apre .	Ober seguras sienet	ER Docrinescence NPLeyre (http://www.chitesc) Ethoms (1959 Lan) EThoms (1959 Lan) EThoms (195 Automatic) EThoms	• • • • • • • • • • • • • • • • • • • •
List al. 2012b Definese et al. 2012	Between	No		wit wagtor	5m	1-DIC 3-BIW	Lati EN-bes (INDRE Lati	
Defines at al. 2012 Methodoline et al. 2012	Repared of	reca Tela	24	dit maple	ben Bein	194	EFLosia (DE-schesae) EFLosia (DE-schesae)	
Listal 2013e	Balant.P	Pala		W7 waster	Beta	100.014	Efficience (and Effect	•••••
Defense at al. 2012	Barbarol Af	Phile .		WT waster	bes .			
Event 2010	Baheol M	PAGA		WT waytor WT waytor		AR-1 14046 34846	Distance (Construction) (Constructio	•••
Lottet, 2012 Defines et al. 2012 Defines et al. 2012	Report of	Hista Hista		WT works Name ranges	lans Bate Bate	2494	delle All Phone (DR-scheme)	• •••
Dathese at al. 2010 United, 2010b United, 2010b	Baheolaf	Hela HepG2 Hes/12	4	Marri receptor WT worktor	bes .	1000	(Homo (HDPC Let)	
Local 2018	Replaced of	Heyl3 Heyl3		Ultransplar Ultransplar	Bria Bria	410-194 AF 1	EPiteria (x12 EPR) Unit EPiteria (x12 EPR)	*
Local 2012	Report of	Physic2			Bela	1.8%	GACI WIT ETCODe (CFE (Loc)	
Liveral 2010 Liveral 2010 Liveral 2010 Defineer et al 2010	Bighanal AP Bighanal AP	kitelauk bitikowo MCP 7	8	Mit mayba Drugs vector Mit mayba	Bela Bela Entogeneue	1494 1494 1494 3494	Michael Jack I Col Vit Billiele (FB Au) Vit Billiele (FB Au) Vit Billiele (FB Au) (FB	*****
Defines et al. 2012	Report of	909-1 907-7		Witnesslar Witnesslar	frigment	odre separation	EPLidates (EPIC-Inchester) EPLICED-Statistics	• 444444 4 44 4 4 4 44 4 •
Marrora et al. 2008 Bang 2014 Bernadoz et al. 2018 Tang et al. 2013	Balwal M	MON7 MUN 1470-REAZ	4 7 8	WT washing	Britigenau Dritigenau	Ohe represented	ER (suffering) (D. (suffering)	
Seguid 2013	Report of	01	н	WT washing	Apr 1	Here:		
Defense at al. 2012 Link al. 2012	Report of	Pala Pala		WT waster	Apre A	1494	Efficience (DE-schenaut) WT Efficience	
Defense at al. 2012	Balwold'	THE R		Name .	201	HER	Calls-18-01-4/16 (TRI-tal/Index)	•••••
Electric 2010	Bahest.W	nest	•	WT wontor	A\$7.4	Hex	WT Eli-spine	••••
Sound 2012 Round 2014	Represented in	ankara .	1	wit wanter	-	SHERE	WT EN-IGNA (EVELING)	
Definition of all 2012	Balance of	HER		WT washing	80	2495	(hele geter besterne) EP-Letter EP-Letterney	
Mauline 6.6 273	Balance.W	MAGA	н	WT mappy	843	1996	EPI-Loca (FPC-socherence)	
Destance of al. 2012	Balanci M	PREA PREA		Wit wasplor	and a	10%	WT Efficies (EFE-tur) Orts-NB-Di-Cotts	· · · · · · · · · · · · · · · · · · ·
Entrat. 2010 Entrat. 2010 Entrat. 2010 Element et al. 2020	Balterol M	Hapld Mikewa	1	WT waysor WT waysor	ana Des	ordini. Other response element	WT ER-outs (CRE-suc) WT ER-outs (CRE-suc)	::::
Dang et al. 2016 Dang et al. 2016 Dang et al. 2016	Report IV	MOP 7	24	WT wants	Alfa Alfa	Oher requires stoned	the higher in state and	• • •
Depris 2016	Reptored 10"			WT months		Oher requires stated	Dhalpho (ac-2) Dhalpho (ac-2)	•
Rong at al. 2014; Tempode et al. 2012	Estrent E	CAUX No.4	24 24	WT washing the second s	Alfra Alfra	Other suppressionent andres	Dhape (schese) Efficient (DE-FENCLE)	
Derbose at al. 2010 Derbose at al. 2010	Bagharol B	Phile		WT waytor	Apre	HER	(FLape	• • • • • • • • • • • • • • • • • • • •
Technol et al. 2010 Technol et al. 2014 Disale et al. 2011	Especial States	pant pant	5	Huteri receptor Mill scoperor Mill scoperor	Ages Ages	Other response observed	della-18-01-dotte (040-schesal) (01-dotte (040-schesal) (040-schesal) (040-schesal)	*******
Divide of al. 2011 Divide of al. 2011	Report 1			WT maple	Apte Apte	Other sequence element	EPLables (hete-peterboldesc)	•
Divergent al. 2011 Rivergent al. 2014;	Separat 8	-	4 24	WT washin	Apre 1	Other supported alarment	El-apra deto-precheideac (F-apra (harmonica)	
Dang et al. 2016 Definise et al. 2012	Esteri 3	pent Pica		Vill works Vill works	Apro Des	Other supprise alement	(Fi-Apho (Int-Z)	•••••
Defines at al. 2012	Report 8	Phia Phia		Mit wanter Recent	Bela Bela	1-DW	EPC-techerane) (EPC-techerane) (EPE-techerane) (EPE-techerane)	• • • • • • • • • • • • • • • • • • • •
Rosered et al. 2014 Barrer et al. 2014 Riservat et al. 2016 Riservat et al. 2016 Riservat et al. 2016	Report 1		22 24	MT wanter	Deleganase Belleganase	INTER OFFICE	EPI Jucketer	• • • • • • •
Riserura et al. 2010 Risery et al. 2010	Representation	NOTION ARX NOTION ARX NOTION	22 34 34 34	will wontor	Entropress Apres	Other temporate-alement	ER (ERE)-Grecoust	
	Reparent	peer		WT womby	1010	Of a suppressent		
Riscous et al 2020	Automatical Barriero Ba						(Assessment)	
Ring at al. 2014c	Bigharol C	MOH P	24	Wit washin Wit washin	Entroperant Alpha	Ohe separational	(hammarke) ER ((INE) > EHO (a) EF-dyle (achese)	• • • • • • • • • • • • • • • • • • • •
Norg et al. 2016 Disaleret al. 2011 Norg et al. 2016	Basharot C Basharot C Basharot C	CAUX pani	N 1 20	WT mapler WT mapler WT mapler	Antoprose Apter Apter		(Summerce) EP(10902)-2040-544 (FLab)ine (Serberse) EP(ab)ine Solito-principationidese) EP(ab)ine	• • • • • • • • • • • • • • • • • • • •
Norg et al. 2014: Disate et al. 2011 Norg et al. 2016: Disarg et al. 2016:	Replaced C Replaced C Replaced C Replaced C	pani		WT washin WT washin WT washin WT washin	Religional Agine Agine Agine	Other responses stimuted	EPLatyles (furmicance)	• • • • • • • • • • •
Norg et al. 2014: Disets et al. 2011 Norg et al. 2016: Disetg et al. 2016: Microsoft al. 2010	Replaced C Replaced C Replaced C Replaced C Replaced C Replaced C	pani	н	VII monto VII monto VII monto VII monto VII monto VII monto VII monto		Other responses stimuted	EPulphe (Summarrot) EPulphe (an-Z) EX (1945(2-1945-ba)	• • • • • • • • • • •
Norg et al. 2014; Distant al. 2011 Rong et al. 2016; Dang et al. 2016; Norg et al. 2016; Norg et al. 2016; Norg et al. 2016; Norg et al. 2016;	Naphanei C Raphanei C Raphanei C Raphanei C Raphanei C Raphanei C Raphanei C	pani MCF-7 CAUX		VII magka VII magka VII magka VII magka VII magka VII magka VII magka VII magka		Oher requires strend Oher requires strend	EPulphe (Summarrot) EPulphe (an-Z) EX (1945(2-1945-ba)	• • • • • • • • • • •
Norg et al. 2014; Distant al. 2011 Rong et al. 2016; Derug et al. 2016; Norg et al. 2016; Norg et al. 2016; Norg et al. 2016; Norg et al. 2016; Defuses et al. 2017	Represei C Represei C Represei C	preni MCH-7 CAUX preni MCP 7 Hala	л л	WT waster WT waster WT waster	Ages Ages Delegenes	Other requires stimut Other requires stimut Other requires stimut Other requires stimut Other requires stimut Other requires stimut Other stigures stimut	EFiliphe (histocree) EFiliphe (ar2) EFiliphe (ar2) EFiliphe (histocree) EFiliphe (histocree) EFiliphe (histocree) EFiliphe EFiliphe (histocree)	
Norg et al. 2014; Distant al. 2011 Rong et al. 2016. Design et al. 2016 Rong et al. 2016 Rong et al. 2016 Rong et al. 2016 Rong et al. 2016 Defense et al. 2010	Bigharol C Bigharol C Bigharol C Bigharol E Bigharol E	pani MCFT DRUK pani MCFT NGS	24 24 24 24	WT waster WT waster WT waster	Agro Agro Agro Agro	Other requires strend Other strends	Disapine Chammore() Elisapine Jane 21 Disapine Jane 21 Disapine Schemen Chammore() Elisapine Chammore() Elisapine (Disapine Schemene) Chammore() Disapine (Disapine Schemene)	
Nong et 2, 2016 Dealer et 2 2017 Nong et 2, 2016 Nong et 2, 2016 Defines et 2, 2017 Defines et 2, 2017 Defines et 2, 2017 Defines et 2, 2017 Defines et 2, 2017	Replaced C Replaced C Replaced C Replaced C Replaced E Replaced E	peeri MCF-7 CAULX peeri NCF 7 NECA NECA NECA	N N N	VII scopio VII scopio VII scopio VII scopio VII scopio VII scopio VII scopio	Agino Agino Agino Agino Agino Agino	Oter reporter stered Oter reporter stered	Display	
Nong et 2, 2016 Dealer et 2 2017 Nong et 2, 2016 Nong et 2, 2016 Defines et 2, 2017 Defines et 2, 2017 Defines et 2, 2017 Defines et 2, 2017 Defines et 2, 2017	Replaced C Replaced C Replaced C Replaced C Replaced E Replaced E	peeri MCF-7 CAULX peeri NCF 7 NECA NECA NECA	N N N	VII scopio VII scopio VII scopio VII scopio VII scopio VII scopio VII scopio	Agino Agino Agino Agino Agino Agino	Oter reporter stered Oter reporter stered	Display	
Nong et al. 2016 Denies et al. 2017 Rong et al. 2016 Nong et al. 2016 Nong et al. 2016 Nong et al. 2016 Nong et al. 2016 Denies et al. 2016 Denies et al. 2017 Denies et al. 2017	National C Replaced C Replaced C Replaced C Replaced C Replaced C Replaced C Replaced C Replaced C Replaced C	pani NGS-7 CRUX pani NGS NGS pani pani NGS	N N N N 1	VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko	Agra Agra Delegemen Agra Agra Agra Agra Agra Agra Bga Bga	Ote representational Oter representational	Produce Mediatro (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof.) (Prof	
Nong of a 2016- Dente of a 2017 Denty of a 2017 Deng of a 2016- Deng of a 2016- Deng of a 2016- Denty of a 2016- Denty of a 2016- Denty of a 2016 Denty of a 2016 Denty of a 2017 Denty of a 2017	Paphenet C Paphenet C	pani MCF7 GRUX pani HCS HCS HCS HCS HCS HCS HCS HCS	N N N N 1	VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko	Agra Agra Delegemen Agra Agra Agra Agra Agra Agra Bga Bga	Ote representational Oter representational	Produce Mediatron (C) (Production (C) (Product	
Nong et al. 2014 Denian et al. 2017 Nong et al. 2014 Nong et al. 2014 Nong et al. 2016 Nong et al. 2016 Nong et al. 2016 Nong et al. 2016 Definiso et al. 2010 Definiso et al. 2010 Reserve et al. 2010	Paphenet C Paphenet C	pani MCF7 GRUX pani HCS HCS HCS HCS HCS HCS HCS HCS	N N N N 1	VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko	Agra Agra Delegemen Agra Agra Agra Agra Agra Agra Bga Bga	Ote representational Oter representational	Produce Mediatron (C) (Production (C) (Product	
Nong et al. 2014 Denian et al. 2017 Nong et al. 2014 Nong et al. 2014 Nong et al. 2016 Nong et al. 2016 Nong et al. 2016 Nong et al. 2016 Definiso et al. 2010 Definiso et al. 2010 Reserve et al. 2010	Paphenet C Paphenet C	peed MCSF7 CRUX peed HGS HGS Peed Peed Peed Peed HGS HGS HGS HGS HGS HGS HGS HGS HGS HGS	N N N N N N N N N N N N N N N N N N N	VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko	Agra Agra Delegemen Agra Agra Agra Agra Agra Agra Bga Bga	Oter reporter stered Oter reporter stered	Produce Mediatron (C) (Production (C) (Product	
Nong of a 2016- Dente of a 2017 Dente of a 2017 Deng of a 2016- Deng of a 2016- Deng of a 2016- Dente of a 2016 Dentes of a 2016 Dentes of a 2017 Dentes of a 2017	Paphenet C Paphenet C	peed MCSF7 CRUX peed HGS HGS Peed Peed Peed Peed HGS HGS HGS HGS HGS HGS HGS HGS HGS HGS	N N N N 1	VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko VIT wangko	Agra Agra Delegemen Agra Agra Agra Agra Agra Agra Bga Bga	Der myren einer Der my	Produce Mediatron (C) (Production (C) (Product	
Neng al a Diri Base al a Diri Base al a Diri Dege al a Diri Neng al a Diri Neng al Diri Neng al Diri Defense al a Diri Defense al Diri Def	Imprové C Imprové C	Peerse MCS-F CALUX Peerse Peer	24 24 24 25 25 25 26 26 26 26 26 26 26 26 26 26 26 26 26	Hi nopy Hi	Agra Agra Agra Agra Agra Agra Agra Agra	Des representant des represen	Photometry (1) Photometry (1)	
Neng al 2014 Estanda 2014 Neng al 2014 Neng	Express C Express C Expres	Penel NGS-7 CAUX Penel NGS Penel NGS Penel		VT souty VT	Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Bes Bes Bes Bes Bes Bes Bes Bes Bes Bes	Der erprer eller Der erprer e	Marker Marker Strandson Harren Strandson	
Neng al 2014 Estanda 2014 Neng al 2014 Seng al 2014 Neng	Improvi C Improvi C	рині MG-F (AUX (AUX AUX AUX AUX AUX AUX AUX AUX		VT souty VT	Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Bes Bes Bes Bes Bes Bes Bes Bes Bes Bes	Der erprer eller Der erprer e	Marker Marker Strandson Harren Strandson	
Neng da 2014 Sender da 2014 Neng da 2014 Seng da 2014	Imment C Explored C	рини SG-F (2000) 2		VT souty VT	Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Alpha Bes Bes Bes Bes Bes Bes Bes Bes Bes Bes	Der erprer eller Der erprer e	Marker Marker Strandson Harren Strandson	
Neng da 2014 Sender da 2014 Neng da 2014 Seng da 2014	Imment C Explored C	рини SG-F (2000) 2		VT souty VT	Arra Aria Aria Arra Arra Arra Arra Arra	Des regres ettes Ore regres ettes	Manan Manan Sanata Sana	Image: Control of the second
Nengel a Division de Statis Nengel a Carlos Rengel a Carlos Re	Improved Improv	рини SG-F (2000) 2		40 app 40 app 41 app	Anna Anna Anna Anna Anna Anna Anna Anna	De regres dens des regres des la regres des des regres des regres des des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des regres des des regres des regres des des regres des regres des regres des regres des	Manana Maraka Angela Sana Sana Sana Sana Sana Sana Sana Sa	
Nengel a Division de Sarri Nengel a Division de Sarri Mangel a Division de Sarri Mangel a Division de Sarri Mangel a Division de Sarri Mangel a Division de Sarri Division de Sarri Division de Sarri Division de Sarri Nengel a Division de	Improvid Improv	ний MG-7 (MG-2 (NG) MG-2 (MG-2 (MG-		40 app 40 app 41 app	Anna Anna Anna Anna Anna Anna Anna Anna	De regres dens des regres des la regres des des regres des regres des des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des regres des des regres des regres des des regres des regres des regres des regres des	Manan Manana Manana Katalan Ka	Image: Control of the second
Nengel a Division de Jamie Nengel a Division Nengel a Div	Interest in the second	рин 303-1 303-1 303-1 303-1 303-1 304-1 30-		40 app 40 app 41 app	Anna Anna Anna Anna Anna Anna Anna Anna	De regres dens des regres des la regres des des regres des regres des des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des regres des des regres des regres des des regres des regres des regres des regres des	Manan Manana Manana Katalan Ka	Image: Control of the second
Hangad Abio Saukad Abio Mangad	Interest in the second	рин 50-17 50-		40 app 40 app 41 app	Anna Anna Anna Anna Anna Anna Anna Anna	De regres dens des regres des la regres des des regres des regres des des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des regres des des regres des regres des des regres des regres des regres des regres des	Manan Manana Manana Katalan Ka	Image: Control of the second
Hangad Abio Saukad Abio Mangad	Interest in the second	рин 50-17 50-		40 app 40 app 41 app	Anna Anna Anna Anna Anna Anna Anna Anna	De regres dens des regres des la regres des des regres des regres des des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des regres des des regres des regres des des regres des regres des regres des regres des	Manan Manana Manana Katalan Ka	Umain Image: Constraint of the constraintof the constraint of the constraint of the constraint of
Nengel a Neve Selecter à UNI Nengel à UNI Nengel à UNI Nengel à UNI Neue Selecter à UN	Needed Sciences Scien	рини 505-г 2007 100		 In support In support	Anna Anna Anna Anna Anna Anna Anna Anna	De regres dens des regres des la regres des des regres des regres des des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des regres des des regres des regres des des regres des regres des regres des regres des	Manan Manana Manana Katalan Ka	Umain Umain A Umain A A Umain
Nengel a Neve Selecter à UNI Nengel à UNI Nengel à UNI Nengel à UNI Neue Selecter à UN	Needed Sciences Scien	рини 505-г 2007 100		 In support In support	Anna Anna Anna Anna Anna Anna Anna Anna	De regres dens des regres des la regres des des regres des regres des des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des des regres des regres des regres des des regres des regres des des regres des regres des regres des regres des	Manan Manana Manana Katalan Ka	Image: Control of the contro
Nengel and Polity Mergel and Po	Interest in the second	րան 505 () 505 (Ann Ann Ann Ann Ann Ann Ann Ann Ann Ann	la apequantation of the sector	Parage Pa	
March 2004 Tardet March March 2004 March 200	Heard, Heard,	րան (2007) 2007 2007 2007 2007 2007 2007 2007			Ann Ann Ann Ann Ann Ann Ann Ann Ann Ann	Participant Partettttttttttttttttttttttttttttttttttt	Amage Amagee<	
March 2004 Tardet March March 2004 March 200	Heard, Heard,	րան (2007) 2007 2007 2007 2007 2007 2007 2007			Ann Ann Ann Ann Ann Ann Ann Ann Ann Ann	Participant Partettttttttttttttttttttttttttttttttttt	Amage Amagee<	
Maria I maria Series and a maria Series and	Interest of the second	mani un se		 In support In support	Ann Ann Ann Ann Ann Ann Ann Ann Ann Ann	A sequence of a	 Manufactoria Manufactoria Marcalanta Marcalanta<td></td>	
	Heard, Heard,	Handian Control of Con			Ann Ann Ann Ann Ann Ann Ann Ann Ann Ann	De apue and	 Andre and Antipation of Antipat	
March I was a second and a seco	Needed Anneed An	mail			Anne Anne Anne Anne Anne Anne Anne Anne	Na approximation of the sector	Non-series Amane And Series Amanee And Series Amane	
March I was a second and a seco	Needing Sectors Sector	mail			Anne Anne Anne Anne Anne Anne Anne Anne	Na approximation of the sector		
	Needed Anneed An	mail			Anne Anne Anne Anne Anne Anne Anne Anne	De apue and		

Figure A-8. Estrogen Receptor Reporter Gene Assays

Stonel et al. 2014 Stonel et al. 2014 Stonel et al. 2014 Namel et al. 2011 Gladok et al. 2015	Chomical	Cell Type	Observation	Receptor	WT or Madaet Receptor	Description	Dete Specifie Effects Relative to Carével IntéDroses Texient 🛕 Increase 🔿 No Danya 👽 Document
	44 Deshared F			Type Apta	Receptor WT sceptor WT sceptor WT sceptor WT sceptor WT sceptor	PR	
Stonai et al. 2014	4.4-Disphenol F	Hele HEF-T	30	Endogenous	WT receptor WT receptor	FR. GREBI PR	:
Romai et al. 2001 Gindok et al. 2015	4.4-Biphond F 4.4-Biphond F 4.4-Biphond F	Intel testis explores	12	Endogenous Endogenous Endogenous	WT sceptor WT sceptor WT sceptor	PR Operant	^ .
	4,4-linphond F 4,4-linphond F	fintel testis explorets fintel testis explorets	72 72	Endogenous Endogenous	WT nospor TW WT nospor	Coprime .	
Sindok et al. 2015 Sindok et al. 2016 Bindok et al. 2016	4,4 disphered F	Neal bezis explores Intel bezis explores Neal bezis explores Intel bezis explores	72	Endogenous Endogenous Endogenous Endogenous	WT receptor WT receptor	Inegr	
Badok et al. 2016 Blows et al. 2016			72 30	Endogenous Alpha		Elar PPE,	•
Street et al. 2014 Street et al. 2014	AADightend 7 AADightend 7		30 24	Deta Dedugenous	volgeon TW volgeon TW	OVER:	v
Deficase et al. 2013 Deficase et al. 2013		Hela Hela	24 24	Agita Agita	WT receptor Meant receptor	GAGET GAGET (sets All-ON apro.)	<u> </u>
Unit el 2012	Restored Mr.	biologue .	10			Order (sets-Aller ages)	
Liver al. 2012 Liver al. 2013b Liver al. 2013 Liver al. 2012	Bisharol M Bisharol M Bisharol M	tehteve tehteve	10	Apha Apha Apha Apha	WT sceptor WT sceptor WT sceptor	orean Grean NCAO PR	Ā
	Bispherol AF	lahkava Ishkava	10	Apha Apha	WT sceptor WT sceptor	PR PR	i i i i i i i i i i i i i i i i i i i
Unit 2018 Unit 2018 Unit 2019 Unit 2019 Unit 2018 Unit 2018	Baghanol AF Baghanol AF Baghanol AF		-	Apha	WT secondar	10	
Lier al. 2012	Baghwood NF Baghwood NF Baghwood NF	thinkowa		AgAs AgAs AgAs AgAs	WT HOUGHLY	PR (in presence of PD (8058 initiality) PR (in presence of PPD vibidar) SDF-1 SPUVE	
Lief al. 2012	Bigherol N	lithera	8	AgAo AgAo	WT receptor WT receptor	SPLAE	÷
Unit al. 2018b	Bisherol N	la hora	10	Agina	volgeon TW volgeon TW	1PU/4 108/2	1
Urent 20186 Urent 20186 Urent 20186 Urent 20186 Urent 20186	Beghanol IV Beghanol IV Beghanol IV Beghanol IV Beghanol IV	NCP-T	16 24	Agina Agina	WT noophy WT noophy	p52 CTRD CTRD	
	Bishanol AF Bishanol AF Bishanol AF		24 1 or 2	Agha Agha Agha	WT works		••••
Livet al. 2014		HCP-7	4.8.24. 40, and 72		WT roceptor	CTED	▲
Lietal 2013e Lietal 2014	Bisherol M	MCP-T	24 24	Alpha Alpha	volgeon TW volgeon TW	04581	• • • • • •
Unit al. 2014 Unit al. 2014 Unit al. 2014	Baghanol M Baghanol M Baghanol M Baghanol M	HEP-F HEP-F HEP-F	1072	Alpha Alpha Alpha	volgeon TW volgeon TW volgeon TW	GATE: CATE:	•
Listal With-	Restant M	MPL7	4, 8, 24, 40, and 72 24		WT receptor	TECT	^
Uret al. 2014 Uret al. 2014 Uret al. 2014	Brackwood AF Brackwood AF Brackwood AF	NCP-T NCP-T	N 1072	Alpha Alpha Alpha	WT rought	1991 1991 1991	• • • • • •
U-et al. 2014	Basherol Nº	HEP-T	4, 8, 24, 40, and 72	Apha	WT rought	1991	A
Liver al. 2014	Bispherol AF	MOF-7	24	Apha	Matarit receptor	CTSD (in the absence of ER-olpha)	
Unit al. 2014	Bispherick AF Bispherick AF	MCP-7	24	Apha	Mularit receptor	ORER1 (in the absence of DR alpha)	v
Listal 2014	Baghwool AF Baghwool AF	HEF-7 HEA-AND/1	24 24	Agita Agita	Mutant receptor	TEP1 (in the absence of ER-alpha) CTED (Nov-ER-alpha)	▼
Ure al 2014 Ure al 2014	Baghanol AF		24	AgAo AgAo	Matarit receptor Matarit	CTED (Mr-RH wptw) CTED (m/he strenge of ER-obtin)	A
List al. 2014	Bigherol AF	HDA-M0221	24	Agita	Motant receptor Motant receptor	GREET (Kon-EP) w(rive)	••••
Liverad. 2014	Bisherol NF	NEA-MICH	24	Apho	Mort receptor	ORERT (in the absence of OR alpha)	•••
Livet al. 2014	Bighanol AP	HDA-MS201	24	Apha	Mutant	1971 (Ach-ER-alpha)	A
Li et al. 2014		HDA-M0221	24	Apha	Nooptar Notant nooptar WT receptor WT receptor WT receptor	TEF1 (in the absence of ER-alpha)	
Livet al. 2013e Livet al. 2014 Livet al. 2014 Livet al. 2014	Bayhanol AF Bayhanol AF Bayhanol AF Bayhanol AF	T47D T47D	24 24 1 or 2	AqAu AqAu	vilgeor Tw vilgeor TW	GT8D GT8D	•••
Uret al. 2014 Uret al. 2014	Brahanol AP Brahanol AP	14/D 14/D	1 or 2 4. 8. 24. 40, and 72	Agina Agina	virgeor Titr virgeor Titr	CTED	
	Bayland M Bayland M	147D				04681	• • •
Lietal 2018a Lietal 2018 Lietal 2018 Lietal 2018	Bayhanol AF Bayhanol AF	Terb	24 24 1	70,94	valquor TW valquor TW valquor TW	over over over	• • • • • • • •
Li et al. 2014	Brahmol NP Brahmol NP	14/D	2.4.8. 24.45 and 72	Again	WT soughtr	04881	A
Lietal. 2013a Lietal. 2014	Brightened AF	T4ID T4ID	24	Agita Agita	wT mapsor WT mapsor	1881 1881	• • • • •
Liveral. 2014 Liveral. 2014	Brighand AF Brighand AF	T47D T47D	10/2	74544 74544 74544	WT rought WT rought	1991 1991 1991	
			4.8.24. 45.and 72				▲
Lietal. 2014 Lietal. 2014	Baghanol AF	T4ID T4ID	24 24	Agita Agita	Mutant receptor Mutant receptor	CTSD GREB1	×
Liver al. 2014	Bughand M.	THID	24	Agina	receptor Maturit	1771	▼ ▼
Delitase at al. 2512 Delitase at al. 2512			24 24	ikra ikra	Nuturi neoptar WT nooptar	GREAT	▲
Deficise at al. 2013 Unit al. 2014	Boghanol AF			inte Dete	receptor	GREAT (anto All-GR alpha) GREA	▲
Unit al. 2014	Bispherick AF	HOP-T	24 24	Deta Deta	Matant receptor Matant receptor	GREEF	▼ ▼
Liver al. 2014	Bisherol NF	MDF-7	26		Mart receiver	1691	▼ ▼
Uret al. 2014	Baghanol AP	14/D	24	Deta	Maart receptor Matant receptor	GTED	▼
	Bisterol AF		24	Deta Deta	Mutant more that	GREBH THEI	▼
U-et al. 2014 U-et al. 2013b	Bayland N ² Bayland N ²	T47D	24 18		Nutant receptor Drepty webr	ORES!	•
Unit al. 2013b	Baghanol AF	lahkawa lahkawa	10 10 10	Endogenous Endogenous	Emply vector		
U et al. 2018 U et al. 2018 U et al. 2018 U et al. 2018 U et al. 2018	Baghanol AF Baghanol AF Baghanol AF Baghanol AF Baghanol AF	bhiava bhiava bhiava bhiava	10 10 10	Endogeneus	Emply vector	50F-1 50F-1 85FV/C 866P2 952	
Liver al. 2013b Liver al. 2013b Delicase at al. 2013	Bioghanol AF Bioghanol AF Bioghanol AF	MORAN BACK-7	10 10 24	Endogenous Endogenous Endogenous Endogenous Endogenous Endogenous Endogenous Endogenous	Empty vector	endeko p52 GREBH	•
Descent at al. 2014	Restance M	10157	24 24 24	Endogenous Endogenous	wT нарах WT нарах	02521	^ .
Deltosse et al. 2012 Roma et al. 2011 Deltosse et al. 2012	Brighwood AF Brighwood AF Brighwood AF	MOF-7 MOF-7 MOF-7		Endogenous Endogenous	rubquor TW rubquor TW rubquor TW rubquor TW rubquor TW Rubquor TW Rubquor rubquor rubquor rubquor rubquor	PR PR NP140	
Dellosse el al 2012 Dellosse el al 2012 Mines el al 2012	Boghanol AF Boghanol AF Boghanol AF	HEP-T HEP-T	24 24	Endogenous Endogenous	WT roughty WT roughty	HBP180 p52 p52	Å
Wows at al. 2012 Unit al. 2014	Brahmol Nº Brahmol Nº	HEP-T	24	Endogenous Endogenous	WT roopsor Nature	GTSD (in the absence of GPER)	• • •
Liver al. 2014	Bispherol M	HEF-T	24	Endogenous	Mont month	GREET (in the absence of GPER)	v
U-#14, 2014	Bispheriol AF	HOP 7	24	Endogenium Endogenium	Malart receptor	1891	▼
Unital 2014	Baghanol AF	T47D	24 24	Endogenous	Mutant receptor	0750 93581	•
List al. 2014		14/0	24	Endogenous Endogenous	ncepter Malant ncepter	1991	▼ ▼
Stored et al. 2014	Bayhand M	Pete	30	Apha	WT NORM	PR.	× X
Donal at al. 2014 Line al. 2014		HEAR	30 24	Agita Agita	WT sceptor WT sceptor	FRE. CTSD (in the presence of IC)	▼ ▲
Listal 2014 Listal 2014 Listal 2014	Baghanol AF Baghanol AF Baghanol AF	HCF-7 HCF-7 HCF-7	н н н	Apha Apha Apha Apha	WT scaptor WT scaptor WT scaptor	CTSD (in the presence of PO98085 or U6120) CTSD (in the presence of PO9 CTSD (in the presence of PO9) CRSBIT (in the presence of PO)	÷
Line al. 2014 Line al. 2014	Baghance AF Baghance AF Baghance AF	MOF-7 MOF-7	24				
Liveral. 2014 Liveral. 2014 Liveral. 2014			24 24	AQA4	wit mapped	GREAT (in the presence of FPQ) TFP1 (in the presence of CQ)	*
Liveral 2014 Liveral 2014 Liveral 2014	Baghwood AP Baghwood AP	HEP-T HEP-T	24	20,84	with societies	1997 Jostine poissence of CC) 1997 Jostine poissence of PC000005 or U21(20) 1997 Jostine poissence of PP2)	V
Unit al. 2014 Unit al. 2014	Baghanol M [*]	THE	24	2014 a	WT sceptor	CTED (in the presence of IC) CTED (in the presence of PO08080 or UE120)	Ť
Unit al. 2014		THE	24	Apha Apha	WT sceptor WT sceptor	CTUD in the summer of DDD	Ť
Clarat. 2014 Clarat. 2014 Clarat. 2014	Bapwo A Bapwo A Bapwo A Bapwo A	14/D 14/D	24	Alpha Alpha Alpha	WT sceptor WT sceptor	GPEEP (in the presence of EQ) GPEEP (in the presence of EQ) GPEEP (in the presence of PC000006 or UE120) GPEEP (in the presence of PP2)	ž
Lienal 2014 Lienal 2014	Baghanol AF Baghanol AF Baghanol AF	T4ID T4ID	24 24	Agita Agita	WT sceptor WT sceptor	GREET (in the presence of FP2) TTF1 (in the presence of City TTF1 (in the presence of PO40005 or U2128)	ž
List at 2014		THID	8	Apas	WT sceptor	TEFT (in the presence of PO40005 or UD108) TEFT (in the presence of PP2)	¥ _
Line al. 2014 Second et al. 2014 Second et al. 2014 Second et al. 2014	Baghanid AF	Hela	30	in a	WT noquar WT noquar WT noquar	P95. 195. GARRE	÷
Stored at al. 2014 Stored at al. 2014	Brighand AP	HEF-T	24 30		WT receptor	04581 PRL	
	Bisshenol AP	HILE HEF-7	20 24	Ento Entogenous	WT Nopplar WT Nopplar	PRL GREAT	A
Stani et al. 2014			30	Agita Into	итнорог итнорог итнорог	196. 196.	
Stoni et al. 2014 Stoni et al. 2014 Stoni et al. 2014	Baghwool AP	1964A				GREB!	3
Stonei et al. 2014 Stonei et al. 2014 Stonei et al. 2014 Stonei et al. 2014 Stonei et al. 2014	Baghanal AP Baghanal AP Baghanal AP	MOP/7	30 34				¥ ¥
Stonei et al. 2014 Stonei et al. 2014 Stonei et al. 2014 Stonei et al. 2014 Stonei et al. 2014	Baghanal AP Baghanal AP Baghanal AP	HEF-T	24		WT sceptor WT sceptor	PR. PR.	
Stand et al. 2014 Stand et al. 2014	Baghanci AP Baghanci AP Baghanci AP Baghanci D Baghanci D Baghanci D	HEF-T HeLa HEF-T HEF-T	20 20 20	Apta Dris	WT sceptor WT sceptor WT sceptor WT sceptor	PRL PRL GREAT pS2	A A
Stand et al. 2014 Stand et al. 2014	Baghanci AP Baghanci AP Baghanci AP Baghanci D Baghanci D Baghanci D Baghanci D Baghanci D	HEF-7 INLA INLA IND-7 IND-7 INLA INLA	24 30 30 34 34 30 80	Apta Des Entogenous Entogenous Apta	WT MARK	P92.	
Scoal et al. 2014 Scoal et al. 2014	Bispherick AP Bispherick AP Bispherick AP Bispherick B Bispherick B Bispherick B Bispherick B Bispherick B	1025-7 19428 19428 1825-7 19428 18428 18428 18429-7	24 30 24 24 30 30 30 30 30 34	Apha Deta Endogenous Endogenous Apha Beta Endogenous	ит норах ит норах ит норах	paz F6L F9L Oklas	
Scoul et al. 2014 Secure et al. 2014	Bispherick AP Bispherick AP Bispherick AP Bispherick B Bispherick B Bispherick B Bispherick B Bispherick B Bispherick B Bispherick C Bispherick C Bispherick C	NGA NGA NGA NGA NGA NGA NGA NGA	24 20 20 24 24 20 20 24 20 20 20	Apha Deta Endogenous Endogenous Apha Beta Endogenous	ит норах ит норах ит норах	PR. PR. OKER PR. PR.	
Sense et al. 2014 Sense et al. 2014	Baghwood AP Baghwood AP Baghwood AP Baghwood AP Baghwood B Baghwood B Baghwood B Baghwood B Baghwood B Baghwood C Baghwood C Baghwood C	NDFT INGA INGA INGFT INGA INGFT INGA INGFT	24 30 24 24 30 30 30 30 30 34	Apha Des Entogenaux Entogenaux Apha Entogenaux Apha Entogenaux Apha Entogenaux	WT souper WT souper WT souper WT souper WT souper WT souper	paz F6L F9L Oklas	
Securit et al. 2014 Securit et al. 2014 Securit et al. 2014 Securit et al. 2019 Securit et al. 2019 Securit et al. 2019 Securit et al. 2014 Securit et al. 2014	Baghand AP Baghand AP Baghand AP Baghand B Baghand B Baghand B Baghand B Baghand B Baghand B Baghand C Baghand C Baghand C Baghand C	1629 7 India In	N 30 30 34 30 30 30 30 30 30 30 30 30 30 30 30 30	Apita Dera Dera Dera Dera Dera Dera Apita Dera Dera Dera Dera Dera Dera Dera Der	varpoor Tar varpoor Tar varpoor Tar varpoor Tar varpoor Tar varpoor Tar varpoor Tar varpoor Tar	922 996, 996, 996, 996, 996, 996, 997, 99	
Sourie et al. 2014 Source et al. 2014 Source et al. 2014 Source et al. 2019 Source et al. 2019 Source et al. 2019 Source et al. 2014 Source et al. 2014	Baghand AP Baghand AP Baghand AP Baghand B Baghand B Baghand B Baghand B Baghand B Baghand B Baghand C Baghand C Baghand C Baghand C	1629 7 India India India India India India India India India India India India India India India	N 30 30 30 30 30 30 30 30 30 30 30 30 30	Apita Dera Dera Dera Dera Dera Dera Apita Dera Dera Dera Dera Dera Dera Dera Der	varpoor Tar varpoor Tar varpoor Tar varpoor Tar varpoor Tar varpoor Tar varpoor Tar varpoor Tar	рах ня, ня, окал ря, ря, раба ня ня, окал ря,	
Sourd et al. 2014	Baghend AP Baghend AP Baghend AP Baghend B Baghend B Baghend B Baghend B Baghend B Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C	10517 INGS INGS 10517 INGS 10517 INGS 10517 INGS 10517 INGS 10517 INGS 10517 INGS 10517 INGS 10517	N 30 30 34 30 30 30 30 30 30 34 30 30 36 30 30 36 30 30 36 30 30 36 30 30 30 30 30 30 30 30 30 30 30 30 30	Agas Bes Entopress Agas Bes Entopress Agas Bes Entopress Agas Agas Agas Agas Bes Entopress Entopress	valgeon Tar valgeon Tar valgeon Tar valgeon Tar valgeon Tar valgeon Tar valgeon Tar valgeon Tar valgeon Tar valgeon Tar valgeon Tar	202 196. 196. 196. 196. 196. 196. 196. 196.	
Score et al. 2014 Store et al. 2014	Baghend AP Baghend AP Baghend AP Baghend B Baghend B Baghend B Baghend B Baghend B Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C	10517 INGS INGS 10517 INGS 10517 INGS 10517 INGS 10517 INGS 10517 INGS 10517 INGS 10517 INGS	N 30 30 34 30 30 30 30 30 30 34 30 30 36 30 30 36 30 30 36 30 30 36 30 30 30 30 30 30 30 30 30 30 30 30 30	Agas Bes Entopress Agas Bes Entopress Agas Bes Entopress Agas Agas Agas Agas Bes Entopress Entopress	vitigeon Titr Vitigeon Titr vitigeon Titr Vitigeon Titr Vitigeon Titr Vitigeon Titr Vitigeon	202 196. 196. 196. 196. 196. 196. 196. 196.	
Sourie et al. 2014 Source et al. 2014 Source et al. 2014 Source et al. 2019 Source et al. 2019 Source et al. 2019 Source et al. 2014 Source et al. 2014	Baghend AP Baghend AP Baghend AP Baghend B Baghend B Baghend B Baghend B Baghend B Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C	807-7 Nata Nata Nata Nata Nata Nata Nata Nat	N 30 30 30 30 30 30 30 30 30 30 30 30 30	Apa Bra Dragenos Cratogenos Apa Bra Bra Bra Dratogenos Apa Apa Bra Dratogenos Dratogenos Apa Bra Dratogenos Dratogenos Dratogenos	WT toopkor WT toopkor	μμ μα μα μα μα μα μα μα μα μα	
Source at 2.014 Source at 2.01	Baghend AP Baghend AP Baghend AP Baghend AP Baghend B Baghend B Baghend B Baghend B Baghend B Baghend B Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C	NG7-7 NG2	N 30 30 30 30 30 30 30 30 30 30 30 30 30	Apa Bra Dragenos Cratogenos Apa Bra Bra Bra Dratogenos Apa Apa Bra Dratogenos Dratogenos Apa Bra Dratogenos Dratogenos Dratogenos	WT toopkor WT toopkor	μμ μα μα μα μα μα μα μα μα μα	
Source at 2.014 Source at 2.01	Baghend AP Baghend AP Baghend AP Baghend AP Baghend B Baghend B Baghend B Baghend B Baghend B Baghend B Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C Baghend C	NG7-7 NG2	N 30 30 30 30 30 30 30 30 30 30 30 30 30	Apa Bra Dragenos Cratogenos Apa Bra Bra Bra Dratogenos Apa Apa Bra Dratogenos Dratogenos Apa Bra Dratogenos Dratogenos Dratogenos	WT toopkor WT toopkor	μμ μα μα μα μα μα μα μα μα μα	
Source et a 2014 Bone e	Baghend AP Baghend AP Baghend AP Baghend AP Baghend B Baghend B Baghend B Baghend B Baghend B Baghend C Baghend C	NRA	8 30 30 30 30 30 30 30 30 30 30	Ара Ара Ва Ва Сабриная Сабриная Ара Ара Сабриная Ара Ара Ара Ара Ара Ва Сабриная Ара Ва Сабриная	WT Noqdar WT Noq		
Source at 2014 Bone of a 2014 Bone o	Baghand AP Baghand AP Baghand AP Baghand A Baghand B Baghand B Baghand B Baghand B Baghand B Baghand C Baghand S Baghand S	807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807 807 807 807 807 807 807 807 807 807	8 30 30 30 30 30 30 30 30 30 30	Ара Ара Ва Ва Сабриная Сабриная Ара Ара Сабриная Ара Ара Ара Ара Ара Ва Сабриная Ара Ва Сабриная	WT Noqdar WT Noq		
Source of a 2014 Sour	Baghand AP Baghand AP Baghand AP Baghand A Baghand B Baghand B Baghand B Baghand B Baghand B Baghand C Baghand S Baghand S	807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807-7 845 807 807 807 807 807 807 807 807 807 807	8 30 30 30 30 30 30 30 30 30 30	Ара Ара Ва Ва Сабриная Сабриная Ара Ара Сабриная Ара Ара Ара Ара Ара Ва Сабриная Ара Ва Сабриная	WT Noqdar WT Noq		
Some of a 1204 Some of	Baghana AP Baghana AP Baghana AP Baghana AP Baghana B Baghana B Baghana B Baghana B Baghana C Baghana C Ba	807-7	M M <t< td=""><td>Hagena Ala Ala</td><td>WT Noquby WT Noquby</td><td>2022 202 2022 2</td><td></td></t<>	Hagena Ala	WT Noquby WT Noquby	2022 202 2022 2	
Design et al. 2014 Bass et al. 2015 Bass et al. 2015 Bass et al. 2014 Bass et al. 2014 Bass et al. 2014 Bass et al. 2015 Bass et al. 2014 Bass et	Aurona (A) Barrano	BCF.7 PIGA	21 20 20 20 20 20 20 20 20 20 20 20 20 20	Haqinaa Aka Da Daganaa Kaba Daganaa Kaba Daganaa Aka Daganaa Aka Daganaa Aka Daganaa D	WT Nequity WT Nequity		
Dens et al 2014 Bear et al 201	Summer AP Summer	NOT P NAA NAA NAA NAA NACT NAA NAA NAA NAA NAA NAA NAA NA	34 35 36 37 38 38 39 30 30 30 30 31 30 31 32 33 34 30 31 32 33 34 35 36 36 37 30 30 30 30 30 30 30 30 31 32	Hagena Ala	WT Nequest WT Nequest		
Denie and 2014 Benaris	Journal APA Source APA	NOP T NAA NAA NAA NAA NACT NAA NAA NAA NAA NAA NAA NAA NA	21 20 20 20 20 20 20 20 20 20 20 20 20 20	Transition T	10) Inappe 20) Inappe	на (на) (
Denie and 2014 Benaris	Support APA Support APA Suppor	NUT I I I I I I I I I I I I I I I I I I I	21 20 20 20 20 20 20 20 20 20 20 20 20 20	Transition T			
Dens on a 2014 Beam of a 2014 Beam o	Journal APA Source APA	NOP T NAA NAA NAA NAA NACT NAA NAA NAA NAA NAA NAA NAA NA	21 20 20 20 20 20 20 20 20 20 20 20 20 20	Aba Ma Aba Ma Ma Aba Ma Aba Aba Aba Aba Aba Aba Aba Aba Aba Ab		۵۷ مر	
	Superior Annual	Norf Mac Nac Nac Nac Nac Nac Nac Nac Nac Nac N	30 20 30 20 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 30	Aba Ma Aba Ma Ma Aba Ma Aba Aba Aba Aba Aba Aba Aba Aba Aba Ab		۵۷ مر	
Description 2014 Resard of 2014	Superior Annual	Norf Mac Nac Nac Nac Nac Nac Nac Nac Nac Nac N	30 20 30 20 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 20 30 30 30 30	Aba Ma Aba Ma Ma Aba Ma Aba Aba Aba Aba Aba Aba Aba Aba Aba Ab		Internet of the second	

Figure A-9. Estrogen Receptor Modulation of Endogenous Gene Expression

Citation	Chemical	Cell Type	Observation Time (H)	Receptor Type	WT or Mutant Receptor	Description	Dose Specific Effects Relative to Control Image: Doses Tested ▲ Increase. ● No Change ▼ Decrease ♦ IC50 ● Cytotoxicity Observed
tossi et al. 2014	4,4-Bisphenol F	MCF-7	24	Endogenous	WT receptor	ER-alpha	▼
Perez et al. 1998	4,4-Bisphenol F	MCF-7	72	Endogenous	WT receptor	PR	• <u>A</u>
Perez et al. 1998	4,4-Bisphenol F	MCF-7	144	Endogenous	WT receptor	pS2	•—• <u> </u>
Stossi et al. 2014	4,4-Bisphenol F	MCF-7	24	Endogenous	WT receptor	ER-alpha	▲
Stossi et al. 2014	Bisphenol AF	MCF-7	24	Endogenous	WT receptor	ER-alpha	\checkmark
Perez et al. 1998	Bisphenol AF	MCF-7	72	Endogenous	WT receptor	PR	
Rivas et al. 2002	Bisphenol AF	MCF-7	72	Endogenous	WT receptor	PR	• <u> </u>
Rivas et al. 2002	Bisphenol AF	MCF-7	144	Endogenous	WT receptor	pS2	• <u> </u>
Perez et al. 1998	Bisphenol AF	MCF-7	144	Endogenous	WT receptor	pS2	• <u> </u>
Rivas et al. 2002	Bisphenol AF	MCF-7	144	Endogenous	WT receptor	pS2	• <u> </u>
etcher et al. 2005.	Bisphenol AF	hepatocytes		Endogenous	WT receptor	VTG	▲
Stossi et al. 2014	Bisphenol AF	MCF-7	24	Endogenous	WT receptor	ER-alpha	▲
etcher et al. 2005.	Bisphenol AF	hepatocytes		Endogenous	WT receptor	VTG	• ····
Stossi et al. 2014	Bisphenol AP	MCF-7	24	Endogenous	WT receptor	ER-alpha	▼
Stossi et al. 2014	Bisphenol AP	MCF-7	24	Endogenous	WT receptor	ER-alpha	Á.
Stossi et al. 2014	Bisphenol B	MCF-7	24	Endogenous	WT receptor	ER-alpha	▼
				•			
Rivas et al. 2002	Bisphenol B	MCF-7	72	Endogenous	WT receptor	PR	
Perez et al. 1998	Bisphenol B	MCF-7	72	Endogenous	WT receptor	PR	·
Rivas et al. 2002	Bisphenol B	MCF-7	144	Endogenous	WT receptor	pS2	• •
Perez et al. 1998	Bisphenol B	MCF-7	144	Endogenous	WT receptor	pS2	
Stossi et al. 2014	Bisphenol B	MCF-7	24	Endogenous	WT receptor	ER-alpha	
Stossi et al. 2014	Bisphenol C	MCF-7	24	Endogenous	WT receptor	ER-alpha	$\mathbf{\nabla}$
Perez et al. 1998	Bisphenol C	MCF-7	72	Endogenous	WT receptor	PR	
Perez et al. 1998	Bisphenol C	MCF-7	144	Endogenous	WT receptor	pS2	
etcher et al. 2005.	Bisphenol C	hepatocytes		Endogenous	WT receptor	VTG	•—▲
Stossi et al. 2014	Bisphenol C	MCF-7	24	Endogenous	WT receptor	ER-alpha	
etcher et al. 2005.	Bisphenol C	hepatocytes		Endogenous	WT receptor	VTG	•• - • \
Rivas et al. 2002	Bisphenol E	MCF-7	72	Endogenous	WT receptor	PR	•—• <u> </u>
Rivas et al. 2002	Bisphenol E	MCF-7	144	Endogenous	WT receptor	pS2	●●▲
etcher et al. 2005.	Bisphenol P	hepatocytes		Endogenous	WT receptor	VTG	•—•
etcher et al. 2005.	Bisphenol P	hepatocytes		Endogenous	WT receptor	VTG	•—• — •
/inas et al. 2013	Bisphenol S	GH3/B6/F10	1	Alpha	WT receptor	PRL	
Stossi et al. 2014	Bisphenol S	MCF-7	24	Endogenous	WT receptor	ER-alpha	▼
/inas et al. 2013	Bisphenol S	GH3/B6/F10	1	Alpha	WT receptor	PRL V	
Stossi et al. 2014	Bisphenol S	MCF-7	24	Endogenous	WT receptor	ER-alpha	
Stossi et al. 2014	Bisphenol Z	MCF-7	24	Endogenous	WT receptor	ER-alpha	
Stossi et al. 2014	Bisphenol Z	MCF-7	24	Endogenous	WT receptor	ER-alpha	
				-			
Stossi et al. 2014 etcher et al. 2005.	TMBPA TMBPA	MCF-7	24	Endogenous Endogenous	WT receptor WT receptor	ER-alpha VTG	▼
		hepatocytes	24	*			
Stossi et al. 2014	TMBPA	MCF-7	24	Endogenous	WT receptor	ER-alpha	
etcher et al. 2005		hepatocytes		Endogenous	WT receptor	VTG	
etcher et al. 2005.	IMBPA	hepatocytes		Endogenous	WT receptor	VTG	

Figure A-10. Estrogen Receptor Modulation of Protein Expression

	Citation	Chemical	Cell Type	Observation Time (H)	Measured Steroid	H Doses tested 🔺 Increase No Change Decrease EC50 Cyto
	mai et al. 2014	4,4-Bisphenol F	H295R		17-OH progesterone	
ai ad al 20 Baphenya Bayesya Ba	mai et al. 2014	Bisphenol B	H295R		17-OH progesterone	
air all 2014 4.4.5.5.proof P 1005R 17.5.5.5.s.s.s.s.s.s.s.s.s.s.s.s.s.s.s.s.	mai et al. 2014	Bisphenol E	H295R		17-OH progesterone	• • • • • • •
rad at 2014 4.88phond P 1928 17.1040-entradial i at 2014 Baphond B 1928 17.1040-entradial i at 2014 Baphond B 1928 17.1040-entradial i at 2014 Baphond B 1928 4 andotabenologic i at 2014 Baphond B 1928 4 andotabenologic i at 2014 Baphond B 1928 4 andotabenologic i at 2014 Baphond B 1928 contocotrow andotabenologic i at 2014 Baphond B 1928 contocotrow andotabenologic i at 2014 Baphond B 1928 contocotrow andotabenologic i at 2014 Baphond B	mai et al. 2014	Bisphenol S	H295R		17-OH progesterone	
ai ai al 201 BigArord BigAror	mai et al. 2014	4,4-Bisphenol F	H295R		17-beta-estradiol	
ai al ad 201 Bipharoffie 1928 17 Joda.estradad ai al ad 201 Bipharoffie 1629R 48 17 Joda.estradad ai ad 201 D-8 1629R 48 17 Joda.estradad ai ad 201 D-8 1629R 48 17 Joda.estradad ai ad 201 Paper 48 17 Joda.estradad 49 49 17 Joda.estradad ai ad 201 Bipharoffie 129R 48 DFA 49	ger et al. 2015	4,4-Bisphenol F	H295R	48	17-beta-estradiol	• • • • • •
an at 3 de 3 Baghard S 6288, 3 17 dela estradori r et al 2016 Baghard S 10288, 48 17 dela estradori et al 2016 Baghard S 10588, 48 17 dela estradori 17 dela estradori 18 al 2016 Baghard S 10588, 48 17 dela estradori 18 al 2016 Baghard S 10588, 48 076 4 18 al 2016 Baghard S 10588, 48 076 4 18 al 2016 Baghard S 10588, 48 076 4 18 al 2016 Baghard S 10588, 58 4 18 al 2018 Baghard S 10588, 58 4 18 al 201	mai et al. 2014	Bisphenol B	H295R		17-beta-estradiol	• • • • • • • • • • • • • • • • • • •
an at 3 de 3 Baghard S 6288, 3 17 dela estradori r et al 2016 Baghard S 10288, 48 17 dela estradori et al 2016 Baghard S 10588, 48 17 dela estradori 17 dela estradori 18 al 2016 Baghard S 10588, 48 17 dela estradori 18 al 2016 Baghard S 10588, 48 076 4 18 al 2016 Baghard S 10588, 48 076 4 18 al 2016 Baghard S 10588, 48 076 4 18 al 2016 Baghard S 10588, 58 4 18 al 2018 Baghard S 10588, 58 4 18 al 201	mai et al. 2014	Bisphenol E	H295R		17-beta-estradiol	• • <u>• • • • • •</u>
re et al. 2015 D-9 H29R 48 17 beta estatado re et al. 2016 Pergenera 21 H20R 48 DHEA Estatado Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 5 H20R 5 C Control H20R 5 H20R 5 H20R 5 H20R 5 C Control H20R 5 H	mai et al. 2014	Bisphenol S	H295R		17-beta-estradiol	
re et al. 2015 D-9 H29R 48 17 beta estatado re et al. 2016 Pergenera 21 H20R 48 DHEA Estatado Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 48 and cataneodora at et al. 2014 Benera C H20R 5 H20R 5 C Control H20R 5 H20R 5 H20R 5 H20R 5 C Control H20R 5 H	ger et al. 2015	Bisphenol S	H295R	48	17-beta-estradiol	
ra al 2015 Parglant 201 H25R 46 DPEA 47 DPEA 48 DPEA	•					
al. 2014c Baghand B H205R 48 DHEA al. 2014c Bighand C H205R androstenedice al. 4 2014c Bighand B H205R controstenedice al. 4 2014 Bighand B H20	•					
Lat. 2014. Baphenol C H258R 4 Baphenol B H258R androstanedione Lat. 2014. Baphenol B H258R 4 androstanedione Image: Control Contro Control Control Contro Control Control Contro Control C	-	-				
ai et al. 2014 4.4-Bisphend F 1295R and obtenedione and autone Bisphend E 1295R 48 and obtenedione at al. 2014 Bisphend E 1295R 48 and obtenedione at al. 2014 Bisphend E 1295R 2017 2017 2017 2017 2017 2017 2017 2017						
ai ai al 2014 Biphend B 125R 48 androsencione 1258 48 androsencione 246				40		
tal 2014c Bisphenol B H295R 4.4 androstemedione tal 2014c Bisphenol E H295R 4.4 androstemedione at at at 2014 Bisphenol E H295R						
La Jondo L Bispheno L H2BSR - andrastenedione at at d. 200 Bispheno L H2BSR - andrastenedione at at d. 200 Bispheno L H2BSR - andrastenedione at at d. 200 Bispheno L H2BSR - corticosterone -						
	et al. 2014c					
ai et al. 2014 84.95 hand S 1/295R controcaterone 1/2010	et al. 2014c			48		▼
ai et al 2014 4.4-Bisphenol F 1429R conficosterone at al 4.2018 Bisphenol B 1429R conficosterone at al 4.2014 Bisphenol B 1429R conficosterone at al 4.2014 Bisphenol F 1429R conficosterone at al 4.2014 Bisphenol B 1429R conficosterone at al 4.2014 Bisphenol F 1429R conficosterone conficosterone conficosterone at al 4.2014 Bisphenol F 1429R conficosterone conficoste	mai et al. 2014					
ai at al 2014 Bisphen E H295R corticolstoren ai at al 2014 Bisphen E H295R corticolstoren ai at al 2014 Al-Bisphen F H295R corticolstoren ai at al 2014 Al-Bisphen F H295R corticol Cortex ai at al 2014 H39bren B H295R corticol Cortex Corticol Cortex ai at al 2014 Bisphen B H295R corticol Cortex Corticol Cortex Cortex ai at al 2014 Bisphen B H295R corticol Cortex	mai et al. 2014	Bisphenol S	H295R		androstenedione	
ai et al. 2014 Bisphend E H295R C corticolserone C	mai et al. 2014	4,4-Bisphenol F	H295R		corticosterone	
ai et al. 2014 4.4Bisphend F H259R ··· cortisol ··· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·	mai et al. 2014	Bisphenol B	H295R		corticosterone	• • • • • • • • •
ai et al. 2014 4.4.Bisphenol F H295R cortisol ai et al. 2014 Bisphenol E H295R dehydrospiandrosterone ai et al. 2014 Bisphenol E H295R eetrone ai et al. 2014 Bisphenol E H295R eetrone ai et al. 2014 Bisphenol E H295R metrone ai et al. 2014 Bisphenol E H295R metrone ai et al. 2014 Bisphenol E H295R more ai et al. 2014 Bisphenol E H295R metrone ai et al. 2014 Al-Bisphenol F H295R metrone ai et al. 2014 Al-Bisphenol F fedal tests explants 44 testosterone ai et al. 2014 Al-Bisphenol F fedal tests explants 44 testosterone ai et al. 2014 Al-Bisphenol F fedal tests explants 44 testosterone ti al. 2015 Al-Bisphenol F fedal tests explants 44 testosterone ti al. 2015 Al-Bisphenol F fedal tests explants 44 testosterone ti al. 2015 Al-Bisphenol F fedal tests explants 44 testosterone ti al. 2015 Al-Bisphenol F fedal tests explants 44 testosterone ti al. 2015 Al-Bisphenol F H295R testosterone ti al. 2015 Al-Bisphenol F H295R testosterone ti al. 2015 Al-Bisphenol F H295R Al-Bisphenol F H295R testosterone ti al. 2015 Al-Bisphenol F fedal tests explants 44 testosterone ti al. 2015 Al-Bisphenol F fedal tests explants 44 testosterone ti al. 2015 Al-Bisphenol F H295R testosterone ti al. 2015 Al-Bisphenol F H295R testosterone ti al. 2015 Al-Bisphenol F H295R testosterone ti al. 2016 Bisphenol B H295R K testosterone ti al. 2015 Bisphenol F H295R K testosterone ti al. 2015 Bisphenol F H295R K testosterone	mai et al. 2014	Bisphenol E	H295R		corticosterone	
ai et al. 2014 Bisphend E H295R ··· cortisol ··· ··· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··	mai et al. 2014	Bisphenol S	H295R		corticosterone	• • • • • • • • • • • • • • • • • • •
al el al 2014 Bisphend E H295R · cortisol	mai et al. 2014	4,4-Bisphenol F	H295R		cortisol	•••
ai el al 2014 4.Bisphend S 295R Cortisol el 2076 cortisol el 2076 e	mai et al. 2014	Bisphenol B	H295R		cortisol	• • • • • • • • • •
al et al. 2014 4.4-Bisphenol F H295R dehydrospiandrosterone ai et al. 2014 Bisphenol E H295R dehydrospiandrosterone ai et al. 2014 Bisphenol F H295R estrone ai et al. 2014 Bisphenol F H295R progesterone ai et al. 2014 Bisphenol F H295R progesterone ai et al. 2014 Bisphenol F H295R estrone ai et al. 2014 Bisphenol F H295R testosterone ai et al. 2014 Bisphenol F H295R progesterone ai et al. 2014 Bisphenol F H295R testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone ai et al. 2014 Bisphenol S H295R 48 testosterone ai et al. 2015 Bisphenol S H295R 48 testosterone ai et al. 2014 Bisphenol S H295R 48 testosterone ai et al. 2015 Bisphenol S fetal testis explants 72 testosterone ai et al. 2015 Bisphenol S fetal testis explan	mai et al. 2014	Bisphenol E	H295R		cortisol	• • • • • • • • • • •
al et al. 2014 4.4-Bisphenol F H295R dehydrospiandrosterone ai et al. 2014 Bisphenol E H295R dehydrospiandrosterone ai et al. 2014 Bisphenol F H295R estrone ai et al. 2014 Bisphenol F H295R progesterone ai et al. 2014 Bisphenol F H295R progesterone ai et al. 2014 Bisphenol F H295R estrone ai et al. 2014 Bisphenol F H295R testosterone ai et al. 2014 Bisphenol F H295R progesterone ai et al. 2014 Bisphenol F H295R testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone ai et al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone ai et al. 2014 Bisphenol S H295R 48 testosterone ai et al. 2015 Bisphenol S H295R 48 testosterone ai et al. 2014 Bisphenol S H295R 48 testosterone ai et al. 2015 Bisphenol S fetal testis explants 72 testosterone ai et al. 2015 Bisphenol S fetal testis explan	mai et al. 2014	Bisphenol S	H295R		cortisol	
ai et al. 2014 Bisphend B H295R // 449droepiandrosterone ai et al. 2014 Bisphend E H295R // 449droepiandrosterone ai et al. 2014 Alsphane B H295R // 495R // 449droepiandrosterone ai et al. 2014 Alsphane B H295R // 495R // 449droepiandrosterone ai et al. 2014 Alsphane B H295R // 495R // 449droepiandrosterone ai et al. 2014 Alsphane B H295R // 495R // 449droepiandrosterone ai et al. 2014 Alsphane B H295R // 495R // 449droepiandrosterone ai et al. 2014 Alsphane B H295R // 495R // 449droepiandrosterone ai et al. 2014 Alsphane B H295R // 495R // 49		· · · · · · · · · · · · · · · · · · ·				
ai et al. 2014 Bisphenol E H295R H295R dehydrospiandrosterone Ad-Ad-Ad-Ad-Bisphenol F H295R estrone at at al. 2014 Bisphenol F H295R estrone estrone estrone at at al. 2014 Bisphenol F H295R estrone estrone estrone estrone at at al. 2014 Bisphenol F H295R estrone						
al et al 2014 Bisphenol F 1295R ··· estrone ··· ·· · · · · · · · · · · · · · · ·						
ai et al. 2014 4.4-Bisphenol F H295R estrone estrone ai et al. 2014 Bisphenol F H295R estrone estrone ai et al. 2014 Bisphenol F H295R estrone						
ai et al. 2014 Bisphenol B H295R estrone ai et al. 2014 Bisphenol E H295R estrone ai et al. 2014 Bisphenol F H295R regesterone ai et al. 2014 Al-Bisphenol F H295R regesterone Al. 2015 Al-Bisphenol F fetal testis explants 48 testosterone Al. 2015 Al-Bisphenol F fetal testis explants 72 testosterone Al. 4LBisphenol F fetal testis explants 72 testosterone Al. 2015 Al-Bisphenol F fetal testis explants 72 testosterone Al. 2015 Al-Bisphenol F fetal testis explants 72 testosterone Al. 2016 Bisphenol F 1925R 48 testosterone Al. 2017 Bisphenol F 1925R 48 testosterone Al. 2016 Bisphenol F 1925R 48 testosterone Al. 2017 Bisphenol F 1925R 48 testosterone Al. 2016 Bisphenol F 1925R 48 testosterone Al. 2017 Bisphenol F 1925R 48 testosterone Al. 2016 Bisphenol F 1925R 48 testosterone Al. 2017 Bisphenol F 1925R 48 testosterone Al. 2016 Bisphenol F 1925R 48 testosterone Al. 2017 Bisphenol F 1925R 48 testosterone Al. 2017 Bisphenol F 1925R 48 testosterone Al. 2016 Bisphenol F 1925R 48 testosterone Al. 2015 Bisphen						*
ai et al. 2014 Bisphenol E H295R Eestrone estrone estrone estrone estrone ai et al. 2014 A.4-Bisphenol F H295R Free progesterone ai et al. 2014 Bisphenol F H295R Free progesterone ai et al. 2014 Bisphenol F H295R Free progesterone ai et al. 2014 Bisphenol F H295R Free progesterone estrone free dat. 2014 A.4-Bisphenol F H295R Free progesterone estrone free dat. 2014 A.4-Bisphenol F H295R Free progesterone estrone free dat. 2014 A.4-Bisphenol F H295R Free dat. 2015 A.4-Bisphenol F fetal testis explants A 8 testosterone estrone free dat. 2015 A.4-Bisphenol F fetal testis explants A 8 testosterone free dat. 2015 A.4-Bisphenol F fetal testis explants A 8 testosterone free dat. 2015 A.4-Bisphenol F fetal testis explants A 8 testosterone free dat. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone free dat. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone free dat. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone free dat. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone free dat. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2015 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2016 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2016 A.4-Bisphenol F fetal testis explants A 12 testosterone fetal. 2016 A.4-Bisphenol F fetal. 2016 A.8-Bisphenol F f						
ai et al. 2014 Bisphenol S H295R H295R F000 H295R F0000 H20000 H2000 H2					estrone	
ai et al. 2014 4.4-Bisphenol F H295R progesterone progesterone ai et al. 2014 Bisphenol B H295R progesterone ai et al. 2014 Bisphenol F H295R Progesterone ai et al. 2014 4.4-Bisphenol F H295R progesterone ai et al. 2014 4.4-Bisphenol F H295R testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone tal. 2015 4.4-Bisphenol F H295R 48 testosterone tal. 2016 Bisphenol F fetal testis explants 72 testosterone tal. 2016 Bisphenol F fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisphenol S fetal testis explants 72 testosterone tal. 2016 Bisp		Bisphenol E			estrone	· · · · ·
lai et al. 2014 Bisphenol B H295R · progesterone progesterone in the second Bisphenol E H295R · progesterone ·	mai et al. 2014	Bisphenol S	H295R		estrone	•••••
ai et al. 2014 Bisphenol E H295R · progesterone ·	mai et al. 2014	4,4-Bisphenol F	H295R		progesterone	
lai et al. 2014 Bisphenol S H295R P395R regesterone t al. 2015 4.4-Bisphenol F H295R testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2016 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2016 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2016 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal testis explants 72 testosterone t al. 2016 8isphenol S fetal tes	mai et al. 2014	Bisphenol B	H295R		progesterone	•••••
lai et al. 2014 4.4-Bisphenol F H295R testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone t al. 2015 4.4-Bisphenol F H295R 48 testosterone t al. 2014 Bisphenol B H295R 48 testosterone t al. 2014 Bisphenol B H295R 48 testosterone t al. 2014 Bisphenol S H295R 48 testosterone t al. 2014 Bisphenol S H295R 48 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 72 testosterone t al. 2015 Bisphenol S fetal testis explants 48 testosterone t al. 2015 Bisphenol S fetal testis explants 48 testosterone t al. 2015 Bisphenol S fetal testis explants 48 testosterone t al. 2015 Bisphenol S fetal testis explants	mai et al. 2014	Bisphenol E	H295R		progesterone	
at. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2014 Bisphenol F MA-10 Leydig 48 testosterone at al. 2014 Bisphenol F H295R 48 testosterone at al. 2014 Bisphenol F H295R 48 testosterone at al. 2014 Bisphenol F H295R testosterone Image (Control Control Contro	mai et al. 2014	Bisphenol S	H295R		progesterone	• • <u>• • </u> • • •
at. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at. 2015 4.4-Bisphenol F MA-10 Leydig 48 testosterone at. 2014 Bisphenol B H295R 48 testosterone at. 2014 Bisphenol C H295R 48 testosterone at. 2014 Bisphenol B H295R 48 testosterone at. 2014 Bisphenol C H295R testosterone Image: Composition of testosterone at. 2014 Bisphenol S fetal testis explants 72 testosterone Image: Composition of testosterone Imag	mai et al. 2014	4,4-Bisphenol F	H295R		testosterone	• • • • • • • •
at al. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 24 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F MA-10 Leydig 48 testosterone at al. 2014 Bisphenol B H295R 48 testosterone at al. 2014 Bisphenol B H295R 48 testosterone at al. 2015 Bisphenol B H295R 48 testosterone at al. 2014 Bisphenol B H295R testosterone Image: Content in the intert in the int	et al. 2015	4,4-Bisphenol F	fetal testis explants	48	testosterone	▼
4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 48 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F MA-10 Leydig 48 testosterone at al. 2014 Bisphenol B H295R 48 testosterone at al. 2014 Bisphenol B H295R 48 testosterone at al. 2014 Bisphenol C H295R 48 testosterone at al. 2014 Bisphenol E H295R 48 testosterone at al. 2014 Bisphenol E H295R testosterone Image: Composition of testosterone at al. 2015 Bisphenol E H295R testosterone Image: Composition of testosterone at al. 2015 Bisphenol E H295R testosterone Image: Composition of testosterone at al. 2015 <td>et al. 2015</td> <td></td> <td></td> <td></td> <td>testosterone</td> <td>▼ ● ● ▼</td>	et al. 2015				testosterone	▼ ● ● ▼
tal. 2015 4,4-Bisphenol F fetal testis explants 48 testosterone tal. 2015 4,4-Bisphenol F fetal testis explants 72 testosterone et al. 2015 4,4-Bisphenol F fetal testis explants 72 testosterone et al. 2015 4,4-Bisphenol F MA-10 Leydig 48 testosterone et al. 2014 Haisphenol F H295R 48 testosterone al et al. 2014 Bisphenol R H295R 48 testosterone al et al. 2014 Bisphenol R H295R 48 testosterone tal 2015 Bisphenol R H295R testosterone Image: Composition R tal 2014 Bisphenol R H295R testosterone Image: Composition R tal 2015 Bisphenol R fetal testis explants 72 testosterone tal 2015 Bisphenol R fetal testis explants <td< td=""><td>et al. 2015</td><td></td><td></td><td></td><td></td><td>V V V</td></td<>	et al. 2015					V V V
4.4-Bisphenol F fetal testis explants 24 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F fetal testis explants 72 testosterone at al. 2015 4.4-Bisphenol F H295R 48 testosterone at al. 2016 Bisphenol F H295R 48 testosterone at al. 2014 Bisphenol F H295R testosterone Image: Composition of the testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone Image: Composition of testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone Image: Composition of testosterone Image: Composition of testosterone Image: Composition of testosterone Image: Composition of testosterone <td< td=""><td>et al. 2015</td><td></td><td></td><td></td><td></td><td></td></td<>	et al. 2015					
at 2015 4.4-Bisphenol F fetal testis explants 72 testosterone et al. 2015 4.4-Bisphenol F MA-10 Leydig 48 testosterone ati et al. 2015 4.4-Bisphenol F H295R 48 testosterone ati et al. 2014 Bisphenol B H295R 48 testosterone ati et al. 2014 Bisphenol B H295R 48 testosterone ati et al. 2014 Bisphenol E H295R 48 testosterone ati et al. 2014 Bisphenol E H295R 48 testosterone ati et al. 2014 Bisphenol E H295R 48 testosterone ati et al. 2014 Bisphenol E H295R testosterone Image: Composition of the testosterone at al. 2015 Bisphenol E H295R testosterone Image: Composition of the testosterone at al. 2015 Bisphenol E fetal testis explants 72 testosterone Image: Composition of the testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone Image: Composition of testosterone at al. 2015 Bisphenol S fetal testis e			******	24		
at 2015 4,4-Bisphenol F MA-10 Leydig 48 testosterone at et al. 2014 Bisphenol B H295R 48 testosterone at al. 2014c Bisphenol E H295R 48 testosterone at al. 2014c Bisphenol E H295R 48 testosterone at al. 2014c Bisphenol E H295R 48 testosterone at al. 2014 Bisphenol E H295R testosterone Image: Comparity on the comp				72		
ar et al. 2015 4,4-Bisphenol F H295R 48 testosterone tal. 2014 Bisphenol B H295R 48 testosterone tal. 2014 Bisphenol C H295R 48 testosterone tal. 2014 Bisphenol C H295R 48 testosterone tal. 2014 Bisphenol S H295R 48 testosterone tal. 41. 2014 Bisphenol S H295R 48 testosterone tal. 2014 Bisphenol S H295R testosterone tal. 41. 2014 Bisphenol S H295R testosterone tal. 41. 2014 Bisphenol S H295R testosterone tal. 41. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
lai et al. 2014 Bisphenol B H295R 48 testosterone t al. 2014 Bisphenol C H295R 48 testosterone t al. 2014 Bisphenol C H295R 48 testosterone ali et al. 2014 Bisphenol S H295R 7 testosterone t al. 2015 Bisphenol S H295R 7 testosterone t al. 2015 Bisphenol S fetal testis explants 24 testosterone t al. 2015 Bisphenol S fetal testis explants 24 testosterone t al. 2015 Bisphenol S fetal testis explants 24 testosterone t al. 2015 Bisphenol S fetal testis explants 24 testosterone t al. 2015 Bisphenol S fetal testis explants 48 testosterone t al. 2015 Bisphenol S fetal testis ex						
tal. 2014c Bisphenol B H295R 48 testosterone tal. 2014c Bisphenol C H295R 48 testosterone tal et al. 2014 Bisphenol E H295R 48 testosterone tal et al. 2014 Bisphenol E H295R testosterone Image: Composition of the testosterone tal et al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al	-			48		
tal. 2014c Bisphenol C H295R 48 testosterone tal. et al. 2014 Bisphenol E H295R testosterone tal. et al. 2014 Bisphenol S H295R testosterone tal. et al. 2014 Bisphenol S H295R testosterone tal. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 Bisphenol S fetal testis explants 24 testosterone tal. 2015 Bisphenol S fetal testis explants 72 testosterone tal. 2015 Bisphenol S fetal testis explants 72 testosterone tal. 2015 Bisphenol S fetal testis explants 72 testosterone tal. 2015 Bisphenol S fetal testis explants 72 testosterone tal. 2015 Bisphenol S fetal testis explants 88 te	mai et al. 2014					
ai et al. 2014 Bisphenol E H295R testosterone ai et al. 2014 Bisphenol S H295R testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 48 testosterone ar et al. 2015 Bisphenol S	et al. 2014c					▼
ali et al. 2014 Bisphenol S H295R testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S H295R 48 testosterone	et al. 2014c			48	testosterone	▼
at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 48 testosterone ar et al. 2015 Bisphenol S H295R 48 testosterone	mai et al. 2014	Bisphenol E	H295R		testosterone	• • • •
at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 48 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 48 testosterone ar et al. 2015 Bisphenol S H295R 48 testosterone	mai et al. 2014	Bisphenol S	H295R		testosterone	
at al. 2015 Bisphenol S fetal testis explants 24 testosterone at al. 2015 Bisphenol S fetal testis explants 48 testosterone at al. 2015 Bisphenol S fetal testis explants 72 testosterone at al. 2015 Bisphenol S fetal testis explants 48 testosterone at al. 2015 Bisphenol S fetal testis explants 48 testosterone ar et al. 2015 Bisphenol S H295R 48 testosterone	et al. 2015	Bisphenol S	fetal testis explants	24	testosterone	• • • • •
et al. 2015 Bisphenol S fetal testis explants 48 testosterone et al. 2015 Bisphenol S fetal testis explants 72 testosterone et al. 2015 Bisphenol S fetal testis explants 48 testosterone er et al. 2015 Bisphenol S H295R 48 testosterone	et al. 2015	Bisphenol S	fetal testis explants	72	testosterone	• • • • •
et al. 2015 Bisphenol S fetal testis explants 48 testosterone et al. 2015 Bisphenol S fetal testis explants 72 testosterone et al. 2015 Bisphenol S fetal testis explants 48 testosterone er et al. 2015 Bisphenol S H295R 48 testosterone	et al. 2015	Bisphenol S	fetal testis explants	24	testosterone	▼ ● ● ▼
et al. 2015 Bisphenol S fetal testis explants 72 testosterone et al. 2015 Bisphenol S fetal testis explants 48 testosterone er et al. 2015 Bisphenol S H295R 48 testosterone	et al. 2015				testosterone	· · · · · · · · · · · · · · · · · · ·
et al. 2015 Bisphenol S fetal testis explants 48 testosterone	et al. 2015					• • • • • • • •
er et al. 2015 Bisphenol S H295R 48 testosterone	et al. 2015					• • • • • • • • •
et al. 2015 Bisphenol S MA-10 Leydig 48 testosterone	s et al. 2015					
	ger et al. 2015 ger et al. 2015					

Figure A-11. <u>Steroidogenesis Assays</u>

Citation	Chemical	Cell Type	Observation	Receptor Type	Assay Type	Endpoint Description	Dose Specific Effects Relative to Control
Citation	chemical	Cen Type	Time (H)	Receptor Type	Assay 1900		H Doses Tested A Increase V No Change V Decrease V ECSU V ICSU U Cytotoxicity
itossi et al. 2014	4,4-Bisphenol F	HeLa	30	Alpha	DNA binding	ER-alpha binding to PRL ERE	•-••••
Stossi et al. 2014	Bisphenol AF	HeLa	30	Alpha	DNA binding	ER-alpha binding to PRL ERE	•-••_
Stossi et al. 2014	Bisphenol AP	HeLa	30	Alpha	DNA binding	ER-alpha binding to PRL ERE	• • • • • • •
Ashcroft et al. 2011	Bisphenol B	HeLa	48	Alpha	DNA binding	ER-alpha binding to PRL ERE	••-••••• • •
Stossi et al. 2014	Bisphenol B	HeLa	30	Alpha	DNA binding	ER-alpha binding to PRL ERE	•-••-•
Stossi et al. 2014	Bisphenol C	HeLa	30	Alpha	DNA binding	ER-alpha binding to PRL ERE	• • • <u>•</u> <u>4</u>
Stossi et al. 2014	Bisphenol S	HeLa	30	Alpha	DNA binding	ER-alpha binding to PRL ERE	•-•-•
Stossi et al. 2014	Bisphenol Z	HeLa	30	Alpha	DNA binding	ER-alpha binding to PRL ERE	• • • <u>• • </u>
Stossi et al. 2014	TMBPA	HeLa	30	Alpha	DNA binding	ER-alpha binding to PRL ERE	••-•
Stossi et al. 2014	4,4-Bisphenol F	HeLa	30	Beta	DNA binding	ER-beta binding to PRL ERE	• • _ • _ •
Stossi et al. 2014	Bisphenol AF	HeLa	30	Beta	DNA binding	ER-beta binding to PRL ERE	
Stossi et al. 2014	Bisphenol AP	HeLa	30	Beta	DNA binding	ER-beta binding to PRL ERE	• • • •
Stossi et al. 2014	Bisphenol B	HeLa	30	Beta	DNA binding	ER-beta binding to PRL ERE	
Stossi et al. 2014	Bisphenol C	HeLa	30	Beta	DNA binding	ER-beta binding to PRLERE	• • • • • •
Stossi et al. 2014	Bisphenol S	HeLa	30	Beta	DNA binding	ER-beta binding to PRL ERE	• • • • • • • •
Stossi et al. 2014	Bisphenol Z	HeLa	30	Beta	DNA binding	ER-beta binding to PRLERE	
Stossi et al. 2014	TMBPA	HeLa	30	Beta	DNA binding	ER-beta binding to PRL ERE	
/inas and Watson 2013	Bisphenol S	GH3/B6/F10	0.083	Endogenous	Non-genomic signaling assay	ERK activation (pERK)	
/inas and Watson 2013	Bisphenol S	GH3/B6/F10	0.083	Endogenous	Non-genomic signaling assay	JNK activation (pJNK))
Ashcroft et al. 2011	Bisphenol B	HeLa	48	Alpha	Other	Pol II Recruitment	A
Ashcroft et al. 2011	Bisphenol B	HeLa	48	Alpha	Other	nuclear localization	
/inas and Watson 2013	Bisphenol S	GH3/B6/F10	8	Endogenous	Other assay	Caspase 8 activity	A
/inas and Watson 2013	Bisphenol S	GH3/B6/F10	8	Endogenous	Other assay	Caspase 9 activity	• • •
e and Belcher 2010	Bisphenol AF	mature granule cell neurons	24	Endogenous	Other assay	LDH release	• • • • • • • • •
e and Beicher 2010	Bisphenol C	mature granule cell neurons	24	Endogenous	Other assay	LDH release	••-•
Vang et al. 2014c	Bisphenol B	not reported		Alpha	Protein interaction assay	ER-alpha-LBD-His binding to NCOA1_677_700 coregulator motif	
Vang et al. 2014c	Bisphenol C	not reported		Alpha	Protein interaction assay	ER-alpha-LBD-His binding to NCOA1_677_700 coregulator motif	
Stossi et al. 2014	Bisphenol AF	HEK293	8	Alpha	Protein interaction assay	ER-alpha homodimerization	• • • • <u>•</u> <u>•</u>
Stossi et al. 2014	Bisphenol AP	HEK293	8	Alpha	Protein interaction assay	ER-alpha homodimerization	• • • • • • •
Stossi et al. 2014	Bisphenol S	HEK293	8	Alpha	Protein interaction assay	ER-alpha homodimerization	• • • • • • •
Dgawa et al. 2006	4,4-Bisphenol F	yeast	4	Endogenous	Yeast two-hybrid assay	beta-galactosidase activity	• • <u>•</u> • <u>•</u> • <u>•</u>
lashimoto and Nakamura 2000	4,4-Bisphenol F	yeast	4	Endogenous	Yeast two-hybrid assay	beta-galactosidase activity	• • • <u>•</u>
lashimoto and Nakamura 2000	Risphenol S	veast	4	Endogenous	Yeast two-hybrid assay	beta-galactosidase activity	

Figure A-12. Estrogen Receptor Other Endpoints



Figure A-13. Data Pivot of Hershberger Assay

Citation	Chemical	Cell Type	Observation	Assay Type	Endpoint Description	Dose Specific Effect Relative to Vehicle Control
onation	onenneur	oen type	Time (H)	Addig Type	Enapoint Description	H Doses tested 🛕 Increase No Change Decrease EC50 Cytotoxicity Observed
Molina-Molina et al. 2013	4,4-Bisphenol F	MCF-7	120	Proliferation assay	WT AR (SRB absorbance)	•••••
Aolina-Molina et al. 2013	4,4-Bisphenol F	PC3	40	Reporter gene assay	AR (MMTV-Luc-SV-Neo)	•••••
Gaido et al. 2000	4,4-Bisphenol F	HepG2	24	Reporter gene assay	AR (luciferase)	▼ ▼
Kitamura et al. 2005b	4,4-Bisphenol F	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	▼ ● ▼
Fic et al. 2014	4,4-Bisphenol F	yeast	18	Reporter gene assay	hAR (beta-galactosidase)	
Kitamura et al. 2005b	Bisphenol AF	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	• • • •
leng et al. 2013	Bisphenol AF	CV1	24	Reporter gene assay	pSG5-AR (MMTV-Luciferase)	••••••
Kitamura et al. 2005b	Bisphenol B	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	•••
Kitamura et al. 2005b	Bisphenol C	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	• • • •
Gaido et al. 2000	Bisphenol E	HepG2	24	Reporter gene assay	AR (luciferase)	••
Kitamura et al. 2005b	Bisphenol E	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	• • • •
Molina-Molina et al. 2013	Bisphenol S	MCF-7	120	Proliferation assay	WT AR (SRB absorbance)	•••• • • • •
Molina-Molina et al. 2013	Bisphenol S	PC3	40	Reporter gene assay	AR (MMTV-Luc-SV-Neo)	••••• • • • •
Kitamura et al. 2005b	Bisphenol S	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	• • • •
Kitamura et al. 2005b	TMBPA	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	• • • •
					0.0000998	

Figure A-14. <u>Androgen Receptor Agonism Assays</u>

Citation	Chemical	Cell Type	Observation Time (H)	Assay Type	Endpoint Description	H Doses Tested ▲ Increase ● No Change ▼ Decrease ♦ IC50 🕂
Roelofs et al. 2015	4,4-Bisphenol F	yeast	24	Receptor binding assay	AR (yEGFP)	
Gaido et al. 2000	4,4-Bisphenol F	HepG2	24	Reporter gene assay	AR (luciferase)	▼ ▼
Delfosse et al. 2012	4,4-Bisphenol F	HeLa		Reporter gene assay	AR, ER-alpha DBD (ERE-luciferase)	••• · •••
Kitamura et al. 2005b	4,4-Bisphenol F	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	<u>▼ ▼ </u>
Molina-Molina et al. 2013	4,4-Bisphenol F	PC3	40	Reporter gene assay	AR (MMTV-Luc-SV-Neo)	•••• • •• • •
Rosenmai et al. 2014	4,4-Bisphenol F	СНО		Reporter gene assay	AR (MMTV-Luc)	·····
Stroheker et al. 2004	4,4-Bisphenol F	MDA-MB453	24	Reporter gene assay	AR (pMMTVneo-Luc)	
Vinggaard et al. 2008	4,4-Bisphenol F	CHO-K1	20	Reporter gene assay	AR (luciferase)	•
Gaido et al. 2000	4,4-Bisphenol F	HepG2	24	Reporter gene assay	AR (luciferase)	∀-∀ ▼
Fic et al. 2014	4,4-Bisphenol F	yeast	18	Reporter gene assay	hAR (beta-galactosidase)	
Kolsek et al. 2015	4,4-Bisphenol F	MDA-kb2	24	Reporter gene assay	AR (luciferase)	. ▼
Cabaton et al. 2009	4,4-Bisphenol F	MDA-MB453-kb2	24	Reporter gene assay	AR (pMMTV-neo-Luc)	
Teng et al. 2013	Bisphenol AF	CV1	24	Reporter gene assay	pSG5-AR (MMTV-Luciferase)	
Kolsek et al. 2015	Bisphenol AF	MDA-kb2	24	Reporter gene assay	AR (luciferase)	. ▼
Delfosse et al. 2012	Bisphenol AF	HeLa		Reporter gene assay	AR, ER-alpha DBD (ERE-luciferase)	••• · ••• · •
Fic et al. 2014	Bisphenol AF	yeast	18	Reporter gene assay	hAR (beta-galactosidase)	
Kitamura et al. 2005b	Bisphenol AF	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	▲
Fang et al. 2003	Bisphenol B	bacteria	18-20	Receptor binding assay	AR (radioactivity)	· • •
Wang et al. 2014c	Bisphenol B	CALUX	24	Reporter gene assay	AR (luciferase)	
Wang et al. 2014c	Bisphenol B	yeast	24	Reporter gene assay	AR (luciferase)	
Delfosse et al. 2012	Bisphenol B	HeLa		Reporter gene assay	AR, ER-alpha DBD (ERE-luciferase)	• • • • • \
Kitamura et al. 2005b	Bisphenol B	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	•
Rosenmai et al. 2014	Bisphenol B	СНО		Reporter gene assay	AR (MMTV-Luc)	~~~~~~
Wang et al. 2014c	Bisphenol C	CALUX	24	Reporter gene assay	AR (luciferase)	
Wang et al. 2014c	Bisphenol C	yeast	24	Reporter gene assay	AR (luciferase)	• • • • • • • • • • • • • • • • • • •
Kolsek et al. 2015	Bisphenol C	MDA-kb2	24	Reporter gene assay	AR (luciferase)	
Kitamura et al. 2005b	Bisphenol C	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	•
Gaido et al. 2000	Bisphenol E	HepG2	24	Reporter gene assay	AR (luciferase)	• -
Gaido et al. 2000	Bisphenol E	HepG2	24	Reporter gene assay	AR (luciferase)	
Kitamura et al. 2005b	Bisphenol E	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	♦
Delfosse et al. 2012	Bisphenol E	HeLa		Reporter gene assay	AR, ER-alpha DBD (ERE-luciferase)	•••• • ••
Rosenmai et al. 2014	Bisphenol E	СНО		Reporter gene assay	AR (MMTV-Luc)	•••
Fang et al. 2003	Bisphenol S	bacteria	18-20	Receptor binding assay	AR (radioactivity)	•
Roelofs et al. 2015	Bisphenol S	yeast	24	Receptor binding assay	AR (yEGFP)	
Delfosse et al. 2012	Bisphenol S	HeLa		Reporter gene assay	AR, ER-alpha DBD (ERE-luciferase)	•••• • -•
Molina-Molina et al. 2013	Bisphenol S	PC3	40	Reporter gene assay	AR (MMTV-Luc-SV-Neo)	
Kolsek et al. 2015	Bisphenol S	MDA-kb2	24	Reporter gene assay	AR (luciferase)	▼
Kitamura et al. 2005b	Bisphenol S	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	۵
Rosenmai et al. 2014	Bisphenol S	СНО		Reporter gene assay	AR (MMTV-Luc)	
Kolsek et al. 2015	Bisphenol Z	MDA-kb2	24	Reporter gene assay	AR (luciferase)	▼
Kitamura et al. 2005b	TMBPA	NIH3T3	24	Reporter gene assay	hAR (ARE)2-luc	A

Figure A-15. <u>Androgen Receptor Antagonism Assays</u>

Citation	Chemical	Species, Strain (Sex, N)	Assessment Age	Exposure Duration	Route of Exposure	Endpoint	Dose (mg/kg-day)	Control NS Diff Sig Diff 95% CI
Higashihara et al. 2007	4,4'-Bisphenol F	Rat, Crj:CD(SD) (♀, N=10)	young adult	28 days	oral gavage	serum T3	0 20 100	
							500	H H
Higashihara et al. 2007	4,4'-Bisphenol F	Rat, Crj:CD(SD) (ੋ, N=10)	young adult	28 days	oral gavage	serum T3	0	⊢∮ −1
		(0)					20 100	
							500	
Higashihara et al. 2007	4,4'-Bisphenol F	Rat, Crj:CD(SD)	young adult	28 days	oral gavage	serum T4	0	
-		(♀, N=10)					20	Here I
							100	⊢● →
							500	⊢ ●−1
Higashihara et al. 2007	4,4'-Bisphenol F	Rat, Crj:CD(SD) (ੋ, N=10-17)	young adult	28 days	oral gavage	serum T4	0	HO-H
							20 100	
							500	
Higashihara et al. 2007	4,4'-Bisphenol F	Rat, Crj:CD(SD)	young adult	28 days	oral gavage	serum TSH	0	
		(♀, N=10)					20	
							100	↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
							500	• • • • • • • • • • • • • • • • • • •
Higashihara et al. 2007	4,4'-Bisphenol F	Rat, Crj:CD(SD) (ੋ, N=10)	young adult	28 days	oral gavage	serum TSH	0	⊢
							20	
							100 500	
Higashihara et al. 2007	4,4'-Bisphenol F	Rat, Crj:CD(SD)	young adult	28 days	oral gavage	thyroid	0	
		(♀, N=10)				gland weight	20	⊢● −4
							100	
							500	P→●→1
Higashihara et al. 2007	4,4'-Bisphenol F	Rat, Crj:CD(SD) (♂, N=10)	young adult	28 days	oral gavage	thyroid gland weight	0	⊢● −1
		(0)				3	20	
							100 500	
Umano et al. 2012	Bisphenol AF	Rat, Sprague-Dawley		28 days	oral gavage	serum T4	0	
		(♀, N=10)					10	
							30 100	
Umano et al. 2012	Bisphenol AF	Rat,		28 days	oral gavage	serum T4	0	
		Sprague-Dawley (3, N=10)					10	⊢ ●
		(0)					30	+-●1
							100	⊢● →
Yang et al. 2014b	Bisphenol AF	Zebrafish, unspecified (♀,		28 days	whole body	Free T3	0	•
		N=36)					0.05	•
							0.25	•
Yang et al. 2014b	Bisphenol AF	Zebrafish,		28 days	whole body	Free T3	0	
		unspecified (3, N=36)					0.05	•
							0.25	•
							1	•
Naderi et al. 2014a	Bisphenol S	Zebrafish, wild type		75 days	whole body	plasma T3	0	•
		(♀, N=36)					0.0001	•
							0.001	•
							0.01	•
							0.1	•
Naderi et al. 2014a	Bisphenol S	Zebrafish, wild type (3, N=36)		75 days	whole body	plasma T3	0	
							0.0001	
							0.01	•
							0.1	•
Naderi et al. 2014a	Bisphenol S	Zebrafish, wild type		75 days	whole body	plasma T4	0	•
		(♀, N=36)					0.0001	•
							0.001	•
							0.01	•
Naderi et al. 2014a	Bisphenol S	Zebrafish, wild type		75 days	whole body	plasma T4	0.1 0	
	and the second s	(♂, N=36)				productions 1.14	0.0001	
							0.001	↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
							0.01	•
							0.1	•
Yamasaki and Okuda 2012	Bisphenol Z	Rat, Crl:CD(SD)	young adult	28 days	oral gavage	serum T4	0	Here I
		(♀, N=10)					6	⊢ ●
							30	⊢●
		B-1 0		aa :			150	
			young adult	28 days	oral gavage	serum T4	0	HOH
Yamasaki and Okuda 2012	Bisphenol Z	Rat, Crl:CD(SD) (ੋ, N=10)	young addit				20	
Yamasaki and Okuda 2012	Bisphenol Z		young usun	,			30 100	
Yamasaki and Okuda 2012	Bisphenol Z		joung count	,-			30 100 300	

Figure A-16. <u>Thyroid Hormone Disruption</u>

Citation	Chemical	Cell Type	Observation Time (H)	Assay Type	Endpoint Description	Dose Specific Effect Relative to Vehicle Control
Kitamura et al. 2005b	4,4-Bisphenol F	GH3	48	Protein production assay	GH	••
Kitamura et al. 2005b	Bisphenol AF	GH3	48	Protein production assay	GH	•••
Kitamura et al. 2005b	Bisphenol B	GH3	48	Protein production assay	GH	••
Kim et al. 2006	Bisphenol C	GH3	120	Proliferation assay	GH3 cell proliferation	
Kitamura et al. 2005b	Bisphenol C	GH3	48	Protein production assay	GH	• •
Kitamura et al. 2005b	Bisphenol E	GH3	48	Protein production assay	GH	••
Kitamura et al. 2005b	Bisphenol S	GH3	48	Protein production assay	GH	••
Kim et al. 2006	TMBPA	GH3	120	Proliferation assay	GH3 cell proliferation	••
Kitamura et al. 2005b	TMBPA	GH3	48	Protein production assay	GH	•• <u>A</u>
Shiizaki et al. 2010	TMBPA	yeast	16	Reporter gene assay	TRα (SRC-1)	●●-●-●-●-●-●
Shiizaki et al. 2010	TMBPA	yeast	16	Reporter gene assay	TRβ (SRC-1)	•• • <u>****</u> •
					0.000099999	99999999 3999 1 0.01 0.1 1 10 100 1,000 10,0 µM

Figure A-17. <u>Thyroid Receptor Agonism Assays</u>

Citation	Chemical	Cell Type	Observation Time (H)	Assay Type	Endpoint Description	Dose Specific Effect Relative to Vehicle Control
Butt et al. 2011	Bisphenol AF	microsomes	1	Enzyme inhibition	deiodinase inhibition (T3 deiodinase)	•——•—• ~ •
Butt et al. 2011	Bisphenol AF	microsomes	1	Enzyme inhibition	deiodinase inhibition (rT3 deiodinase)	F∳I
Butt et al. 2011	Bisphenol AF	microsomes	1	Enzyme inhibition	deiodinase inhibition (3,3'-T2 deiodinase)	⊢−−−−− +
Butt and Stapelton 2013	Bisphenol AF	cytosol	0.5	Enzyme inhibition	sulfotransferase inhibition (3,3'-T2 sulfotransferase	se)
Kitamura et al. 2005b	Bisphenol B	GH3	48	Protein production assay	GH	••
Kitamura et al. 2005b	Bisphenol C	GH3	48	Protein production assay	GH	••
Kitamura et al. 2005a	Bisphenol C	MtT/E-2	40	Receptor binding assay	endogenous receptor	••• •\
Kitamura et al. 2005a	Bisphenol C	CHO-K1	24	Reporter gene assay	ΤRα	data not shown, cytotoxicity noted
Kitamura et al. 2005a	Bisphenol C	CHO-K1	24	Reporter gene assay	ΤRβ	data not shown, cytotoxicity noted
Kitamura et al. 2005b	TMBPA	GH3	48	Protein production assay	GH	••
Kitamura et al. 2005a	TMBPA	MtT/E-2	40	Receptor binding assay	endogenous receptor	• • • • • • • • • • • • • • • • • • • •
Shiizaki et al. 2010	TMBPA	yeast	16	Reporter gene assay	TRa (SRC-1)	••• <u>***</u> •
ihiizaki et al. 2010	TMBPA	yeast	16	Reporter gene assay	TRβ (SRC-1)	
litamura et al. 2005a	TMBPA	CHO-K1	24	Reporter gene assay	ΤRβ	data not shown, cytotoxicity noted
Kitamura et al. 2005a	TMBPA	CHO-K1	24	Reporter gene assay	ΤRα	data not shown, cytotoxicity noted
					0.0000	99999999999999999999999999999999999999

Figure A-18. Thyroid Receptor Antagonism Assays

Citation	Chemical	Cell Type	Receptor	Observation Time (H)	Receptor Type	Assay Type	WT or Mutant Receptor	Endpoint Description	Cytotoxicity Observed
Ma et al. 2015	Bisphenol S	COS-7	Ahr1		Endogenous	Reporter gene assay	WT receptor	Ahr1 (ERE-luc)	
Dring et al. 2010	4,4-Bisphenol F	HuH-7	CAR	20	CAR1	Reporter gene assay	Mutant receptor	pM-CAR1 (pFR-Luc)	▲
Dring et al. 2010	Bisphenol AF	HuH-7	CAR	20	CAR1	Reporter gene assay	Mutant receptor	pM-CAR1 (pFR-Luc)	A
Dring et al. 2010	Bisphenol S	HuH-7	CAR	20	CAR1	Reporter gene assay	Mutant receptor	pM-CAR1 (pFR-Luc)	•
Dring et al. 2010	Bisphenol Z TMBPA	HuH-7	CAR	20 20	CAR1 CAR1	Reporter gene assay	Mutant receptor Mutant receptor	pM-CAR1 (pFR-Luc)	A
Dring et al. 2010 Dring et al. 2010	4,4-Bisphenol F	HuH-7	CAR	20	CAR1 CAR3	Reporter gene assay Reporter gene assay	Mutant receptor Mutant receptor	pM-CAR1 (pFR-Luc) pM-CAR3 (pFR-Luc)	
Dring et al. 2010	Bisphenol AF	HuH-7	CAR	20	CAR3	Reporter gene assay	Mutant receptor	pM-CAR3 (pFR-Luc)	
Dring et al. 2010	Bisphenol S	HuH-7	CAR	20	CAR3	Reporter gene assay	Mutant receptor	pM-CAR3 (pFR-Luc)	
Dring et al. 2010	Bisphenol Z	HuH-7	CAR	20	CAR3	Reporter gene assay	Mutant receptor	pM-CAR3 (pFR-Luc)	▲
Dring et al. 2010	TMBPA	HuH-7	CAR	20	CAR3	Reporter gene assay	Mutant receptor	pM-CAR3 (pFR-Luc)	A
imai et al. 2013	4,4-Bisphenol F	HepG2	CAR	24	Endogenous	Reporter gene assay	WT receptor	hCAR (tk-pGL3)	••••
mai et al. 2013	4,4-Bisphenol F		CAR	24	Endogenous	Reporter gene assay	WT receptor	mCAR (tk-pGL3)	••••
mai et al. 2013	Bisphenol S	HepG2	CAR	24	Endogenous	Reporter gene assay	WT receptor	hCAR (tk-pGL3)	
Imaiet al. 2013 Dring et al. 2010	Bisphenol S 4.4-Bisphenol F	HepG2	CAR	24	Endogenous CAR1	Reporter gene assay	WT receptor Mutant receptor	mCAR (tk-pGL3) pM-CAR1 (pFR-Luc)	••••
Dring et al. 2010 Dring et al. 2010	4,4-bisphenol F Bisphenol AF	HuH-7	CAR	20	CAR1	Reporter gene assay Reporter gene assay	Mutant receptor	pM-CAR1 (pFR-Luc)	
Dring et al. 2010	Bisphenol S	HuH-7	CAR	20	CAR1	Reporter gene assay	Mutant receptor	pM-CAR1 (pFR-Luc)	•
Dring et al. 2010	Bisphenol Z	HuH-7	CAR	20	CAR1	Reporter gene assay	Mutant receptor	pM-CAR1 (pFR-Luc)	A
Dring et al. 2010	TMBPA	HuH-7	CAR	20	CAR1	Reporter gene assay	Mutant receptor	pM-CAR1 (pFR-Luc)	•
Helies-Toussaint et al. 2014	Bisphenol S	3T3-L1	ERR	240	Alpha	RNA transcription assay	WT receptor	(ERR-alpha)	••
lelies-Toussaint et al. 2014	Bisphenol S	3T3-L1	ERR	240	Gamma	RNA transcription assay	WT receptor	(ERR-gamma)	V V
Delfosse et al. 2012	4,4-Bisphenol F	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	•
Delfosse et al. 2012	Bisphenol AF	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	• ▲ ▲ ▲ ▲
Delfosse et al. 2012	Bisphenol B	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	•
Delfosse et al. 2012	Bisphenol E	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	•
Delfosse et al. 2012 Delfosse et al. 2012	Bisphenol S 4,4-Bisphenol F		ERR		Gamma	Reporter gene assay Reporter gene assay	WT receptor WT receptor	ERR-gamma (ERE-luc) ERR-gamma (ERE-luc)	
Delfosse et al. 2012 Delfosse et al. 2012	4,4-Bisphenol F Bisphenol AF	HeLa	ERR		Gamma	Reporter gene assay	WT receptor WT receptor	ERR-gamma (ERE-luc)	• • • • • •
Okada 2008	Bisphenol AF	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	
Delfosse et al. 2012	Bisphenol B	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	•
Delfosse et al. 2012	Bisphenol E	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	
Okada 2008	Bisphenol E	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	• <u> </u>
Delfosse et al. 2012	Bisphenol S	HeLa	ERR		Gamma	Reporter gene assay	WT receptor	ERR-gamma (ERE-luc)	•
Roelofs et al. 2015	4,4-Bisphenol F	yeast	GR	24	Endogenous	Receptor binding assay	WT receptor	GR (yEGFP)	• • • • • • • • • • • • • • • • • • • •
Kolsek et al. 2014	Bisphenol P	MDA-kb2	GR		Endogenous	Receptor binding assay	WT receptor	GR (fluorescence polarization)	
Roelofs et al. 2015 Kolsek et al. 2014	Bisphenol S Bisphenol P	yeast MDA-kb2	GR GR	24 24	Endogenous	Receptor binding assay Reporter gene assay	WT receptor WT receptor	GR (yEGFP) GR (luciferase)	V V V V V V V V V V V V V V V V V V V
Kolsek et al. 2014	Bisphenol P	MDA-kb2	GR	24	Endogenous	Reporter gene assay	WT receptor	GR (luciferase)	La construction de la constructi
									-
Sui et al. 2012 Sui et al. 2012	Bisphenol B Bisphenol B	LS180 LS180	PXR PXR		Endogenous Endogenous	RNA transcription assay RNA transcription assay	WT receptor WT receptor	CYP3A4 UGT1A1	
Sui et al. 2012 Sui et al. 2012	Bisphenol B	LS180	PXR		Endogenous	RNA transcription assay	WT receptor	MDR1	
Dring et al. 2010	4,4-Bisphenol F		PXR	20	Endogenous	Reporter gene assay	Mutant receptor	p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	•
Molina-Molina et al. 2013	4,4-Bisphenol F		PXR	16	Endogenous	Reporter gene assay	WT receptor	hPXR (luciferase)	
Sui et al. 2012	4,4-Bisphenol F	HepG2	PXR	24	Endogenous	Reporter gene assay	WT receptor	hPXR (CYP3A4-luc)	
Sui et al. 2012	4,4-Bisphenol F	HepG2	PXR	24	Endogenous	Reporter gene assay	WT receptor	mPXR ([CYP3A2]3-luc)	660
Dring et al. 2010	Bisphenol AF	HuH-7	PXR	20	Endogenous	Reporter gene assay	Mutant receptor	p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	
Sui et al. 2012	Bisphenol AF	HepG2	PXR	24	Endogenous	Reporter gene assay	WT receptor	hPXR (CYP3A4-luc)	
Sui et al. 2012	Bisphenol AF	HepG2	PXR	24	Endogenous	Reporter gene assay	WT receptor	mPXR ([CYP3A2]3-luc)	•••
Sui et al. 2012	Bisphenol B	HepG2	PXR	24	Endogenous	Reporter gene assay	WT receptor	mPXR ([CYP3A2]3-luc)	ee0
Sui et al. 2012 Sui et al. 2012	Bisphenol B	HepG2	PXR PXR	24	Endogenous	Reporter gene assay	WT receptor	hPXR (CYP3A4-luc)	
Sui et al. 2012 Sui et al. 2012	Bisphenol B Bisphenol E	HepG2 HepG2	PXR	24	Endogenous Endogenous	Reporter gene assay Reporter gene assay	WT receptor WT receptor	hPXR (CYP3A4-luc) hPXR (CYP3A4-luc)	•••
Sui et al. 2012	Bisphenol E	HepG2	PXR	24	Endogenous	Reporter gene assay	WT receptor	mPXR ([CYP3A2I3-luc)	600
Dring et al. 2010	Bisphenol S	HuH-7	PXR	20	Endogenous	Reporter gene assay	Mutant receptor	p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	▼
Volina-Molina et al. 2013	Bisphenol S	HeLa	PXR	16	Endogenous	Reporter gene assay	WT receptor	hPXR (luciferase)	
Sui et al. 2012	Bisphenol S	HepG2	PXR	24	Endogenous	Reporter gene assay	WT receptor	hPXR (CYP3A4-luc)	
Sui et al. 2012	Bisphenol S	HepG2	PXR	24	Endogenous	Reporter gene assay	WT receptor	mPXR ([CYP3A2]3-luc)	
Peyre et al. 2014	Bisphenol S	HepG2/hPXR	PXR	24	Endogenous	Reporter gene assay	WT receptor	PXR (luciferase)	•—••••••••
Dring et al. 2010	Bisphenol Z	HuH-7	PXR	20	Endogenous	Reporter gene assay	Mutant receptor	p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	A
Dring et al. 2010	TMBPA	HuH-7	PXR	20	Endogenous	Reporter gene assay	Mutant receptor	p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	A
Dring et al. 2010	4,4-Bisphenol F		PXR	20	Endogenous	Reporter gene assay	Mutant receptor	p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	•
Dring et al. 2010	Bisphenol AF	HuH-7	PXR	20	Endogenous	Reporter gene assay	Mutant receptor	p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	▼
Suietal. 2012 Dring et al. 2010	Bisphenol B Bisphenol S	HepG2 HuH-7	PXR	20	Endogenous	Reporter gene assay	WT receptor Mutant receptor	hPXR (CYP3A4-luc) p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	* .
Dring et al. 2010 Dring et al. 2010	Bisphenol Z	HuH-7 HuH-7	PXR	20	Endogenous	Reporter gene assay Reporter gene assay	Mutant receptor	p3AFLAG-PAR (pCYP3A4-AREM-TK-Luc) p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	
Dring et al. 2010	TMBPA	HuH-7	PXR	20	Endogenous	Reporter gene assay	Mutant receptor	p3XFLAG-PXR (pCYP3A4-XREM-TK-Luc)	▼
eyre et al. 2014	Bisphenol S	HepaRG	PXR/CAR		Endogenous	Protein production assay		PERK2	•
Peyre et al. 2014	Bisphenol S	HepaRG	PXR/CAR		Endogenous	Protein production assay	WT receptor	GSTA4	A•
Peyre et al. 2014	Bisphenol S	HepaRG	PXR/CAR		Endogenous	Protein production assay		PERK1	••
Peyre et al. 2014	Bisphenol S	HepaRG	PXR/CAR		Endogenous	RNA transcription assay		CYP286	••
Peyre et al. 2014 Peyre et al. 2014	Bisphenol S	HepaRG	PXR/CAR PXR/CAR		Endogenous	RNA transcription assay		ABCB1 CYP3A4	• •
Peyre et al. 2014 Peyre et al. 2014	Bisphenol S Bisphenol S	HepaRG	PXR/CAR PXR/CAR		Endogenous Endogenous	RNA transcription assay RNA transcription assay		GSTA4	
Peyre et al. 2014	Bisphenol S	HepaRG	PXR/CAR		Endogenous	RNA transcription assay		PLIN2	
Peyre et al. 2014	Bisphenol S	HepaRG	PXR/CAR		Endogenous	RNA transcription assay		FASN	••
Kamata et al. 2008	4,4-Bisphenol F	yeast	RAR	1	Gamma	Receptor binding assay	WT receptor	RAR-gamma (beta-galactosidase) <pgaad424-tif-2></pgaad424-tif-2>	
Kamata et al. 2008	Bisphenol B	yeast	RAR	1	Gamma		WT receptor	RAR-gamma (beta-galactosidase) <pgaad424-tif-2></pgaad424-tif-2>	600000
Kamata et al. 2008	Bisphenol E	yeast	RAR	1	Gamma	Receptor binding assay		RAR-gamma (beta-galactosidase) <pgaad424-tif-2></pgaad424-tif-2>	400000
Kamata et al. 2008	Bisphenol Z	yeast	RAR	1	Gamma		WT receptor	RAR-gamma (beta-galactosidase) <pgaad424-tif-2></pgaad424-tif-2>	600000
Vishigori et al. 2012	4,4-Bisphenol F		ROR	2	Gamma		WT receptor	ROR-gamma ([3H]25-HC)	
Nishigori et al. 2012 Nishigori et al. 2012	Bisphenol AF Bisphenol AP	bacteria bacteria	ROR	2	Gamma	Receptor binding assay Receptor binding assay		ROR-gamma ([3H]25-HC) ROR-gamma ([3H]25-HC)	• • • • • • •
Nishigori et al. 2012	Bisphenol C	bacteria	ROR	2	Gamma	Receptor binding assay		ROR-gamma ([3H]25-HC) ROR-gamma ([3H]25-HC)	
lishigori et al. 2012	Bisphenol E	bacteria	ROR	2	Gamma	Receptor binding assay		ROR-gamma ([3H]25-HC)	
		bacteria	ROR	2	Gamma		WT receptor	ROR-gamma ([3H]25-HC)	·
ishigori et al. 2012	Bisphenol PH								
	Bisphenol PH Bisphenol S	bacteria	ROR	2	Gamma	Receptor binding assay	WT receptor	ROR-gamma ([3H]25-HC)	I

Figure A-19. <u>Other Nuclear Receptor Activities</u>

Citation Calasion et al. 2009 Calasion et al. 2009 Calasion et al. 2009	Chemical								Dose Specific Effect Relative to Vehicle Control
Cabaton et al. 2009		Coll Species	Cell Strain	Cell Type	Observation Time (H)	Assay Type	Notabelic Activation	Endpoint Description	Ind Tested Doess 🛓 Increase No Damps Decrease Cytotexicity Observed
Cabalon et al. 2010	4.4-Bispherol F	Saincrela typtimurum	TA 100	tedala bedala	1	Arres assay	with metabolic activation	(number of revertant colonies) (number of revertant colonies)	
	4,4-Bispherel F	Sainceals (gitimuture	TA 1535 TA 1537	becieria	1	Arms annay	with metabolic activation	(number of nevertant colonies)	A • • • • • • • • • • • • • • • • • • •
Cabalon et al. 2000 Cabalon et al. 2009	4.4-Bishinol F 4.4-Bishinol F	Saincrella typismurium El cell	W2 unApr0101	beclaria	1	Arma assay Arma assay	with metabolic activation with metabolic activation	(number of reventant colonies) (number of reventant colonies)	
Fic et al. 2013	4.4 Bischorel F	Samonello tustimuniare	TA 100	becteria	48	Arres assay	with metabolic activation	(# revertants)	
Fic et al. 2013	4,4-Bisphenal F	Sainorella typiinturiun Sainorella typiinturiun	TA-98 TA-98	bedieria	72	Arres assay	with metabolic activation without metabolic activation	(#revertants) (number of revertant colories)	
Cabaton et al. 2009 Cabaton et al. 2009	4,4-Bisphenel F	Sainceeks typicmarian	TA 100	bedieria	1	Arres assay	without metabolic activation	(number of revertant colonies)	
Cabaton et al. 2009	4.4-Bisphenol F	Saincrela typtimurum	TA 1537	bedieria	1	Artes assay	without metabolic activation	(number of revertant colonies)	A 7 7 1
Cabaton et al. 2009 Cabaton et al. 2009	4.4 Bisteroi F	E. coli Saincrella tystimurum	W2 unA (#08101 TA 1535	bedietis Pertietis	1	Асна валяу Асна валяу	without metabolic activation without metabolic activation	(number of nevertant colonies) (number of nevertant colonies)	
Fic et al. 2013	A.A.Basharat F.	The second scheme stress	TA 100	becteria	48	Arms assay	without metabolic activation	(Anvertants)	• • • •
Fic et al. 2013	4.4 Bishenel F	Samorello tystimurium	TA 08	besteria	72	Arres assay	without metabolic activation	(# revertants)	• • • •
Kanai et al. 2001	4.4-Bisphenel F	herslor	Syrian	8HE	218	Cell transformation assay Cell transformation assay	not reported	morphologically transformed colonies optimies with >93 cols	AAA ••••
Texteul et al. 2000	4,4-Bispherel F	hermin	Syrian	546	216	Cell transformation assay	not reported		•••
						Editor in the second		number of surviving colonies with 150 cells after cells were treated for 48 hours, pleted, and incubated for 7 days	••••
						Cell transformation assay	not reported	merphologically inami formed colonies after cells were treated for 48 hours, plated, and incubated for 7 days	•••
Morita et al. 2012	4,4-Bispherol F	hamatar	Chinese	CHL		Overosceni abertation	not reported	(percent of cells with structural chromosomel abenations)	
Toutoui et. al. 2000	4.4-Bispheriel F	herslar	Durian.	se.	20	Overesenal abenation	not reported		-
			- Share				The region and	dwaresonal abenations after cells were treated for 6 hours, washed, and incubated for 15 hours.	•••
Les et al. 2013b	4,4-Bisphenai F	chicken	nat reported	DTeD	48	Chronosomal abertation	not reported	WT (nelaphase aberrations)	₩-₩-●
Texterul et al. 2000						Overesceni abertation Overesceni abertation	not reported	RADS4-1- (metaphase aberrations)	AA.
Thomas et al. 2000 Fic et al. 2013	4.4 Bigherol F	hereiter	net applicable	Hep02	4	Constance abortation	not reported	dromosome number (comet tall in 50 sandomly selected nuclei)	
Cabalon et al. 2009	4.4-Bisphonel F	lumo.	net opplicatile	Line (12)	24	Cornel assay	and appendixed	inuder) alive tail moment	
Fic et al. 2013	4,4-Bispherol F	human	net applicable	HepG2	24	Cornet assay	not reported	(corrected in 50 randomly selected mater)	
Audebert et al. 2011	4.4 Bisherel F	haman	nel applicable	HepG2	24	is-cel weaters as any	not reported	(general QAX fluorescence)	A AA A*
Audebert et al. 2011	4,4-Bispherol F	human	net applicable	ACHN	24	in-cell watern assary	not reported	(genmaH2AX fluorescence)	A A+ ++
Audebert et al. 2011 Pfeillier et al. 1997	4.4 Bisherel F 4.4 Bisherel F	haman	ret opplicable Chinose	L8174T V79	24 6	In-cell weatern assay Micronucleus assay	not reported not reported	(germaH2AX fluorescence) (fluorescence)	A AA +•
Cababoo et al. 2009	4.4-Bisphenel F 4.4-Bisphenel F	human	net applicable	HepG2 DTe0	20	Micronacieus assay	not reported	(number of micronuclei) WT (ATP lumineconice)	A4#77
Lee et al. 2013b	4.4-Bisphenel F	chicken	net reported	OTe0	48	Micronucleus assay Problemation	not reported not reported	WT (ATP luminescence)	
						Prolifecation Prolifecation	not reported not reported	RU70+ (ATP laninescence) Politete-l- (ATP luminescence)	•••• ••• <u>*</u>
						Problemation	not reported	RADS4-> (ATPiLaninescence)	• • • •
						Proliferation	not reported	REV3-/- (ATP luminescence)	•••
Rosemmal et al. 2014	4.4-Bishirel F	haman	net oppicatile	U205	24	Problemation Reporter pane assey	not reported not reported	37%-1 (ATP luminoscence) (p52)	
	4,4-Biphenol P Bisphenol AF			Jane					
Fic et al. 2013 Fic et al. 2013	Bisphenci AF	Samorella tystimurium Samorella tystimurium	TA 100 TA 66	bedaria bedaria	48 72	Arres assay Arres assay	with metabolic activation with metabolic activation	(firevertants) (firevertants)	
Fic et al. 2013	Gisphenol AF	Sainceela typtimurium	TA 100	bedieria	41	Arres assay	without metabolic activation	(#revertants)	V
Fic et al. 2013 Kanal et al. 2001	Baphenci AF Baphenci AF	Samonella typhimurura harrafar	TA DE Syrian	tedeta SHE	72 296	Area assay Cell traveformation assay	without metabolic activation not recented	(# revertants) morphologically transformed colonies	A A · · · ·
	Sequence rel		-1-00			Cell transformation assay Cell transformation assay		colories with >52 cells	
Testoui et al. 2000	Baphenol AP	hemster	Dyrian	8×6	218	Cell transformation assay		number of surviving colonies with HSD cells after cells were treated for 48 hours, plated, and incubated for 7 days	•**
						Call traveformation assay	and respectively	hours, pixled, and incubated for 7 days	
						und the encoded as any	- ALA TREPARTING	morphologically itera formed colories after cells were insoled for 48 hours, plated, and incubated for 7 days	<u>***</u>
Toutoul et al. 2000	Bapterol AP	hemstor	Byrian	9HE	30	Overescent abenation	not reported	otromosomal abenations after only were treated for 6 hours, weefed, and incideded for 16 hours.	
								incubaled for 15 hours	
Texteul et al. 2000 Law et al. 2013b	Baphenol AF	hamator chickes	Syrian net reported	5HE D140	45 48	Overescent abertation Overescent abertation	not reported not reported	dronosone sunber WT (relaphase abenatione)	• <u>4</u> • <u>4 4</u> •
						Overesenal abenation	not reported		
Fic et al. 2013	Bischenol AP	heman	net oppficable	Hep02	4	Correct assay	not reported	increatively and in \$2 services to advected	• • •
Fic et al. 2013	Bisphenci AF	heteo	netapplicable	HepG2	24	Cornel assay	not reparted	nuclei) (correctual in 50 randomly selected nuclei)	• • •
Photfler et al. 1997	Supherci Aff	hereler	Chinese	V79		Mororacieus annay	not reported		
Lee et al. 2013b	Stophenol AP	chicken	retreported	D740	48	Proliferation	not reported not reported	KU73-F (ATP luminescence)	****
						Problemation	not reperted not reperted	Polibeto-I. (ATP luminoscence) RAD54-J. (ATP luminoscence)	::::
						Prolderation	not reported	REV3-/- (ATP laminescence)	
						Problecation	not reported	30%-> (ATP luminescence)	::::
						Problecation	not reported	WT (ATP luminescence)	
Lee et al. 2013b	Bisphenol AP	chicken	net reported	D740	48	Oronosonal abenation Oronosonal abenation	not reported not reported	WT (metaphase abertations) RADS4-1- (metaphase abertations)	A
						Profileration	not reported	WT (ATP luminescence) RU75-F (ATP luminescence)	••••
						Problemation Problemation	not reported	RU73-F (ATP luminescence) Psi/beta-F (ATP luminescence)	*****
						Problecation	not reported	Publela-II (ATP luminescence) RADS4-II (ATP luminescence)	
						Problecation	not reported	3PM-1 (ATP luminescence)	****
						ProMeration	not reported	REV3-1 (ATP lamineecence)	••••
Roservnai et al. 2014	Gisphenci G	human	net opplicable	U205	24		not reported	((53)	•••••
Fic et al. 2013	Baphere/C	Saincrels typicsurum	78.100			Arms assay	with metabolic activation		
				Cecteria	40			(#novertants)	• • •
Fic et al. 2013	Bisphenol C	Saincrello typitimurium	TA 06	bedena	12	Arres assay	with metabolic activation	(# novertants)	
Fic et al. 2013 Fic et al. 2013	Baphenel C Baphenel C	Samonella tystemunum Samonella tystemunum	TA 06	becteria	45	Arres assay	with metabolic activation without metabolic activation	(# rovertants) (# rovertants)	• • •
Fic et al. 2013 Fic et al. 2013 Fic et al. 2013 Kanai et al. 2001	Baphenol C Baphenol C Baphenol C Baphenol C	Salmonella tystemuniam Salmonella tystemuniam Salmonella tystemuniam heinster	TA 56 TA 100 TA 56 Syrian	becteria becteria SHE	48 72 48	Arms assay Arms assay Arms assay Cell transformation assay	with restability activation without metabolic activation without metabolic activation not reparted	(# swartants) (# swartants) (# swartants) acianies with >50 cells	
Fic et al. 2013 Fic et al. 2013 Fic et al. 2013 Kanai et al. 2001 Kanai et al. 2001	Bisphere/C Bisphere/C Bisphere/C	Samonello tystimurium Samonello tystimurium Samonello tystimurium	TA 58 TA 100 TA 68 Syrian Syrian	bederia bederia	45 72 48 235	Ames assey Ames assey Ames assey Cell transformation assey Cell transformation assey	with residuals activation without residuals activation without restabilis activation not reported not reported	(# sovertants) (# sovertants) (# sovertants) ocionies with >90 cels morphologically transformed colories.	
Fic et al. 2013 Fic et al. 2013 Fic et al. 2013 Kanai et al. 2001	Baphenol C Baphenol C Baphenol C Baphenol C	Salmonella tystemuniam Salmonella tystemuniam Salmonella tystemuniam heinster	TA 56 TA 100 TA 56 Syrian	becteria becteria SHE	48 72 48	Arms assay Arms assay Arms assay Cell transformation assay	with residuals activation without residuals activation without restabilis activation not reported not reported	(# sovertants) (# sovertants) (# sovertants) ocionies with >90 cels morphologically transformed colories.	
Fic et al. 2013 Fic et al. 2013 Fic et al. 2013 Kanai et al. 2001 Kanai et al. 2001	Baphenol C Baphenol C Baphenol C Baphenol C	Salmonella tystemuniam Salmonella tystemuniam Salmonella tystemuniam heinster	TA 58 TA 100 TA 68 Syrian Syrian	becteria becteria SHE	45 72 48 235	Areas assay Areas assay Areas assay Cel toneformation assay Cel toneformation assay Cel toneformation assay	with metabolic activation without metabolic activation without metabolic activation not reported not reported	(if revertants) (if revertants) (if revertants) colorises with r40 cels monther of any tring colorise still r50 cels after cells verse tostatel for 45 hours, pieted, mit coloratel for 7.6 days	
Pic et al. 2013 Pic et al. 2013 Fic et al. 2013 Fic et al. 2013 Kanal et al. 2001 Tautud et al. 2000	Bapterol C Bapterol C Bapterol C Bapterol C Bapterol C Bapterol C	Salmonella tystemuniam Salmonella tystemuniam Salmonella tystemuniam heinster	TA DE TA 100 TA 08 Syrian Syrian Syrian	bedaria bestaria SHE SHE SHE	45 72 48 295 296	Arma assay Arma assay Arma assay Calitonationation assay Calitonationation assay Calitonationation assay	with metabolic activation without metabolic activation without metabolic activation not reported not reported not reported	(# root far fb) (# root far fb) (# root far fb) (# root far fb) cottines with >55 cols metphologically travelormed cobinies metphologically travelormed cobinies metphologically and for cobines (# fb) fb) hours, plated, and incohered (* fb) for any after cells wave travelor (fb r d) for any after cells wave travelor (fb r d) for any	
Fic et al. 2013 Fic et al. 2013 Fic et al. 2013 Kanai et al. 2001 Kanai et al. 2001	Baphenol C Baphenol C Baphenol C Baphenol C	Salmonella tystemuniam Salmonella tystemuniam Salmonella tystemuniam heinster	TA 58 TA 100 TA 68 Syrian Syrian	becteria becteria SHE	45 72 48 235	Areas assay Areas assay Areas assay Cel toneformation assay Cel toneformation assay Cel toneformation assay	with metabolic activation without metabolic activation without metabolic activation not reported not reported not reported	(# root far fb) (# root far fb) (# root far fb) (# root far fb) cottines with >55 cols metphologically travelormed cobinies metphologically travelormed cobinies metphologically and for cobines (# fb) fb) hours, plated, and incohered (* fb) for any after cells wave travelor (fb r d) for any after cells wave travelor (fb r d) for any	
Pix et al. 2013 Pix et al. 2013 Fix et al. 2013 Konai et al. 2001 Konai et al. 2001 Toutoui et al. 2000	Bapterol C Bapterol C Bapterol C Bapterol C Bapterol C Bapterol C	Satronelo tytimurum Satronelo tytimurum Samorelo tytimurum hanslar hanslar hanslar	TA DE TA 100 TA 08 Syrian Syrian Syrian	bectaria bectaria SHE SHE SHE	48 72 48 236 236 236	Areas assay Areas assay Catoxetoreation assay Catoxetoreation assay Catoxetoreation assay Catoxetoreation assay Catoxetoreation assay	with residuois activations without metabolic activations moli reparted and reparted and reparted and reparted and reparted and reparted	(# vone texts) (# vone texts) (# vone texts) (# vone texts) consists vet / 8 - 56 - 56 method of analysis colosiss all x - 50 vone texts / 56 - 56 method of analysis colosiss all x - 50 vone texts / 56 - 56 method of analysis colosis all x - 50 method operating in the text / 56 method	
Pin et al. 2013 Pin et al. 2013 Pin et al. 2013 Konal et al. 2001 Roma et al. 2001 Touteul et al. 2000 Touteul et al. 2000	Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C	Saltocreals tystimucian Saltocreals tystimucian Saltocreals tystimucian hamalar hamalar hamalar	16.08 16.100 16.08 Syrian Syrian Syrian Syrian	bedaria beataria SHE SHE SHE SHE	48 72 48 256 256 256 30 48	Areas assay Areas assay Areas assay Call toxellonation assay Call toxellonation assay Call toxellonation assay Cut toxellonation assay Cut toxellonation assay Chronosceni aberration Chronosceni aberration	with residuois activations without metabolic activation not reparted not reparted not reparted not reparted not reparted not reparted not reparted not reparted	(# von tert htt) (# von tert htt) (# von tert htt) (# von tert htt) (# von tert htt) statistiss set 3- Sit of htt marker of survivag colosisse all htt https://sites/statistics/statistics/ statistics/statistics/ planks, and tere oblands (for 7 days synthykyputh synthykyter i johnson splanks, and tere oblands (for 7 days synthykyter) statistics/ statistic	
Pie et al. 2013 Pie et al. 2013 Reveal at 2013 Romai et al. 2001 Thomas et al. 2000 Thomas et al. 2000 Leve et al. 2010 Thomas et al. 2000	Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C	Saltocreals tystimucian Saltocreals tystimucian Saltocreals tystimucian hamalar hamalar hamalar	16.06 TA-100 TA-06 System System System	bedaria bedaria SHE SHE SHE SHE DTe0	45 72 48 235 235 235 25 25 48 48	Anna assay Anna asay Anna asay Calitanatumation assay Calitanatumation assay Calitanatumation assay Calitanatumation assay Omoroconal aboration Omoroconal aboration Omoroconal aboration	with restabilities activation with all restabilities activation with all restabilities activation not imported not imported not imported not imported not imported not imported not imported	(# von tert htt) (# von tert htt) (# von tert htt) (# von tert htt) (# von tert htt) consists with 2 - 56 ofter method of analysis of colores method of analysis of colores method of analysis of colores method of analysis of colores method of analysis of the offer of the method of analysis of the offer of the method of the offer of the offer offer method offer of the offer offer method offer offer offer offer offer offer method offer offer offer method offer offer method offer offer method offe	
Pie et al. 2015 Pie et al. 2015 Korne et al. 2015 Korne et al. 2001 Turbud et al. 2000 Turbud et al. 2000 Lee et al. 2013 Turbud et al. 2000 Pie et al. 2013	Baphensi C Baphensi C Baphensi C Baphensi C Baphensi C Baphensi C Baphensi C Baphensi C Baphensi C Baphensi C	Saltoreki lyitteutur Saltoreki lyitteutur Saltoreki lyitteutur Iaraki Iaraki Iaraki Iaraki Cicken Iaraki Iaraki Iaraki	TA 68 TA 100 TA 100 TA 68 Systam Systam Systam Systam net reported Systam ret reported	bedaria bedaria SHE SHE SHE SHE DTE0 SHE HapG2	48 72 48 216 216 216 30 30 48 48 44 4	Anna assay Anna asay Anna asay Anna asay Calitarathumation asay Calitarathumation assay Calitarathumation assay	with metabolic activation without metabolic activation metal metabolic activation metaleparted metaleparted metaleparted metaleparted metaleparted metaleparted	ji Anoshani Anoshani Anoshani Ji Anoshani	• • • • • • • • • • • • • • • • • • •
Pe et al. 2013 Fe et al. 2013 File et al. 2013 Roma et al. 2001 Teoma et al. 2001 Teoma et al. 2000 Les et ol. 2013 Teoma et al. 2000 File et al. 2013	Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C Baptensi C	Saltocreals tystimucian Saltocreals tystimucian Saltocreals tystimucian hamalar hamalar hamalar	16.08 16.100 16.08 Syrian Syrian Syrian Syrian	bedaria bertaria SHE SHE SHE DTe0 SHE HepG2 HepG2	45 72 48 235 235 235 25 25 48 48	Anna assay Anna assay Anna asay Anna assay Calitarathematian assay Calitarathematian assay Calitarathematian assay Calitarathematian assay Calitarathematian Constructional abortation Constructional abortation Constructional abortation Constructional abortation Constructional abortation Constructional abortation Constructional abortation Constructional abortation Constructional abortation	with restanded activation without restanded activation and requested and requested and requested activationed and requested and requested activationed activativationed activativationed activativativativativativativativativativa	ji Anoshani ji Ji Anoshani Ji Ji Anoshani Ji Ji Anoshani Ji Anoshani Ji Anosha	• • • • • • • • • • • • • • • • • • •
Pe et al. 2015 Pie et al. 2015 Rear et al. 2015 Rear et al. 2017 Testenia et al. 2001 Testenia et al. 2000 Line et al. 2000 Pie et al. 2015 Pie et al. 2015 Pie et al. 2015 Pie et al. 2015	Baphensi C Baphensi C	Sateronki tytimutur Sahoreki tytimutur Sateronki tytimutur Iaratar Iaratar Iaratar Astalar Iaratar Iaratar Iaratar Iaratar Iaratar	16.68 Th 100 Th 100 System System System System Int reported System ret reported System ret reported System ret reported Chorees	bedaria tenteria SHE SHE SHE DTe0 SHE HepG2 V79	49 72 48 225 235 235 48 48 48 4 24 5	Ama asse; Ama asse; Ama asse; Cal tandutantion assay Cal tandutantion assay Cal tandutantion assay Cal tandumation assay Cal tandumation assay Cal tandumation assay Cromosci abortation Cromosci abortation Cromosci abortation Cromo assey Cred assey Cimed assey	with resolute activations without availabulic activations nativates and activations nativates and activates nativates activates nativate	ji Anoshani ji Ji Anoshani Ji Ji Anoshani Ji Ji Anoshani Ji Shani Shahi Nang Jiang Ji Xiao Marka Katala Yang Jiang	
Pa et al. 2013 Pa et al. 2013 Fa et al. 2013 Kone et al. 2011 Kone et al. 2011 Kone et al. 2011 Kone et al. 2010 Line et al. 2015 Turnul et al. 2010 Fa et al. 2013 Pa et al. 2013 Pa et al. 2013 Pa et al. 2013	Baphensi C Baphensi C	Sateronik tytimutur Sahorekk tytimutur Sateronik tytimutur Iaraki Iaraki Iaraki Iaraki Iaraki Iaraki Iaraki Iaraki Iaraki Iaraki	14.68 15.100 14.66 System System System System System System System System Chrones Chrones net applicable Chrones	betaria Leataria SHE SHE SHE DTED DTED SHE HapGZ HapGZ V79 AGOTSZG	49 72 48 295 296 296 48 48 44 20 4 20 4 4 20 4 4 4 4 20 4 5 20 4 5 20 5 20	Anna anny Anna anny Anna anny Cail tarathumation anny Cail tarathumation anny Cail tarathumation anny Cail tarathumation anny Cail tarathumation anny Cail tarathumation anny Cail tarathumation Carrona anny Cail Cail tarathumation Carrona anny Cail tarathumation Carrona anny Cail tarathumation Carrona anny Cail tarathumation Carrona anny	win weekeeke achaeve wind a standor achaeve ac	ji Amartini ji Amartini ji Amartini ji Amartini ji Amartini Samart	• • • • • • • • • • • • • • • • • • •
Pe et al. 2013 Fe et al. 2013 File et al. 2013 Roma et al. 2001 Teoma et al. 2001 Teoma et al. 2000 Les et ol. 2013 Teoma et al. 2000 File et al. 2013	Baphensi C Baphensi C	Sateronki tytimutur Sahoreki tytimutur Sateronki tytimutur Iaratar Iaratar Iaratar Astalar Iaratar Iaratar Iaratar Iaratar Iaratar	16.68 Th 100 Th 100 System System System System Int reported System ret reported System ret reported System ret reported Chorees	bedaria tenteria SHE SHE SHE DTe0 SHE HepG2 V79	49 72 48 225 235 235 48 48 48 4 24 5	Ama asse; Ama asse; Ama asse; Cal tandutantion assay Cal tandutantion assay Cal tandutantion assay Cal tandumation assay Cal tandumation assay Cal tandumation assay Cromosci abortation Cromosci abortation Cromosci abortation Cromo assey Cred assey Cimed assey	with resolute activations without availabulic activations nativates and activations nativates and activates nativates activates nativate	ji Amartini ji Amartini ji Amartini ji Amartini ji Amartini Samart	
Pe et al. 2013 Pe et al. 2013 Fe et al. 2013 Fe et al. 2013 Konse et al. 2014 Konse et al. 2010 Teoret al. 2000 Teoret al. 2000 Teoret al. 2000 Teoret al. 2013 Pet et al. 2014 Leinemen and Netder 2006 Leinemen and Netder 2006	Baphensi C Baphensi C	Selencela typisoura Selencela typisoura Selencela typisoura Selencela typisoura Selente Selecta Select	14.66 Th ToO Th ToO System System System System System Chronos Chronos Chronos Chronos met applicable met applicable	betania tentaria Si-E Si-E Si-E Si-E Si-E DTe0 Si-E Hap02 Hap02 V79 A0015220	43 72 44 295 295 295 295 44 4 4 4 4 24 4 5 24 5 12 13	Area anez Area anez Area anez Area anez Cal transformation anez Cal transformation anez Cal transformation anez Cal transformation anez Cal transformation anez Carporocent abortation Organocent abortation	white sectories actualizes white actualized actualizes white actualized actualizes actualized actualitualized actualized actualized actualized a	Jimusta) Jimusta) Jimusta) Jimusta) Jimusta Jimusta Jimusta Jimusta Andre Andream An	
Pa et al. 2013 Pa et al. 2013 Pa et al. 2013 Pa et al. 2013 None et al. 2001 Turnes et al. 2000 Danies et al. 2000 Danies et al. 2000 Danies et al. 2000 Pa et al. 2013 Pa et al. 2013 Part et al. 2013 Definition et al. 2000 Danies et al. 2013 Danies et al. 2014 Danies et al. 2015 Danies et	Baphensi C Baphensi C	Selencela typisoura Selencela typisoura Selencela typisoura Selencela typisoura Selente Selecta Select	14.66 Th ToO Th ToO System System System System System Chronos Chronos Chronos Chronos met applicable met applicable	betania tentaria Si-E Si-E Si-E Si-E Si-E DTe0 Si-E Hap02 Hap02 V79 A0015220	43 72 44 295 295 295 295 44 4 4 4 4 24 4 5 24 5 12 13	Area anez Area anez Area anez Area anez Cal transformation anez Cal transformation anez Cal transformation anez Cal transformation anez Cal transformation anez Carporocent abortation Organocent abortation	white sectories actualizes white actualized actualizes white actualized actualizes actualized actualitualized actualized actualized actualized a	Jimusta) Jimusta) Jimusta) Jimusta) Jimusta Jimusta Jimusta Jimusta Andre Andream An	
Pe et al. 2013 Pe et al. 2013 Fe et al. 2013 Fe et al. 2013 Konse et al. 2014 Konse et al. 2010 Teoret al. 2000 Teoret al. 2000 Teoret al. 2000 Teoret al. 2013 Pet et al. 2014 Leinemen and Netder 2006 Leinemen and Netder 2006	Baphensi C Baphensi C	Selencela typisoura Selencela typisoura Selencela typisoura Selencela typisoura Selente Selecta Select	14.66 Th ToO Th ToO System System System System System Chronos Chronos Chronos Chronos met applicable met applicable	betania tentaria Si-E Si-E Si-E Si-E Si-E DTe0 Si-E Hap02 Hap02 V79 A0015220	43 72 44 295 295 295 295 44 4 4 4 4 24 4 5 24 5 12 13	Ares sees Ares sees Cartes sees Cartes and the		Hansels) Hansels) Hansels H	
Pa et al. 2013 Pa et al. 2013 Pa et al. 2013 Pa et al. 2013 None et al. 2001 Turnes et al. 2000 Danies et al. 2000 Danies et al. 2000 Danies et al. 2000 Pa et al. 2013 Pa et al. 2013 Part et al. 2013 Definition et al. 2000 Danies et al. 2013 Danies et al. 2014 Danies et al. 2015 Danies et	Baphensi C Baphensi C	Selencela typisoura Selencela typisoura Selencela typisoura Selencela typisoura Selente Selecta Select	14.66 Th ToO Th ToO System System System System System Chronos Chronos Chronos Chronos met applicable met applicable	betania tentaria Si-E Si-E Si-E Si-E Si-E DTe0 Si-E Hap02 Hap02 V79 A0015220	43 72 44 295 295 295 295 44 4 4 4 4 24 4 5 24 5 12 13	Area sawy Area sawy Area sawy Carloradwindow any Carloradwindow away Carloradwindow away Carloradwindow away Carloradwindow away Carloradwindow away Carloradwindow Carlora	white sectories actualizes white actualized actualizes white actualized actualizes actualized actualitualized actualized actualized actualized a		
Pa et al. 2013 Pa et al. 2013 Pa et al. 2013 Pa et al. 2013 None et al. 2001 Turnes et al. 2000 Danies et al. 2000 Danies et al. 2000 Danies et al. 2000 Pa et al. 2013 Pa et al. 2013 Part et al. 2013 Definition et al. 2000 Danies et al. 2013 Danies et al. 2014 Danies et al. 2015 Danies et	Bayhensi C Bayhensi C	Sevenda (generate Sevenda (generate) Sevenda (generate) Neator Ne	14.66 Th ToO Th ToO System System System System System Chronos Chronos Chronos Chronos met applicable met applicable	betensa teensa Seré Seré Seré Seré OTeo Seré HegO2 HegO2 HegO2 Adonto220 DTeo	43 72 44 294 294 294 294 44 4 4 24 4 24 4	Ares sees Ares sees Cartes sees Cartes and the		Hansels) Hansels) Hansels H	
Pa et al 2010 Pa et al 2010 Pa et al 2010 Nora et al 2010 Nora et al 2010 Nora et al 2010 Total et al 2010 Total et al 2010 Total et al 2010 Total et al 2010 Particular 2010 Particul	Bayhensi C Bayhensi C	Sevenda (generate Sevenda (generate) Sevenda (generate) Neator Ne	In Edit State The Tool Tool State State System System System Rest registration Rest registration Res	betress beersa SHE SHE SHE SHE SHE D740 SHE HepQ2 HepQ2 HepQ2 A0015220 D740	43 72 44 294 294 294 294 44 4 4 24 4 24 4	Area sawy Area sawy Area sawy Carton-burnet ana any Carton-burnet ana any Carton-burnet ana any Carton-burnet ana any Carton-burnet and any Carton-burnet an			
Pa et al 201 Pa et al 201 Pa et al 201 None et al 200 None et al 200 None et al 200 Les et al 200 Pa et al 201 Pa et al 201 Rober et al 200 Rober et al 200	Baghers C Baghers C	Selencela typisoura Selencela typisoura Selencela typisoura Selencela typisoura Selente Iaentar Iaentar Iaentar Iaentar Iaentar Iaentar Iaentar Iaentar Iaentar Iaentar Iaentar	14.68 14.10 14.68 19.49 19.49 19.49 19.49 19.49 19.49 19.49 10.49	berthol tentros selic se	45 44 250 250 200 200 44 44 4 224 4 3 3 3 3 3 4 4 4 224 22 4	Area sarey Area sarey Area sarey Calcardentiana sare Calcardentiana sarey Calcardentiana sarey Calcardentiana sarey Calcardentiana Caracteriana Cara			
Pa et al 201 Pa et al 201 Pa et al 201 None et al 200 None et al 200 None et al 200 Les et al 200 Pa et al 201 Pa et al 201 Rober et al 200 Rober et al 200	Bayhensi C Bayhensi C	Sevenda (generate Sevenda (generate) Sevenda (generate) Neator Ne	In Edit State The Tool Tool State State System System System Rest registration Rest registration Res	betress beersa SHE SHE SHE SHE SHE D740 SHE HepQ2 HepQ2 HepQ2 A0015220 D740	43 72 44 294 294 294 294 44 4 4 24 4 24 4	Area serve; Area serve; Area serve; Coll calcularitation serve; Coll calcularitation serve; Coll calcularitations serve; Coll calcul			
Pa et al 201 Pa et al 201 Pa et al 201 None et al 200 None et al 200 None et al 200 Les et al 200 Pa et al 201 Pa et al 201 Rober et al 200 Rober et al 200	Baghers C Baghers C	Sevenda (generate Sevenda (generate) Sevenda (generate) Neator Ne	In Edit State The Tool Tool State State System System System Rest registration Rest registration Res	berthol tentros selic se	45 44 250 250 200 200 44 44 4 224 4 3 3 3 3 3 4 4 4 224 22 4	Area surg Area surg Area surg Calculations and Calculations and Calculations Calculation			
Pa et al 201 Pa et al 201 Pa et al 201 None et al 200 None et al 200 None et al 200 Les et al 200 Pa et al 201 Pa et al 201 Rober et al 200 Rober et al 200	Baghers C Baghers C	Sevenda (generate Sevenda (generate) Sevenda (generate) Neator Ne	In Edit State The Tool Tool State State System System System Rest registration Rest registration Res	berthol tentros selic se	45 44 250 250 200 200 44 44 4 224 4 3 3 3 3 3 4 4 4 224 22 4	Area sarey Area sarey Area sarey Area sarey Area sarey Area sarey Area sarey Carlo and and area Carlo and area Carlo and area Carlo and area Carlo and Carlo		Handbolk Januardo Martina Mart	
Pa et al 201 Pa et al 201 Pa et al 201 None et al 200 None et al 200 None et al 200 Les et al 200 Pa et al 201 Pa et al 201 Rober et al 200 Rober et al 200	Baghers C Baghers C	Sevenda (generate Sevenda (generate) Sevenda (generate) Neator Ne	In Edit State The Tool Tool State State System System System Rest registration Rest registration Res	berthol tentros selic se	45 44 250 250 200 200 44 44 4 224 4 3 3 3 3 3 4 4 4 224 22 4	Ame service Ame se			
Phy and 2013 Phy and 2013 Phy and 2013 Phy and 2013 Phy and 2013 Phy and 2013 Phy and 2013 Physics at 2010 Physics at	Baghers C Baghers C	Sevenda (generate Sevenda (generate) Sevenda (generate) Neator Ne	In Edit State The Tool Tool State State System System System Rest registration Rest registration Res	berthol tentros selic se	45 44 250 250 200 200 44 44 4 224 4 3 3 3 3 3 4 4 4 224 22 4	Ame serve; Ame serve;			
The set al 201 The set al al 201 The set al al 201 The set al al 201 The set al 201 The s	Bependi Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni Busheni	Second (symbol) Second (symbol	Net Total Total Sean Sean Sean Sean An arcepedia Sean An arcepedia Sean An arcepedia An arcepedia An arcepedia An arcepedia An arcepedia An arcepedia	berten Bereiten Seite Se	45 44 250 250 200 200 44 44 4 224 4 3 3 3 3 3 4 4 4 224 22 4	Ame service Ame se			
No. et al. 2010 Proj. et al. 2010 No. et al. 2010 Proj. et al. 2010 No. et al. al. 2010 Proj. et al. 2010 No. et al. al. 2010 Proj. et al. 2010 No. et al. 201	Newer() Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert) Repert)	Anexel (genue) Anexel (genue	Net Store Store Span Span Span Span marpha Span marpha Span marpha Cases an expediation marpha marph	berten Berein Seif Seif Seif Seif Seif Seif Page2 Die Approxes Die Die Die Die Die Die Die Die Die Die	44 47 48 49 291 291 291 291 291 291 291 29	Ame samp; Ame samp;			
Marcel and 2010 Provide 2011 Marcel and 2011 Provide 2011 Marcel and 2010 Provide 2012 Marcel and 2012 Provide 2014	Bepheni C Bepheni C	Anexel (genue) Second (genue) Second (genue) Second (genue) Second (genue) Anexel Anexe	Net 104	berten Bereiten Seite Se	45 44 250 250 200 200 44 44 4 224 4 3 3 3 3 3 4 4 4 224 22 4	Ame samp; Ame samp;			
No. of 2010 No. of 2010 No. of 2010 No. of 2010 No. of a 100 No. of a 100	bankent banken	Anexel (genue) Second (genue) Second (genue) Second (genue) Second (genue) Anexel Anexe	Net Secont Secont Secont Secont Secont Secont encoded	berne leven set set set set set set branc hapto	44 45 46 47 274 274 274 44 44 47 17 17 14 48 44 44 44 44 44 44 44 44 4	Ame smoot see smoot and see sm			
No. of 2010 No. of 2010 No. of 2010 No. of 2010 No. of a 100 No. of a 100	Bepheni C Bepheni C	Anexel (genue) Second (genue) Second (genue) Second (genue) Second (genue) Anexel Anexe	Net Secont Secont Secont Secont Secont Secont encoded	benne Benen Sei Sei Sei Sei Sei Sei Sei Sei Hagiz Abritzio Dite Abritzio Dite Dite Sei Sei Sei Sei Sei Sei Sei Sei Sei Se	44 44 43 244 244 244 244 44 44 44 44 44 44 44 44	Ame smort and smort and amount annot deliveration annot deliveration annot deliveration annot deliveration annot a		Piersbell Piersbell <t< td=""><td></td></t<>	
No. et al. 2010 No. et al. 2010	Newenic Sevence Sevenc	Seconda (general) Seconda (general) Seconda (general) Seconda (general) Seconda (general) Seconda (general) Seconda (general) Seconda (general) Seconda (general) Seconda (general)	Net Sea Sea Sea Sea Sea Sea Correst Sea Correst Corres	benne see see see see see crasses see see see see see see see see se	44 45 46 47 274 274 274 44 44 47 17 17 14 48 44 44 44 44 44 44 44 44 4	Ame sensition of the se		Pierrely	
Marcia da 2010 Marcia da 2010 Marcía da 2010 Marcía da 2010 Marcía da 2010 <td< td=""><td>Newers's Reverse</td><td>Anexel (generate Anexel (gen</td><td>NH NH Stop Stop Stop Stop</td><td>berne ame and and and and and and and and and and</td><td>44 45 47 40 40 40 40 40 40 40 40 40 40</td><td>Ame same) Ame same) Conservations and Conservations and Conservations and Conservations and Conservations and Conservations and Conservations and Conservations and Conservations Conser</td><td></td><td>Piersbeit Piersbeit Piersbeit Piersbeit</td><td></td></td<>	Newers's Reverse	Anexel (generate Anexel (gen	NH NH Stop Stop	berne ame and and and and and and and and and and	44 45 47 40 40 40 40 40 40 40 40 40 40	Ame same) Ame same) Conservations and Conservations and Conservations and Conservations and Conservations and Conservations and Conservations and Conservations and Conservations Conser		Piersbeit Piersbeit	
Marcine and 2010 Marcine and 2010 Marcine and a 2010 Marcine and 2010 Marcine and an an 2008 Marcine and 2010 Marcine and 2010 Marcine and 2010	Newers's Research Res	Hencelster, jernener Seconde igeneration Instante Ins	Net Sea Sea Sea Sea Sea Annot Sea Annot An	bechne and and and and and and and and and and	44 45 47 44 49 40 40 40 44 44 40 40 40 40 40	Ame seek Ame seek ame seek ame seek Colleaderhandles autor Colleaderhandles autor Colleaderhandles autor Colleaderhandles Colleade		Pierbell	
Note of a 2010 Note of a 2010	Newers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's Bookers's	Herestellingeneration Seconde lingeneration learning and and and seconde lingeneration facati	Net Store Store Store Store Store Store Store Store Anapotet anapo	berne and and and and and and and and and and	44 45 47 40 40 40 40 40 40 40 40 40 40	Ame same) Ame same) Conservations and Conservations and Conservations and Conservations and Conservations and Conservations Cons		Piestell	
May of A 2010 A 2010 Market 1000 A 2010 Market 1000 A 2010 Market 1000 A 2010 Market 1000 A 2010	Newers's Reverses's Reverses's Reverses's Reverses Revere	Hencelster, jernener Seconde igeneration Instante Ins	Net Secont Secont Secont Secont Secont Secont Secont encode encod	bechne and and and and and and and and and and	44 43 44 44 244 244 44 44 44 44 44	Ame seek Ame se		Pierbeil	
No. of a 1990 No. of a 1990 No. of a 1990 No. of a 1990 <t< td=""><td>Newers Sources</td><td>Seconda Lances Seconda Lances</td><td>Net Store St</td><td>benne anne antenne ant</td><td>44 43 44 244 244 244 44 4 4 4 7 7 7 44 4 4 4 4 4 4 4 4 4 4 4 4</td><td>Ame small Ame small</td><td></td><td></td><td></td></t<>	Newers Sources	Seconda Lances Seconda Lances	Net Store St	benne anne antenne ant	44 43 44 244 244 244 44 4 4 4 7 7 7 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame small Ame small			
Pare of a 2019 Pare of a 2019 Name of a 2019 <td< td=""><td>Neberti Sebert</td><td>Handandara Manadara M</td><td>Neil Seator Seator Seator Seator Seator Seator Seator Concellent Concellent Seator Concellent Conce</td><td>benere and and and and and and and and and and</td><td>44 43 44 44 44 47 44 4 4 4 4 4 4 4 4 4 4 4 4</td><td>Ame seek Ame se</td><td></td><td></td><td></td></td<>	Neberti Sebert	Handandara Manadara M	Neil Seator Seator Seator Seator Seator Seator Seator Concellent Concellent Seator Concellent Conce	benere and and and and and and and and and and	44 43 44 44 44 47 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame seek Ame se			
The set al 2014 t	Newers Sources	Seconda Lances Seconda Lances	Neil Seator Seator Seator Seator Seator Seator Seator Concellent Concellent Seator Concellent Conce	benne anne antenne ant	44 43 44 244 244 244 44 4 4 4 7 7 7 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame seek Ame se			
Not of 2010 Not of 2010 Not of 2010 Not of 2010 Not of an 2010 Not of an 2	Neberti Sebert		Neil Solo Solo Solo Solo Solo Solo Solo eraphone	benere and and and and and and and and and and	44 43 44 44 44 47 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame sensition of a se			
Mar at 2010 Mar at 2010 Mar at 2010 Mar at 2010 Mar at at 2010 Mar at 2010	Newer() September Septembe	Handandara Manadara M	Net State St	benere and and and and and and and and and and	44 43 44 44 44 47 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame seek Ame se			
Not all 2010 Not all 2010 Not all 2010 Not all 2010 Not all all 2010 Not all 2010 <	Neberti Solution Neberi Neberi Solution Neberi N		Neil Solo Solo Solo Solo Solo Solo Solo So	benere and and and and and and and and and and	44 43 44 44 44 47 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame sensition of a se			
	Neberia Sectors Sector		Net State St	benete leases leases are ore ore ore ore ore ore ore ore ore o	44 45 77 44 47 270 48 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame sense Ame sense			
	Neberti Solution Neberi Neberi Solution Neberi N		Neil Solo Solo Solo Solo Solo Solo Solo So	benere and and and and and and and and and and	44 44 77 44 44 47 48 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame sensition of a se			
	Neberia Sectors Sector		Net State St	benete leases le	44 45 77 44 47 270 48 44 4 4 4 4 4 4 4 4 4 4 4 4	Ame small Ame small			
Par al a 2010 Par al a 2010 <td< td=""><td>Newer() Newer() Newer() Newer() Newer() Newer() Research</td><td></td><td>Neil Solo Solo Solo Solo Solo Solo Solo So</td><td>Jennes Jene</td><td>44 45 75 76 76 76 76 76 76 76 76 76 76</td><td>Ame see in a constraint of a c</td><td>de reductés de la de la</td><td></td><td></td></td<>	Newer() Newer() Newer() Newer() Newer() Newer() Research		Neil Solo Solo Solo Solo Solo Solo Solo So	Jennes Jene	44 45 75 76 76 76 76 76 76 76 76 76 76	Ame see in a constraint of a c	de reductés de la		
Parial 2010	Newer() Newer(Incontention of the sector of	Neil Solo Solo Solo Solo Solo Solo Solo So	benetes lesses autores autores autores autores lesses autores lesses autores a	44 45 77 44 47 44 44 44 44 44 44 44	Ame small Ame small			
Paral al 2010	Newer() Newer(Net Southernet Souther	lamita lamina la	44 45 75 44 44 44 44 44 44 44 44 44 4	Ame service Ame s			
Parial 2010	Newer() Newer(Net Southernet Souther	lamita lamina la	44 45 75 44 44 44 44 44 44 44 44 44 4	Ame small Ame small			
Parial 2010	Newer() Newer(Net Southernet Souther	lamita lamina la	44 45 75 44 44 44 44 44 44 44 44 44 4	Ame service Ame s			
Parial and Sile Paria	Neneria Sector S		Net Southernet Souther	kenke kenke ass ass ass be be be be be be be be be be be be be	44 45 47 47 47 48 48 47 47 47 48 47 48 47 48 48 48 48 48 48 48 48 48 48	Amagenet Ama	einendenenenenenenenenenenenenenenenenen		
Na id a 2010		Incentempor Incen	Net Control of Control	lamita lamina la		Any a	en en de la		
Na id a 2010	Newerich Sectors Secto	Handenberger Ha	Nei Southannes Southan	kenke kenke ass ass ass be be be be be be be be be be be be be		Ame small Ame small	einendenendenendenendenendenendenendene		
Par al a 2010 Par al a 2010 Par al a 2010 Nana al al al 2010 Nana al 2010 Nanal 2010 Nana al 201	August	Handenberger Ha	Nei Southerner Souther			Ame series Ame se	erendense en		
Parad a 2010		Incentempor Incen	Nei Southannes Southan			Ame small Ame small			
Parad a 2010		Incentempor Incen	Nei Souther So	Jennico Jenerologia and and and and and and and and and and		Ame service Ame s			
Par al a 2010 Par al a 2010 Par al a 2010 Nan al an al 2010 Nan al an al 2010 Nan al an al 2010 Par al an al 2010 Nan al 2010		Incentempor Incen	Nei Southannes Southan			Amagna Am			
Para da 2010 Para da 2010 Para da 2010 Nana da 2010 </td <td>Nemeric Nemeric <td< td=""><td>Andengemper andeng</td><td>Nei Southerstein S</td><td>lamba lamba</td><td></td><td>Ana sand Ana sa</td><td></td><td></td><td></td></td<></td>	Nemeric Nemeric <td< td=""><td>Andengemper andeng</td><td>Nei Southerstein S</td><td>lamba lamba</td><td></td><td>Ana sand Ana sa</td><td></td><td></td><td></td></td<>	Andengemper andeng	Nei Southerstein S	lamba lamba		Ana sand Ana sa			
Parial and Sile Paria	Network Network Network <	Andengemper andeng	Nei Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser	lamba ama ama ama ama ama ama ama ama ama		Ana sand Ana sa			

Figure A-20. In vitro Genotoxicity Assays



Figure A-21. Assessment of Active and Inactive Assay of BPA Analogues in ToxCast



Figure A-22. Risk of Bias of Animal Evidence from Published Literature



Figure A-23. Risk of Bias of Animal Evidence from ECHA Data



National Toxicology Program NTP Central Data Management, MD K2-05

NTP Central Data Management, MD K2-05 National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, NC 27709

http://ntp.niehs.nih.gov

ISSN 2473-4756